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PREFACE 
 
The present PhD thesis “HETEROGENEITY IN BRONCHIAL-PULMONARY CARCINOMAS: 
IMMUNOHISTOCHEMICAL AND MOLECULAR CHARACTERIZATION” is submitted in fulfilment of 
the requirements of the PhD degree at the Faculty of Medicine, University of Coimbra, on the 
basis of data obtained in the Pathology Department of the Coimbra Hospital and University 
Centre (SAP – CHUC) and in the Pathology Institute of the Faculty of Medicine, University of 
Coimbra (IAP – FMUC).  
The thesis is divided into a general introduction and six accompanying manuscripts, of which 
four have already been published, one is accepted for publication and one is undergoing 
revision. The manuscripts are present in six chapters. They are:  
I – Sousa V, Espírito Santo J, Silva M, Cabral T, Alarcão AM, Gomes A, Couceiro P, Carvalho L. 
EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of 
bronchial epithelium: an immunohistochemical and genetic study. Virchows Arch. 2011 May; 
458(5):571-81. 
II – Couceiro P, Sousa V, Alarcão A, Silva M, Carvalho L. Polysomy and amplification of 
chromosome 7 defined for EGFR gene in epidermoid carcinoma of the lung together with 
exons 19 and 21 wild type. Rev Port Pneumol. 2010 May-Jun;16(3):453-62. 
III – Sousa, V; Bastos, B; Silva, M; Alarcão, A; Carvalho, L. Bronchial-Pulmonary 
Adenocarcinoma Subtyping Relates With Different Molecular Pathways. In publication in 
Revista Portuguesa de Pneumologia - Received 30 October 2013, accepted 30 May 2014, 
available online 5 March 2015 – doi:10.1016/j.rppnen.2014.05.006. 
IV – Sousa, V; Rodrigues, C; Silva, M; Alarcão, A; Carvalho, L. Lung adenocarcinoma: sustained 
subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status. Rev Port 
Pneumol. 2015; 21:113-25. 
V – Sousa, V; Silva, M; Alarcão, A; D’Aguiar, M; Ferreira, T; Carvalho, L. EGFR and KRAS 
mutations coexistence in lung adenocarcinomas. Diagnostic Pathology 2015, 1:13 - 
http://www.diagnosticpathology.eu/content/index.php/dpath/article/view/13. 
VI – Sousa, V; Silva, M; Alarcão, A; Reis, D; Ladeirinha, AF, D’Aguiar, M; Ferreira, T; Carvalho, L. 
Targeted therapy for FGFR1 may be independent of the histological type of bronchial-
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pulmonary carcinomas. Manuscript submitted for publication – Submited / undergoing 
revision – Virchows Archive. 
The manuscripts reflect the Material, Methods and Results and are organized in chapters, 
followed by twelve posters presented at national and international meetings, with relevance 
or related to the published abstracts, as follows: 
I – “EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 AND P53 EXPRESSION IN PRENEOPLASTIC 
LESIONS OF BRONCHIAL EPITHELIUM”  
The 16th International Charles Heidelberger Symposium on Cancer Research, Coimbra, 
Portugal, September 26-28, 2010. 
BMC Proceedings 2010, 4(Suppl 2):P64. 
 
II – “EGFR UNUSUAL MUTATION STATUS IN LUNG ADENOCARCINOMAS” 
The 16th International Charles Heidelberger Symposium on Cancer Research, Coimbra, 
Portugal, September 26-28, 2010. 
BMC Proceedings 2010, 4(Suppl 2):P61. 
III – “KRAS AND EGFR MUTATIONS COEXISTING IN LUNG ADENOCARCINOMA”  
The 16th International Charles Heidelberger Symposium on Cancer Research, Coimbra, 
Portugal, September 26-28, 2010. 
BMC Proceedings 2010, 4(Suppl 2):P57. 
 
IV – “EGFR and KRAS mutations in mixed type of Pulmonary Adencocarcinoma”  
Intercongress Meeting of the European Society of Pathology, Krakow – Poland, 31st August - 
4th September, 2010.  
Virchows Arch (2010) 457: 91-281. 
 
V – “KRAS Mutations in Lung Adenocarcinomas may be Relevant in Histological Patterns, EGFR 
Mutational Status and Male Smokers” 
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
Virchows Archiv 2011; Supplement 459: SI – S320. 
 
VI – “TTF1 Negative Solid Pattern in Lung Adenocarcinomas May Reflect Morphogenesis” 
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
Virchows Archiv 2011; Supplement 459: SI – S320. 
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VII – “Lung Adenocarcinomas Subtyping is not Relevant for EGFR Mutations, Gene Copy 
Number and Protein Expression” 
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
Virchows Archiv 2011; Supplement 459: SI – S321. 
 
VIII – “ALK Gene Rearrangment in EGFR and KRAS Positive Lung Adenocarcinomas”  
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
Virchows Archiv 2011; Supplement 459: SI – S320. 
 
IX – “ALK expression in Pulmonary Adenocarcinomas”  
24thEuropean Congress of Pathology, Prague, September 8 – 12, 2012.  
Virchows Arch (2012) 461: S1-S332. 
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ABSTRACT  
 
Lung cancer is still one of the most frequent cancers in the world, with a high mortality rate. 
Bronchial-pulmonary carcinomas are still undergoing morphological, immunohistochemical 
and genetic characterization, with important clinical implications. The characterization of 
preneoplastic lesions may bring a better understanding of carcinogenesis. 
Bronchial-pulmonary carcinomas and preneoplastic lesions of epidermoid carcinoma were 
studied using immunohistochemical and molecular pathology techniques, on a morphological 
pattern-based approach.  
Basal cell origin was proposed for preneoplastic epidermoid carcinoma lesions, where Ki67, 
p53 and EGFR constitute biomarkers of agressiveness. EGFR amplification is not the main 
mechanism for overexpression in preneoplastic lesions. 
High EGFR gene copy number and EGFR overexpression may play a role in epidermoid 
carcinoma carcinogenesis. EGFR mutations are rare. Epidermoid carcinomas with solid, large or 
clear cell phenotype or with CK7 or Vimentin (EMT phenotype) expression should be 
submitted to EGFR mutational analysis. 
Expression differences between adenocarcinoma patterns reinforce the importance of pattern 
classification due to their implications for diagnosis, pathogenic understanding and therapeutic 
outcome. There was higher expression of the gene products studied in adenocarcinomas 
compared to normal tissue, reinforcing their importance in adenocarcinoma carcinogenesis.   
Non-smoking female adenocarcinomas were diagnosed in earlier stages and showed higher 
ERCC1 expression. Advanced stages (IIA and IIIA) adenocarcinomas were characterized by 
higher Ki67, APC, ERCC1 expressions and lower TTF1 expression, reflecting more mitotically 
aggressive adenocarcinomas and a possible non-TRU origin. Solid patterns showed lower 
expression of nuclear TTF1 and higher expression of Ki67, reflecting aggressive biological 
behaviour, to be reported to clinicians avoiding poorly differentiated carcinoma reports. TTF1 
provides significant guidance for therapy concerning lung adenocarcinoma as EGFR mutations 
were more frequent in TTF1 positive TRU-type adenocarcinomas. On the other hand TTF1 
negative adenocarcinomas, some representing non-TRU adenocarcinomas are less prone to 
harbour EGFR mutations. Three clusters of adenocarcinoma patterns were identified: 1 – 
papillary; 2 – solid; and 3 – lepidic/BA, acinar and micropapillary. 
ABSTRACT 
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Molecular markers related to therapy resistance were explored and were found to 
demonstrate higher MRP1 and LRP expression in adenocarcinomas, indicating acquisition of 
drug-resistance mechanisms during carcinogenesis. Micropapillary, solid and also lepidic 
patterns showed ERCC1 expression indicating a capacity for Cisplatin-adducts removal. 
EGFR mutations were generally present in all the patterns of the same adenocarcinoma 
reinforcing mutational evaluation in small biopsies.  Complex EGFR mutations and KRAS and 
EGFR mutations coexistence were detected, demonstrating molecular complexity.  
FGFR1 protein expression was present in the majority of the bronchial-pulmonary carcinomas, 
and is higher in adenocarcinomas and pleomorphic carcinomas. Higher expression in 
pleomorphic carcinomas may reflect the importance of FGFR1 controlling EMT pathways. 
FGFR1 amplification is identified in adenocarcinomas (14.7%), epidermoid carcinomas (20.8%), 
adenosquamous carcinoma (25%) and pleomorphic carcinomas (30%), without significant 
differences. 
Although FGFR1 amplification has been observed more frequently in epidermoid carcinomas 
than in adenocarcinomas, these results suggest that the other histological types harbouring 
FGFR1 amplification, such as adenosquamous, pleomorphic carcinomas, adenocarcinomas and 
even small cell lung carcinoma, may benefit from targeted therapy. 
 
Bronchial-pulmonary carcinomas have particular biological, clinical and therapeutic 
implications. The importance of precise pathological diagnosis, adenocarcinoma patterns 
recognition, and bronchial-pulmonary carcinogenesis related to biomarker predictive value for 
targeted therapy is highlighted. 
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RESUMO 
 
O cancro do pulmão continua a ser um dos cancros mais frequentes no mundo, com elevada 
taxa de mortalidade. Os carcinomas bronco-pulmonares estão ainda a ser caracterizados 
morfologicamente, imunohistoquimicamente e geneticamente, com importantes implicações 
clínicas. 
  
Os carcinomas bronco-pulmonares e as lesões pré-neoplásicas do carcinoma epidermoide 
foram estudados fazendo uso de técnicas imunohistoquímica e de patologia molecular, numa 
abordagem baseada no padrão morfológico. 
 
Para as lesões pré-neoplásicas do carcinoma epidermoide foi proposta origem em células 
basais, constituindo o Ki67, a p53 e o EGFR biomarcadores de agressividade. 
 
O elevado número de cópias do gene EGFR e a sobreexpressão de EGFR podem desempenhar 
um papel na carcinogénese do carcinoma epidermoide. As mutações do EGFR são raras. Os 
carcinomas epidermoides com fenótipo sólido, com células claras ou grandes ou com 
expressão de CK7 ou Vimentina (fenótipo EMT) devem ser submetidos a análise de mutações 
do EGFR. 
 
As diferenças de expressão entre os padrões de adenocarcinoma reforçam a importância da 
classificação dos padrões devido às implicações para o diagnóstico, compreensão da 
patogénese e para o resultado terapêutico. A expressão mais elevada dos produtos de genes 
estudados em adenocarcinomas comparado com o tecido normal reforça a sua importância na 
carcinogénese dos adenocarcinomas. 
 
Os adenocarcinomas de mulheres não fumadoras foram diagnosticados em estádios mais 
precoces e evidenciaram expressão mais elevada de ERCC1. Os adenocarcinomas 
diagnosticados em estádios mais avançados (IIA e IIIA) caracterizaram-se por expressão mais 
elevada de Ki67, APC e ERCC1 e por expressão menor de TTF1, refletindo adenocarcinomas 
mais mitoticamente ativos e agressivos e uma possível origem não-URT (Unidade Respiratória 
Terminal). Os padrões sólidos evidenciaram uma menor expressão de TTF1 nuclear e uma mais 
elevada expressão de Ki67, refletindo um comportamento biológico agressivo, que deve ser 
referenciado aos clínicos, evitando nos relatórios a terminologia carcinoma pouco 
RESUMO 
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diferenciado. A expressão de TTF1 fornece informação significativa na orientação terapêutica 
para adenocarcinomas do pulmão, tendo sido as mutações do EGFR mais frequentes em 
adenocarcinomas positivos para TTF1, do tipo URT. Por outro lado, os adenocarcinomas TTF1 
negativos, alguns representando adenocarcinomas sem origem na URT, revelaram menor 
propensão a apresentar mutações do EGFR. Três grupos de padrões de adenocarcinoma foram 
identificados: 1 – papilar; 2 – sólido; e 3 – lepídico/BA, acinar e micropapilar. 
 
Foram explorados marcadores moleculares relacionados com a resistência à terapêutica, que 
demonstraram expressão mais elevada de MRP1 e de LRP em adenocarcinomas, indicando 
aquisição de mecanismos de resistência a agentes terapêuticos durante a carcinogénese. Os 
padrões micropapilar, sólido e lepídico demonstraram expressão de ERCC1, indicando 
capacidade para remoção de aditivos de Cisplatina. 
 
As mutações de EGFR estavam presentes, de forma geral, em todos os padrões do mesmo 
adenocarcinoma, reforçando a avaliação de mutações em pequenas biópsias. Mutações 
complexas de EGFR e a coexistência de mutações KRAS e EGFR foram identificadas, 
demonstrando complexidade molecular.  
 
A expressão proteica de FGFR1 estava presente na maioria dos carcinomas bronco-
pulmonares, sendo a expressão mais elevada em adenocarcinomas e em carcinomas 
pleomórficos. A expressão mais elevada em carcinomas pleomórficos pode refletir a 
importância do FGFR1 no controle das vias EMT. 
A amplificação de FGFR1 foi identificada em adenocarcinomas (14.7%), carcinomas 
epidermoides (20.8%), carcinomas adenoescamosos (25%) e em carcinomas pleomórficos 
(30%), sem diferenças significativas. Apesar da amplificação FGFR1 ter sido observada mais 
frequentemente em carcinomas epidermoides que em adenocarcinomas, estes resultados 
sugerem que os outros tipos histológicos, tal como os carcinomas adenoescamosos, 
carcinomas pleomórficos, adenocarcinomas e mesmo os carcinomas de células pequenas, 
podem apresentar amplificação de FGR1 e beneficiar de terapêutica dirigida.  
 
Os carcinomas bronco-pulmonares demonstram particularidades com implicações biológicas, 
clinicas e terapêuticas. A importância do diagnóstico anátomo-patológico preciso, do 
reconhecimento dos padrões dos adenocarcinomas e da carcinogénese bronco-pulmonar 
relacionada com biomarcadores com valor preditivo para terapia dirigida é salientada. 
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CHAPTER 1 – INTRODUCTION  
Lung bronchial pulmonary carcinomas are considered the most frequent cancer worldwide 
[1,2], responsible, in the USA, for 14 % of new cancer cases, and 28 and 26% of cancer related 
death, respectively in men and women. This makes it  a frequent type of cancer and the most 
important cancer related death cause for both genders [3]. 
Bronchial-pulmonary carcinomas are more frequently diagnosed in Western countries 
compared to developing countries. However, it is increasing in developing countries and 
amongst women; while a decline in males incidence rate in most Western countries reflects 
changes in smoking habits and environmental pollution, as well as the progressive 
improvement in life expectancy [4-6]. 
WHO classification for lung cancer recognizes the most important malignant epithelial tumours 
as: small-cell lung cancer, epidermoid carcinoma, adenocarcinoma, large-cell carcinoma 
including large-cell neuroendocrine carcinomas, adenosquamous and sarcomatoid carcinomas 
[6-8]. This classification also recognizes carcinoid tumours and salivary gland-like tumours 
[6,7]. 
Three preinvasive lesions are recognized:  squamous cell carcinoma in situ; atypical 
adenomatous hyperplasia and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
[6,7,9,10]. 
There is a strong association with tobacco consumption, describe mainly in small-cell lung 
carcinomas, epidermoid carcinomas and adenocarcinomas [11]. Relative risk for lung cancer 
development is 8 to 15 times higher among male smokers and 3 to 10 times higher in women 
smokers, when compared to non-smokers [12]. It is estimated that about 85% and 45% of 
bronchial-pulmonary carcinomas diagnosed in men and women respectively are related with 
tobacco exposure [13,14]. The dose and duration of exposure is also important [11]. The risk of 
bronchial-pulmonary carcinomas reduces rapidly with tobacco cessation in about 5 years and it 
nears the risk of non-smokers in about 20 years [11]. Involuntary exposure to tobacco 
increases the lung cancer risk by about 25% [15-17]. Other factors have been associated with 
the risk of bronchial-pulmonary carcinomas development such as exposure to asbestos, silica, 
radon, heavy metal and polycyclic aromatic hydrocarbon [18]. 
 
Major Histological Types: 
 
Epidermoid / squamous cell lung carcinoma is defined as a carcinoma originating in the 
epidermoid bronchial epithelium, and which reveals keratinisation and/or intercellular bridges 
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[6,7]. Differentiation is defined upon the relative presence or absence of those features. 
Therefore, these tumours should be classified as well or poorly differentiated. Papillary, clear 
cell, small cell and basaloid variants are recognized [6,7,19-27]. Survival is usually better when 
compared to adenocarcinomas [28]. Prognosis is especially related on clinical/pathological 
staging. Poorly differentiated epidermoid carcinoma are associated with earlier metastatic risk 
and with a worse behaviour/prognosis when compared to well differentiated tumours [7]. In 
some countries it is still the most frequent lung carcinoma [29] It has the strongest relationship 
with tobacco, and its incidence is greater in men, with a ratio of between 6.6 to 15 men / 1 
women [30-33]. Squamous carcinoma in situ, following squamous dysplasia is considered the 
precursor lesion [6,7,34,35].The segmental and lobar bronchi are the most frequently affected 
[36]. 
 
Macroscopically it consists of firm (according to the extent of stromal fibrosis) white masses 
with imprecise limits. Necrosis and cavitation are present in bigger lesions. Central tumours 
may form masses with endoluminal growth and/or direct invasion of the bronchial wall and 
lung parenchyma. Some cases (a minority) are diagnosed in the peripheral airways [6,7,36]. 
Well differentiated epidermoid carcinomas have clear keratinisation features such as keratin 
pearls, cellular pearls and intercellular bridges. These features are absent or focally present in 
poorly differentiated epidermoid lung carcinomas. 
 
The papillary variant frequently exhibits endobronchial growth with intra-epithelial 
dissemination and bronchial wall invasion [19,20]. 
The clear cell variant has clear cells which constitute the major feature [21,22]. 
 
When a carcinoma is made of small cells with focal epidermoid/squamous differentiation, a 
small cell variant of the epidermoid lung carcinoma is considered in the diagnosis. Differential 
diagnosis, of this poorly differentiated carcinoma, must be made with small cell lung 
carcinoma combined with epidermoid carcinoma. Irregular or vesicular chromatin and 
prominent nucleoli of epidermoid carcinoma are important for the differential diagnosis, as 
well as large cytoplasm and defined cellular limits present in this variant [6,7,23-25]. 
The basaloid variant shows nuclear palisading. If squamous differentiation is not identified, 
these tumours should be diagnosed as the basaloid variant of large cell carcinoma [6,7,26,27]. 
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Epidermoid carcinoma shows high weight cytokeratin positivity, such as CK5, CK6 and 34BE12, 
and also expresses CEA. Fewer cases may express CK7 and even TTF1 (thyroid transcription 
factor 1) [21,37-41], which may indicate adenosquamous differentiation at cellular level.  
 
Adenocarcinoma diagnose is made when a malignant epithelial tumour has glandular/acinar 
differentiation or demonstrate production of mucin [6,7,42]. This type is the most common 
cancer in non-smokers and its incidence has increased in the past years. There is apparently a 
relationship between adenocarcinoma and pulmonary scars. Adenocarcinomas are usually 
localized/developed peripherally from terminal airways and alveolar epithelial cells [6,7,42,43]. 
Adenocarcinomas are sub-classified according to the following patterns: acinar, papillary, 
micropapillary, BA (bronchioloalveolar)/lepidic, solid with mucin production and mixed type 
[6]. Differences between subtypes should be taken into account to improve diagnosis, 
prognosis and the selection of treatment [7,8,43].  
Non-BA/non lepidic adenocarcinoma is usually a peripheral tumour that can have different 
growth patterns. The mixed sub-type is the most common histological pattern in the WHO 
classification [6,7], of which there are at least two individual patterns: the solid or acinar type 
occurs most frequently in the centre, with a BA/lepidic pattern at the periphery [6,7]. When an 
adenocarcinoma has only on pattern, this is more frequently acinar type [6,7]. Also, acinar 
pattern is considered the most frequently subtype present in mixed adenocarcinomas [6,7]. 
Papillary patterns are present in 10% of adenocarcinomas [7]. Sometimes, it is difficult to make 
a clear distinction between papillary adenocarcinoma and BA/lepidic pattern. The important of 
this  distinction lie on implications for therapeutic strategies [42]. The micropapillary type has 
small cellular clusters projected and growing from alveolar septa or present/floating within 
alveolar spaces. The small papillary like cellular structures do not have fibro vascular cores. It is 
observed in papillary adenocarcinomas but also in mixed type tumours, and metastasizes 
earlier, with less favourable prognosis [42]. Solid pattern adenocarcinoma accompanied of 
mucin (solid adenocarcinoma with mucin) production is represented in 15% of mixed-type 
adenocarcinomas [6,7,42]. BA/lepidic tumoural cells grow alongside alveolar septa with aerial 
spread through the pulmonary lobules. It is frequently diagnosed in women, young and non-
smoking patients [6-8,42,44].  
The incidence rate differs according to gender, with roughly 28% occurring in men and 42% in 
women. A new classification was developed by the International Association for the Study of 
Lung Cancer, the American Thoracic Society and The European Respiratory Society 
(ATS/ERS/IASLC) [8]. It recognizes several patterns, such as lepidic /BA, acinar, papillary, solid, 
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and micropapillary [8]. It also recognizes mucinous adenocarcinomas including the former 
mucinous BA carcinomas and colloid carcinomas [8]. 
 
This ATS/ERS/IASLC recognizes new categories such as AIS (adenocarcinoma in situ) and MIA 
(minimally invasive adenocarcinomas) [8]. According to this proposed classification, 
preinvasive lesions include AAH and AIS [8]. AIS correspond to the formers ≤3cm non-
mucinous BA carcinomas while minimally invasive adenocarcinomas (MIA) are similar 
(carcinomas ≤3cm) but with an invasion area of ≤5mm; hence, it is an adenocarcinoma with a 
predominantly lepidic pattern with a small area of invasion (≤5mm) [8]. 
Some recommendations were made in this newly proposed classification. These included: 
discontinuation of the term BAC; the use of these new categories; classification according to 
the predominant pattern with reference to the % of each pattern present in 5% increments; 
apply the terminology LPA (lepidic predominant adenocarcinoma) for the former mixed-type 
adenocarcinomas with non-mucinous BA pattern predominance [8]. It also highlighted the 
need for as assertive diagnosis especially in biopsy material, supported by 
immunohistochemistry, with clinical, prognostic and therapeutic implications [7,8,45,46]. For 
personalized treatment, it is important to differentiate between adenocarcinoma and 
epidermoid carcinoma and to restrict the use of NSCLC terminology [8]. 
 
This classification system also recognizes the importance of pattern identification with 
prognostic implications. Solid and micropapillary patterns are associated with a worse 
prognosis, while acinar and papillary tend to indicate an intermediate prognosis, and non-
mucinous lepidic / BA pattern a good prognosis [8]. 
The WHO classification also recognizes bronchial-pulmonary carcinomas other than 
adenocarcinoma or epidermoid carcinoma, such as small cell carcinoma (pure or in 
combination), large cell carcinoma (including combined, basaloid, lymphoepithelioma-like and 
clear cell carcinomas as well as large cell carcinoma showing rhabdoid features/phenotype), 
adenosquamous, and sarcomatoid carcinomas (including spindle and giant cell carcinomas,  
pleomorphic carcinoma, carcinosarcomas and blastomas), typical and atypical carcinoids and 
salivary gland type neoplasia such as mucoepidermoid carcinoma, adenoid cystic and 
epithelial-myoepithelial carcinomas [6,7]. 
 
Large cell carcinomas (LCC) are undifferentiated bronchial-pulmonary carcinomas that lack the 
morphological and cellular features of the small cell carcinoma, glandular and 
epidermoid/squamous features [6,7]. It is an exclusion diagnosis. Large cell neuroendocrine 
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carcinomas have NE phenotype with cells organized in trabeculae or as rosettes, defining the 
so called organoid morphology [6,7], and may be combined with adenocarcinoma, 
epidermoid/squamous cell carcinoma, or spindle /  giant cell carcinomas [6,7,47]. 
 
Adenosquamous carcinoma (ADSQC) has compound features of epidermoid/squamous cell 
carcinoma and of adenocarcinoma [6]. To make this diagnosis, the squamous and 
adenocarcinoma components must comprise at least 10% of the total tumour [6,7,48-52]. 
Their frequency varies between 0.4-4% of lung carcinomas. The incidence is said to be 
increasing alongside the increasing incidence of the adenocarcinoma [6,7,48,50,52-56]. 
 
Sarcomatoid carcinomas are bronchial-pulmonary lung carcinomas with a sarcoma or 
sarcoma-like (spindle and/or giant cell) differentiation. Pleomorphic Carcinoma, Spindle Cell 
Carcinoma, Giant Cell Carcinoma, Carcinosarcoma and Pulmonary Blastoma are considered as 
sarcomatoid carcinomas [6,7]. 
These are rare tumours, representing only 0.3-1.3% of all lung malignancies [6,7,57-61]. The 
median age at diagnosis is 60 years, and there is a clear predominance of males, with a 
male/female ratio of approximately 4 to 1) [6,7,19,62-66]. Sarcomatoid lung carcinomas 
correspond to a poorly differentiated bronchial-pulmonary carcinoma, namely epidermoid 
carcinoma, adenocarcinoma or large cell carcinoma with areas with spindle cells and/or giant 
neoplastic cells or, to a carcinoma composed exclusively of spindle and giant cells[6]. The 
spindle or giant cell component should comprise a minimum of 10% of the tumour. 
Histological sections demonstrate conventional non-small cell carcinoma, like an 
adenocarcinoma, epidermoid or large cell subtypes, with at least 10% of spindle cells and/or 
giant malignant cells [6,7].  
 
Spindle cell carcinoma is defined as a carcinoma composed of only spindle malignant cells[6,7]. 
Giant cell carcinoma is defined as a carcinoma with highly pleomorphic malignant 
multinucleated or mononucleated giant cells. It is composed entirely of giant cells [6,7].  
 
Carcinosarcoma diagnose is made when a there is a combination of carcinoma and sarcoma; 
the last showing differentiated sarcomatous elements, like bone, malignant cartilage, or 
skeletal muscle malignant elements [6,7]. So, it is considered as a biphasic tumour, which 
means that there is a mixture of a bronchial-pulmonary carcinoma and a sarcoma component 
with differentiated elements [6,7]. The most frequently carcinomatous component identified 
in carcinosarcomas is epidermoid carcinoma (45-70%) [6,7]. The second most frequent 
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carcinomatous component is adenocarcinoma (20-31%), followed by large cell carcinoma 
(representing only 10%) [6,7,67]. 
 
Neuroendocrine tumours comprise: carcinoid tumours, small cell lung carcinoma and large cell 
neuroendocrine carcinoma. Carcinoid tumours morphologically demonstrate typical pattern 
growths, such as rosette-like, organoid, insular, trabecular, ribbon formations and palisading 
[6,7]. These patterns, when present in a tumour, are characteristic or suggestive of 
neuroendocrine differentiation. Tumour cells are relatively uniform. Cytoplasm is frequently 
finely granular and eosinophilic [6,7].  The nucleus shows a characteristic finely granular 
chromatin pattern [6,7]. Carcinoid tumours without necrosis and with less 2 mitoses per 2 
mm2 are diagnosed as typical carcinoid (TC) [6,7].  If there are foci of necrosis and if mitotic 
count is higher (2-10 mitoses per 2 mm2), the carcinoid tumour is classified as atypical [6,7]. 
 
Small cell carcinoma (SCC) is a malignant epithelial tumour with small cells with nuclei 
containing fine granular chromatin [6,7]. Nucleoli are very small or absent. It also has 
neuroendocrine differentiation, necrosis and are characterized by high mitotic index [6,7]. It is 
an aggressive neoplasia that can be combined with adenocarcinomas and / or epidermoid 
carcinomas, large cell carcinomas and less frequently with sarcomatoid carcinomas [6,7,68]. 
 
Complementary Histological Types: 
 
Basaloid carcinoma shows a nodular or trabecular pattern, where peripheral cells have nuclear 
palisading [6,7]. Cells are generally small in size with scant cytoplasm, monomorphic with 
moderately hyper-chromatic nuclei, finely granular chromatin and small or no nucleoli, with a 
high mitotic rate [6,7]. Differential diagnosis is established with epidermoid carcinoma [7,27]. 
Basaloid carcinoma is considered as a LCC variant, with features that resembles basal cell 
carcinomas of the skin [6,7]. These tumours tend to have an endobronchial growth, and the 
adjacent mucosa shows epidermoid/squamous dysplasia. Basal or suprabasal bronchial cells 
are considered as the cells of origin [69,70]. 
 
Lymphoepithelial-like carcinoma (LELC) is a rare carcinoma characterized by syncytial growth 
pattern, large nuclei, prominent nucleoli, and dense lymphocytic infiltration [6,7,71-74]. It 
often presents with epidermoid differentiation [6,7]. These tumours are more frequently 
diagnosed in Asians, with association with EBV and less association with tobacco [6,7]. 
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Abundant lymphocytes and plasma cells surrounds the epithelial cells organized in a syncytial 
pattern [6,7]. Mitosis are frequent but tumour necrosis is rare [72-77]. 
 
Clear cell carcinomas have cells with clear cytoplasm with or without  glycogen [6,7]. Clear cell 
carcinoma is a rare, although almost one third of bronchial-pulmonary carcinomas and rare 
small cell carcinomas show areas with clear cell phenotype [22,78]. So, clear cell variants of 
adenocarcinoma and of SCC are recognized [6,7,22]. 
 
Large cell carcinoma with rhabdoid phenotype is characterized by the presence of rhabdoid 
cells in lung bronchial-pulmonary carcinomas including small cell carcinoma [79-85]. These 
cells contain eosinophilic cytoplasmatic globules (intermediary filaments), frequently positive 
for vimentin and cytokeratins. Pure forms are very rare [6,7,86,87], and bronchial-pulmonary 
carcinomas composed exclusively of rhabdoid cells are extremely rare. Thus, there need to be 
more than 10% rhabdoid cells to diagnose a bronchial-pulmonary carcinoma with rhabdoid 
phenotype [6,7,86,87]. Rhabdoid tumour cells demonstrate immunohistochemical positivity 
for vimentin, and usually for cytokeratin (often CK7 but not CK20) and EMA [83]. 
 
Large cell neuroendocrine carcinoma (LCNEC) corresponds to a large cell carcinoma with 
neuroendocrine histology/morphology and immunohistochemical or ultrastructure 
characteristics of neuroendocrine differentiation [6,7]. This type of tumour may arise in 
combination with other bronchial-pulmonary carcinomas, such as SCC, adenocarcinomas and  
sarcomatoid carcinomas [6,7].  
 
Pulmonary blastoma is diagnosed when there is an epithelial component similar to a fetal 
adenocarcinoma (well-differentiated) and a mesenchymal component with primitive features 
[6,7]. Thus it is considered as a biphasic tumour that sometimes shows small areas of 
chondrosarcoma, osteosarcoma or rabdomyosarcoma differentiation [6,7,66]. 
 
Mucoepidermoid carcinoma is a malignant epithelial tumour that resembles a salivary gland 
mucoepidermoid carcinoma [6,7]. The diagnosis relies in the identification of squamous cells, 
intermediate type cells and cells with mucin production [6,7]. These rare tumours represent 
less than 1% of the bronchial-pulmonary carcinomas [6,7,88-90]. There is equal distribution by 
sex, with a slight predominance in male gender, with a large age range, frequently diagnosed 
in younger patients, with less than 50 years [6,7,88-91]. 
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Adenoid cystic carcinoma is also a rare carcinoma (<1% of bronchial pulmonary carcinomas) 
that resembles its counterpart in salivary glands [6,7,61,92]. There are no differences 
according to gender and it is more frequently diagnosed in the fourth and fifth decades of life 
[6,7,61,92,93]. 
 
Epithelial-myoepithelial carcinomas are characterized by the presence of an epithelial duct-
forming component and of a myoepithelial cells component [6,7]. The last may show a spindle, 
plasmacytoid or clear phenotype. There could be a variable proportion of the two components 
[6,7]. 
 
Pre-Invasive Lesions: 
 
As has already been said, pre-invasive lesions include squamous cell in situ carcinoma and for 
adenocarcinomas, atypical adenomatoid hyperplasia (AAH) and the newly proposed 
adenocarcinomas in situ (AIS, formerly pure BA non-mucinous carcinomas) [6-8]. 
 
AAH is frequently recognized adjacent to lung adenocarcinomas [94-97]. Epidemiological and 
morphological features such as clonality, and other molecular changes like EGFR and KRAS 
mutations as well as TP53 methylation expression, have been described in both AAH and 
adenocarcinomas supporting pre-invasive lesions [6-8,98-102].  
AAH is defined as an epithelial proliferation with atypia, and lines the alveoli and respiratory 
bronchioles for less than 5mm with some gaps between the cells, generally without 
accompanying fibrosis and/or inflammation [6,7]. It is considered an adenocarcinoma 
precursor lesion [103].  
The incidence varies between 5.7% and 21.4% in patients with lung adenocarcinoma [6,7]. AAH 
is identified in 19% of women and 9.3% of men with lung bronchial-pulmonary carcinomas and 
in 30.2% of women and 18.8% of men with adenocarcinoma diagnose [6,7]. It is more frequent 
in smokers than in patients who have never smoked [94,104,105]. It is frequently an incidental 
finding, and forms nodules of up to 5mm, sometimes with more than 10mm [10,106]. AAH 
lesions can be multiple, especially in the peripheral lung parenchyma [6,7]. They are composed 
by a unique layer of cylindrical or cuboidal epithelial cells with mild to moderate dysplasia with 
inconspicuous nucleoli and dense chromatin [6,7,96,97]. 
The differential diagnosis includes the lepidic pattern of lung adenocarcinoma / in situ 
adenocarcinoma of the non-mucinous type, Type II pneumocytes (PII) hyperplasia and 
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papillary adenoma. The AIS / lepidic pattern of adenocarcinoma should be suspected when it is 
larger than 5mm, there are no gaps/spaces between the cells or if there are many pleomorphic 
nuclear features or nuclear stratification [6,7]. PII or Clara cells are believed to be the 
progenitor cells [6,7]. 
Different genetic and molecular alterations have been identified in AAH, such as KRAS, TP53, 
FHIT, P16INK4 and TSC mutations. KRAS mutations could be an earlier event [107-109]; 3p and 
9p allelic losses have also been diagnosed in AAH involving the FHIT (Fragile Histidine Triad) 
gene and P16INK [109-112]. Loss of heterozigoty (LOH) of the suppressor genes TSC1 (9q) and 
TSC2 (16p) (complex of tuberoses sclerosis) have also been described [113]. Chromosome 7 
aneuploidy or polyploidy is increasingly present from AAH till adenocarcinoma [114]. 
 
AIS, is defined as a localized adenocarcinoma of ≤ 3cm with non-mucinous lepidic growth, 
without papillary or micropapillary patterns of growth [6,8].   MIA (Minimally Invasive 
Adenocarcinoma) is defined as a localized adenocarcinoma of ≤ 3cm with lepidic predominant 
growth, with > 5mm invasion area [6,8]. 
 
Squamous dysplasia and squamous cell carcinoma in situ are considered to be preinvasive 
lesions. Basal cell hyperplasia and squamous metaplasia are recognized as non-preinvasive 
precursor lesions [6,7]. Respiratory epithelium squamous metaplasia is related to a history of 
smoking as well as to chronic inflammations, as seen in asthma, chronic obstructive pulmonary 
diseases or chronic irritant exposures [115-118]. Squamous dysplasia and CIS may or may not 
exist in association with epidermoid carcinoma. Generally asymptomatic, they are more 
frequent in smokers, males and in association with chronic obstructive pulmonary diseases 
[34,119,120]. 
Squamous dysplasia should be classified as mild, moderate or severe, taking into account the 
epithelial layers affected by nuclear changes, cellular loss of orientation, absence of superficial 
maturation and mitosis level [6,7].  
Mild dysplasia shows discrete nuclear size increase, fine granular chromatin, small nucleoli or 
their absence, vertical nuclear orientation and rare mitosis [6,7]. These alterations are 
observed in the lower third of the epithelium [6,7]. Moderate dysplasia shows maturation 
limited to the upper third, higher nuclear pleomorphism and mitosis. Severe dysplasia exhibits 
marked pleomorphism and prominent nucleoli, with cellular maturation only in the most 
superficial cells; mitoses are identified in the lower two thirds of the epithelium [6,7]. CIS loses 
nuclear orientation as well as superficial cell maturation; mitoses are identified in all layers 
[6,7]. 
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Basal cells have been considered as the precursor cells for squamous metaplasia and dysplasia 
[9]. 
Frequent cytogenetic changes include aberrations to chromosome 3 and 7 number, 3p, 9p21, 
8p21-23, 13q14 (RB), 17p13 (TP53) LOH, and 5q21 (APC-MCC region) LOH are detected mainly 
in CIS [114,121-125]. 3p LOH was detected in larger regions in CIS when compared to earlier 
lesions, and may involve the entire 3p arm [124,126]. TP53 mutations can be identified in the 
different phases of the sequence [124,125,127]. P16INK4a hypermethylation was identified, 
increasing from basal cell hyperplasia to CIS [128]. Telomerase higher expression was also 
found in more severe lesions [129]. Dysplasia frequently shows LOH 8p22-24 and TP53 
inactivation while CIS and subsequent invasive epidermoid carcinomas show KRAS mutations 
and 5q22 LOH [7]. 
 
Another preneoplastic lesion is DIPNECH (Diffuse Idiopathic Neuroendocrine Cell 
Hyperplasia). It is considered a neuroendocrine cell proliferation with linear distribution or 
forming small nodules, defined as neuroendocrine bodies [6,7]. Neuroendocrine cell nodules 
of 2 to 5mm are classified as tumourlets, while those bigger than 5mm are called carcinoid 
tumours [6,7]. DIPNECH, tumourlets and carcinoids form a lesion continuum [130-133].  
 
Bronchial-Pulmonary Carcinoma Carcinogenesis: 
 
Improvements in diagnostic molecular techniques and the growing knowledge related to 
carcinogenesis have contributed to the recognition of diagnostic markers of early lung 
bronchial-pulmonary carcinomas. Allelic losses (LOH), chromosomal instability, epigenetic gene 
silencing, proto-oncogenes activation, loss of tumour suppressor and DNA repair genes have 
been described in bronchial-pulmonary carcinogenesis [110,134,135]. 
Some of this genetic of molecular changes are considered as early events during bronchial-
pulmonary carcinomas development [136]. 
Lung carcinogenesis is a multicentre, multiphase process with the sequential accumulation of 
molecular and genetic alterations.  It may be caused by smoking, environmental and 
occupational factors, diet (low ingestion of vitamin A and antioxidant micronutrients), family 
and genetic factors (several epidemiologic studies indicate, in some cases, a family and 
individual susceptibility to lung cancer) and lung injury (caused by non-infectious pulmonary 
and systemic diseases, such as chronic obstructive pulmonary diseases and inflammatory or 
fibrotic pulmonary diseases) [42]. 
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Uncontrolled growth is the result of an imbalance between oncogene activation (by mutations, 
amplification, overexpression or rearrangement) and the inactivation of suppressor genes, 
transcription genes and genes involved in DNA repair (mutations, LOH or by aberrant promoter 
methylation) that inactivate or activate four or five different signal transduction pathways 
[137,138]. 
Studies have improved the knowledge related to specific individual genetic pathways or 
molecular events, frequently according to histology subtype. However, carcinogenesis is very 
complex and there is less knowledge related to different pathways or genetic/molecular 
events interactions and of their importance to cancer development and progression. 
Identification of molecular events associated with progression and metastasis would be of 
great relevance. Also, the identification of one or more molecular events altered in early 
phases of cancer development would be of great importance, as an opportunity for early 
diagnosis approaches.  
 
Oncogenes and signal transduction 
Oncogenes are involved in cellular signalling through overexpression or by activating 
mutations [137,139]. 
Growth factors influence cell proliferation, differentiation, survival and apoptosis [137,139-
141]. Extracellular ligands bind to specific receptors, activating messengers in the cytoplasm 
and nuclear transcription factors [140,141]. The activation and inactivation of proteins occurs 
through reversible phosphorylation of tyrosine, serine, or threonine residues made by tyrosine 
kinases and serine/threonine kinases.  There are several classes of receptors including receptor 
tyrosine kinases, G-protein–coupled receptors, and cytokine receptors [137,139]. Molecules in 
the cytoplasm are responsible for signal transduction, acting as “second messengers” 
[137,139]. There is overlap/cross-talking in cell signalling, resulting in redundancy [137,139]. 
Adaptor and scaffolding proteins coordinate signalling cascades [137,139]. 
Membrane Tyrosine Kinase Receptor (RTK) contains different domains, such as  an 
extracellular (for ligand binding), a transmembrane, justamembrane, protein tyrosine kinase, 
and cytoplasmatic domains [137,139]. Ligand binding is responsible for tyrosine kinase 
activation, after the formation of dimmer or oligomer [137,139]. 
RTK alterations are related to cancer development in several ways. Expression of both the 
receptor and the ligand (growth factor) could explain a autocrine loop, favouring tumour 
development and progression [137,139]. Growth factors also act in a paracrine mode 
[137,139]. High gene copy number, by amplification, and overexpression of the receptor are 
also responsible for cancer development (as for EGFR, ERBB2/HER2, and MET ) [137,139]. 
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Gene mutations affecting the tyrosine kinase domain are also implicated, as the receptor is 
constitutively activated even in the absence of the growth factor [137,139]. The RET gene is 
activated by rearrangement [137,139]. MET is associated with cancer development by protein 
overexpression and/or by gene activating mutations [137,139]. Genetic rearrangements are 
also responsible for receptor activation (PDGF-α and ALK), with the resulting fusion proteins 
with constitutively activated TK domain [137,139]. 
 
EGFR 
The erbB family includes EGFR/ErbB-1, HER2/ErbB-2/neu-2, HER3/ErbB-3, and HER4/ErbB-4 
[137,142]. Activation occurs upon ligation to one of the eight known growth factors, like EGF 
and transforming growth factor α (TGF-α) [142]. After ligand attachment, receptor 
dimerization leads to tyrosine auto phosphorylation and activation [137,142]. 
Heterodimerization is important allowing the activation of different signal pathways[142].  
EGFR dysregulation occurs by the overexpression of the ligand, EGFR, or both, and by 
mutations, these last responsible as already said for the constitutive activation [137,142]. 
HER2 does not bind to ligands acting mainly as a co-receptor increasing the ligand affinity of 
the other receptor forming the dimmer [142]. Interactions between EGFR and other different 
receptors (endothelion-1/thrombin/LPA) may also be implicated in EGFR activation [142].  
EGFR is responsible for the activation of different signal transduction cascades. Phosphorylated 
EGFR activates several molecules, such as SRC, SH2, SHP2, GRB2, phosphatidylinositol 3-kinase 
(PI3K), AKT, phospholipase C-γ (PLC-γ), and the STAT transcription family [142]. A 
RAS/RAF/Mitogen-Activated Kinase (MAPK) pathway is activated via GRB2 [142]. EGFR also 
activates the PI3K pathway, important in cancer development and at controlling the 
progression on cell-cycle [142]. PI3K/AKT pathway downregulates p27 (a cell-cycle inhibitor) 
[142]. EGFR activation could be responsible for VEGF upregulation, by activation of PI3K [142]. 
EGFR has relevance in the control of several important cellular functions with implications on 
cell  proliferation and  survival, angiogenesis, invasion capabilities with metastasis 
development [142].  
EGFR mutations occur in approximately 24% of unselected bronchial-pulmonary carcinomas 
and are more common when there is an adenocarcinoma histology, and amongst never-
smokers, East Asians and women [137]. EGFR activating mutations are related with tumour 
sensitivity to TKIs, such as gefitinib (Iressa), erlotinib (Tarceva) [137,142]. Activating  mutations 
occur frequently in exons 18 to 21 and are categorized as deletions, missense point mutations, 
and insertions [137]. T790M mutation (“second mutation”) confers resistance to TKIs [137]. 
T790M mutation can also be found in patients not yet submitted to TKI therapeutics  [137]. 
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Other predictive molecular events have been correlated with TKI response, such as  EGFR 
protein overexpression,  EGFR gene high copy number by amplification, and activation of Akt 
[137]. On the other hand, amplification of c-Met has been related to TKI resistance [137,143-
147]. Some studies demonstrated selective transduction of survival pathways, such as Akt and 
STATs, by EGFR activation mutation [137]. EGFR mutated tumours are more sensitive to 
radiation [137]. 
 
 
Figure 1: Effects of EGFR signal transduction events. Adapted from: Brambilla, E.; Gazdar, A. 
Pathogenesis of lung cancer signalling pathways: roadmap for therapies [148]. 
 
 
HER2 
Activation of HER2 depends on dimerization with other members of the erbB family [142]. 
Heterodimers of HER2-HER3 are considered to have potent mitogenic activity [142]. We know 
that neuregulin (NRG) and heregulin (HRG) are ligands responsible for the activation of HER3 
and HER4 [142]. HER2 is responsible for the increase of affinity for the ligand of the other 
receptor, partner of dimerization, with implications in promotion of increased activation of 
intracellular molecular pathways [142]. 
The greatest progress in HER2-targeted therapies have been related to the use of specific 
monoclonal antibodies (trastuzumab – Herceptin) against the extracellular portion of the HER2 
receptor [142]. HER2 mutations occur in approximately 2% of bronchial-pulmonary carcinomas 
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as in-frame insertions in exon 20 [137]. HER2 mutations frequently occur in female gender, 
non-smokers,  Asians patients  diagnosed with adenocarcinomas [137].  
 
FGFR1 
FGFRs are part of the family of receptor tyrosine kinases and are encoded by 4 genes that are 
located on chromosome 8p11.23 – FGFR1, FGFR2, FGFR3 and FGFR4 [149-151]. Twenty two 
Fibroblast growth factors (FGFs) are known until today [149-151].  
FGFR1 is one of the most important members of this family of receptors, with tyrosine kynase 
features [149,152]. Activation of the receptor, by FGFs with subsequent dimerization, is 
responsible for the activation of different signalling pathways, such as PI3K-AKT, RAS-MEK-
MAPK, STAT, SRC and PLC [149,152].  Functions associated with FGFR1 activation include cell 
growth, differentiation, and survival mechanisms control [149,152]. Epithelial-mesenchymal 
transition (EMT) could also be induced by FGFR1 upregulation [68,153-156].  
 
 
Figure 2: Molecular pathways activated by FGFR1. Adapted from Larsson H, Klint P, Landgren E 
and Claesson-Welsh. Biol Chem 274: 25726-25734, 1999 [152]. 
 
FGFR1 is also associated with the cell cycle control. By RB phosphorylation, promoted by CDK 
(ciclin dependent kinase), transcription factor E2F is released into the nuclei, where DNA 
replication is induced, favouring cell cycle progression [157]. It acts also by inhibition of CDKN 
(ciclin kinase inhibitor), such as p21, p27, p15, p16, p18, and p19 [157]. 
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Figure 3: FGFR1 and cell cycle control. Adapted from: Dombrowski C, Helledie T, Ling L, et al. 
(2013). Stem Cells 31: 2724-2736 [157]. 
 
 
By the control of these pathways, these molecules are engaged in the control of physiological 
processes. Deregulation of these mechanisms could be associated with cancer development 
[149-151]. 
Deregulation could be explained by different events, such as high levels of FGFR1 protein 
expression, which have been diagnosed in lung carcinomas [158,159], co-expression of FGF 
and FGFR1 [160-163], and amplification of the gene FGFR, also described in lung carcinomas 
[164]. 
Alterations of the FGFR gene have been recognized in many different epithelial malignant 
tumours, such as in gastric; breast; oral, ovarian, urothelial and lung carcinomas [165,166]. 
High FGFR1 protein expression, FGF and FGFR co-expression, and FGFR1 gene amplification has 
been described in lung bronchial-pulmonary carcinomas, especially on squamous cell lung 
carcinomas, while mutations are rarely found [158-163,165]. 
FGFR1 genetic alterations are potentially targetable mutations [167], as FGFR1 can be targeted 
by tyrosine kinase inhibitors [167]. Therefore, some authors consider that evaluation of FGFR1 
genetic alterations, such as gene amplification, should be considered in the genomic 
characterization of lung cancers [167]. 
It has been argued that FGFR1 amplification is associated with a response to FGFR inhibitors 
[165,168], and clinical trial investigation is ongoing concerning different FGFR1 inhibitor, such 
as BGJ 398 (Novartis), AZD 4547 (AstraZeneca), TKI 258 (Novartis - Ponatinib), and BIBF 1120 
(Boehringer-Ingelheim), with FGFR1 amplification as an molecular inclusion criteria [168-171].  
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c-KIT 
c-KIT and its ligand (stem cell factor (SCF)) could be overexpressed in SCLC [137]. However c-
KIT mutations are rarely identified in bronchial-pulmonary carcinomas [137]. There are 
therapeutic approaches related to the inhibition of c-KIT, such as Imatinib (Gleevec) [137]. 
 
RAS 
The RAS family is composed of several small proteins with GTPbinding capability, comprising  
HRAS, NRAS, and KRAS, with relevant functions controlling cellular differentiation,  
proliferation, apoptosis and survival [142]. 
Activating mutations, higher protein expression or decreasing in RAS GTPases are associated 
with RAS function deregulation [142]. RAS overexpression is postulated to be a late event in 
lung cancers [142]. RAS activating mutations are more frequently identified involving the 
amino acids 12, 13, 59, and 61 [142]. Other mechanisms responsible for RAS activation include 
the increased stimulation by upstream mediators, related to activating EGFR mutations and, c-
MET, and platelet-derived growth factor receptor (PDGFR) mediated activation [142]. 
RAS activating mutations are described bronchial-pulmonary carcinomas (10%–15%), mainly 
with adenocarcinoma histology, in which the incidence range from 20% to 30%, and are rare in 
small cell carcinomas [137]. Activating RAS mutations are more frequently identified at codons 
12, 13, and 61 [137]. Almost 70% of the KRAS mutations are G-T transversions, related with 
tobacco [137]. KRAS mutations are associated to EGFR TKIs resistance [172-174]. Farnesyl 
transferase inhibitors (FTIs) (such as Tipifarnib and lonafarnib) are the most widely studied 
drugs for targeting KRAS mutated tumours. 
 
c-MET and c-MET-HGF/SF  
The tyrosine kinase receptor c-MET has the hepatocyte growth factor (HGF)/scatter factor (SF) 
as its ligand [142]. The c-MET-GF/SF signalling pathway has implications for angiogenesis 
induction, embryonic and organ development, cellular proliferation,  motility, and invasive 
cellular features [142]. c-MET  overexpression has been described in bronchial-pulmonary 
carcinomas [142]. c-MET activating point mutations are associated with the presence of 
constitutively activated receptors in several tumours [142]. c-MET amplification is associated 
to EGFR TKIs resistance [143,144,175]. 
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SRC Kinase Family 
The SRC family include eight members with functions regulating  proliferation, apoptosis, 
angiogenesis and invasiveness, affecting matrix proteases and decreasing cell adhesion by 
phosphorylation of cadherin with decrease of  cadherin-catenin association [142].  
Activation of SRC is mediated by c-MET, HER2, EGFR and by SRC activating mutations on the 
catalytic region [142].  
 
c-MYC  
MYC family includes c-Myc, b-Myc, l-Myc, n-Myc, and s-Myc [142]. The c-Myc proteins have 
functions in proliferation, growth, apoptosis, and  differentiation [142].  
c-Myc may be activated by translocation, as occurs with lymphomas, by increased gene copy 
number (amplification), by higher protein expression or by deregulation of transcription 
mechanisms [142]. MYC amplification is identified more frequently in SCLCs (ranging from 18% 
to 31%) compared to other  bronchial-pulmonary carcinomas (ranging from 8% to 20%) [137]. 
Occurrences of c-MYC point mutations have been identified [142]. l-Myc high expression is 
described mainly in small cell lung carcinomas [142]. 
c-Myc are implicated in cell cycle control, especially controlling transition G1-S phases, by 
interacting with Cyclins / CDKs and their inhibitors [142]. Myc acts by inducing  higher 
expression of Cyclin A and E with CDK activation [142]. It is also responsible for the 
downregulation of p27 and p21 (CDKs inhibitors) [142]. Transition G1-S phase is also 
dependent on the inactivation of RB with E2F release [142]. Myc also target genes implicated 
in the control of cellular growth [142]. 
 
PI3K/Akt/PTEN/mTOR  
Activation of phosphatidylinositol–3-kinases (PI3Ks) pathway is associated with stimulation of 
cellular growth and proliferative activity, apoptosis control and cytoskeletal rearrangement 
[137]. It acts by the activation of downstream effectors, such as AKT/Protein Kinase B (PKB) 
[137]. As tumour suppressor gene, PTEN controls negatively AKT, loss of PTEN function is 
associated with PI3K/AKT pathway activation  [137]. PTEN is infrequently mutated in lung 
cancer, but reduced or non-existent expression of PTEN protein is common [137].  
 
STATs 
There are seven known members of STAT (signal transducers and activators of transcription): 
STAT1; STAT2; STAT3; STAT4; STAT5A; STAT5B and STAT6 [137]. STAT 3 and STAT5 activation 
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are associated with induction of a proliferation and with a negative control of apoptosis, 
mediated by BEL, MYC and Cyclin D1 [137]. 
 
Tumour suppressor genes  
Tumour suppressor gene products are associated with diverse cellular functions. Some act as a 
transcription factor, such as p53, other are known to downregulate other transcription factors 
, such as RB, other act regulating ubiquitin-mediated degradation of molecules by activating 
ubiquitin ligases, inducing the degradation of oncogene products, such as APC-β-catenin or by 
inhibiting ubiquitin ligases, reducing the degradation of tumour suppressor gene products 
[137,138]. Other (GTPases) are responsible by the inhibition of G-coupled proteins and DNA 
repair, such as MSH2, MLH1, ATM and BRCA1 [137,138]. Other tumour suppressor gene 
products include cytoskeleton and adhesion molecules (such as E-cadherin, α-catenin, NF2 and 
RASSF1), and molecules that are responsible for histone changes like Men1 that is a histone 
methylase associated with transcription silencing  [137,138]. Some tumour suppressor gene 
products act as protein kinases (LKB1) or as kinase inhibitors like PTEN, which is responsible for 
PIP3 degradation [137,138]. Tumour suppressor genes functions are important in transduction 
pathways, cell cycle and apoptosis control [137,138]. Mutations, insertions, deletions, and 
missense mutations, with inactivation of functions, could also be registered in tumour 
suppressor genes [137,138].  
 
Inactivation of Tumour-Suppressor Genes 
Tumour-suppressor pathways, such as p53 and p16-Cyclin D1-CDK4-Rb, are frequently 
inactivated in lung cancer [137].  It is described an increased expression of p53 upon DNA 
damage, with cell cycle arrest, followed by DNA repair or by apoptosis if the DNA damage is 
not repaired [137]. These mechanisms are mediated by p21/WAF/CIP1p53, BAX and GADD45 
[137]. p53 is altered in ≈90% of SCLCs and ≈50% of bronchial-pulmonary carcinomas, especially 
due to missense point mutations (70%–80%), and homozygous deletions [137]. In lung 
bronchial-pulmonary carcinomas, it is frequently only present the mutated TP53 allele, due to 
the deletion of the wild-type TP53 allele [137]. The loss of p53 wild-type function could be 
related with the heterodimer formation with mutant p53 forms [137]. Reacquisition of p53 
wild-type function is associated with apoptosis, even if tumour cells harbour a mutant TP53 
allele [137]. p53 pathway is regulated by MDM2 and p14ARF [137]. MDM2 induces p53 
degradation (by proteosome), reducing p53 levels [137]. It has been described MDM2 
increased gene copy numbers by amplification in approximately 7% of bronchial-pulmonary 
carcinomas [137]. On the other hand, p14ARF gene product binds to MDM2, preventing p53 
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degradation with p53 stabilization [137]. A decreased expression of p14ARF has been 
described in approximately 40% of the bronchial-pulmonary carcinomas and over 50% of small 
cell carcinomas [137].  
P16, Cyclin D1, CDK4 and RB have important functions in control of G1-S phases transition 
[137]. The complex Cyclin D1/CDK4 is responsible for RB phosphorylation, with the consequent 
release of E2F, and G1-S transition [137]. Decrease of RB protein or RB mutations have been 
described especially in SCLC (90%) and is less frequent in bronchial-pulmonary carcinomas 
(ranging from 15% to 30%), and are associated with G1-S checkpoint loss [137]. p16INK4 acts 
by inhibiting RB phosphorylation, mediated by CDK4 [137]. p16INK4 decreased levels or 
inactivation are frequently observed in bronchial-pulmonary carcinomas (≈70%), and are rare 
in small cell carcinomas [137]. RB pathway inhibition could be also related to higher CDK4 
expression and Cyclin D1 expressions [137]. Cyclin D1 overexpression and CDK4 amplification 
have been described in bronchial-pulmonary carcinomas (over 40% and approximately 2% 
respectively) [137]. Cyclin D1  overexpression is frequently associated with smoking [137]. 
 
 
Figure 4: Inactivation of tumour suppressor genes. Adapted from: Brambilla, E.; Gazdar, A. 
Pathogenesis of lung cancer signalling pathways: roadmap for therapies [148]. 
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The 3p Tumour Suppressor Genes 
Genetic alterations involving 3p region are frequently described  in bronchial-pulmonary 
carcinomas (>90%), including deletions and loss of heterozygosity  (LOH), considered as an 
early genetic event in cancer development [137]. Different regions have been identified, 
including 3p14.2 (FHIT/FRAB3), and 3p12 (ROBO1/DUTT1) regions [137]. In the 3p21.3 region, 
25 genes were identified, including FUS1, RASSF1A, TSGs, NPRL2, SEMA3B, SEMA3F and 101F6 
[137]. Alterations in 3p region are described in normal bronchial epithelium, caused by 
smoking [137]. These genes are implicated in control of the apoptosis, cell cycle, angiogenesis 
and proliferations control [137]. 
 
Cell Cycle control 
Cell cycle control deregulation has major importance in cancer development. Five phases are 
recognized: G0 phase (rest phase), G1 phase (allowing the cell to prepare DNA synthesis), S 
phase (DNA synthesis engaged phase), G2 phase and M phase (mitosis phase) [140,141]. Cell 
cycle control is dependent on complexes CDKs (Cyclin Dependent Kinases) with Cyclins 
[140,141]. Cell cycle checkpoints are important preventing cell division when damaged DNA is 
present, thus preventing transmission of damaged DNA to daughter cells, by allowing 
reparation or by the induction of apoptosis [140,141]. There are three important checkpoints:  
G1–S, S-phase and G2–M checkpoints [140,141]. The cell cycle is initiated by growth factor 
signalling [140,141]. RB phosphorylation during G1 phase is induced by Cyclin D1 and CDK4 or 
6 complexes and by Cyclin E and CDK2 complexes before the S phase [140,141]. CDK inhibitors 
(p16INK4, p21WAF1 and p27) control Cyclin–CDK complexes [140,141]. Other Cyclins are 
involved in control of the cell cycle, such as Cyclin A acting in the mitosis phase and in the 
transition G1-S phase, and Cyclin B associated with the transition to mitosis [140,141]. 
When DNA damage is present, p53 (as guardian of the genome) is responsible for stopping the 
cell cycle, allowing DNA repair or inducing apoptosis if the DNA error is not repairable 
[140,141]. p53 arrests the cell cycle, activating p21WAF1 [140,141]. The cell cycle control 
depends also of RB [140,141]. Cell cycle control deregulation could be related to loss of p53 or 
RB function as well by alterations involving other gene products , such as p16, p14, CDKN2A, 
and  MDM2 [140,141]. 
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Figure 5: Cell cycle control. Adapted from: Brambilla, E.; Gazdar, A. Pathogenesis of lung cancer 
signalling pathways: roadmap for therapies [148]. 
 
Apoptosis 
Apoptosis is defined as the programmed cellular death [176,177]. Cell death types include 
apoptosis, necrosis, autophagy, paraptosis, and autoschizis [176,177]. There are some 
interactions between these mechanisms, and the inactivation of one type could lead to the 
activation of another type of cell death [176,177].  
Apoptotic pathways are classified generally as intrinsic (mitochondrial) and extrinsic (receptor 
pathway). A third pathway is observed in T cell-mediated cytotoxicity [176,177]. The three 
pathways share a terminal part, that depends on caspase 3 and 7, leading to several cellular 
events, including protein degradation, DNA fragmentation, apoptotic bodies formation and 
phagocytosis promotion [176,177]. 
The BCL protein family has relevant functions in apoptosis control [176,177]. Some members 
are anti-apoptotic (such as BCL2) and others demonstrated pro-apoptotic proprieties (such as 
BAX/BAD/BAK and BOK) [176,177].  The balance between proteins with pro-apoptotic and 
anti-apoptotic functions are related to the response to apoptotic stimuli [176,177].  
Cancer cells have the capability to evade apoptosis [137]. As already said, p53 and BCL2 are 
two most relevant gene products related to apoptosis pathway control [137]. BCL2, 
responsible for apoptosis inhibition, is overexpressed in bronchial-pulmonary carcinomas 
(ranging from 10% to 35%) and in the majority of SCLCs (ranging from 75% to 95%) [137]. BCL2 
inhibitors are being studied to explore this pathway [137]. 
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DNA repair pathways 
DNA repair has important implications in cancer. Deficient DNA repair function allows genomic 
instability [137,178]. DNA repair impairments could also explain the increased sensitivity of 
tumour cells to radiation and chemotherapy [137,178]. DNA damage could be related to 
spontaneous hydrolysis, cytosine deamination, mismatched bases, and secondary to reactive 
oxygen species (ROS) [137,178]. Also, anticancer agents, such as alkylating agents and 
bleomycin, are responsible for DNA breaks [137,178]. Six different mechanisms are involved in 
DNA repair, and when one is impaired another is frequently upregulated [137,178]. The six 
mechanisms are: mismatch repair (MMR), homologous recombination (HR) and 
nonhomologous end joining (NHEJ), translesion DNA synthesis (TLS), base excision repair (BER), 
and nucleotide excision repair (NER) [137,178].  
Some DNA repair pathways (BER and NER) have important chemotherapeutic implications, as 
are responsible for the DNA bases changes repair, induced by alkylant agents [137,178].  
Knowledge of the level of DNA repair activation or inhibition could be used to evaluate the 
potential response to chemotherapy and to define the best chemotherapy combination 
schemes [137,178]. For example, BRCA1 expression levels are considered as a survival 
biomarker in patients diagnosed with bronchial-pulmonary carcinomas treated with cisplatin-
based chemotherapy agents. Patients with lung cancer with lower ERCC1 levels revealed 
higher cisplatin sensitivity compared to those with high ERCC1 expression [137,178].  
DNA repair biomarkers could be useful to identify tumours resistant to radio or chemotherapy 
and in the selection of drugs that could selectively inhibit repair pathways/function as chemo 
sensitizers [137,178]. 
Genomic instability is frequent in cancer cells and it is associated with at least one DNA repair 
pathway defect [137,178].  
 
Telomerase activation  
Cancer cell immortalization depends on telomere maintenance, regulated by telomerase [137]. 
hTERT levels are important  in control of telomerase activity [137]. 
 
Angiogenesis 
Angiogenesis, measured by micro-vessel density, is correlated with metastasis risk and with 
the patient’s survival. VEGF is the most studied angiogenic factor, frequently demonstrating 
higher expression in bronchial-pulmonary carcinomas [137].  
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Cancer Stem Cells 
The cancer stem cell model hypothesizes that cancer stem cells are less sensitive to  
radiotherapy and/or chemotherapy, this related to the lower proliferation rate and drug 
resistance phenotype (by expressing drug transporters) [137]. Thus, cancer stem cells would 
be able to regenerate tumours [137].The molecular factors related to cancer stem cell 
phenotype could be explored as potential molecular therapeutic targets [137]. 
 
Epigenetic Modifications 
Recent evidence suggests that aberrant DNA promoter methylation could be identified early in 
cancer development [137]. Hypermethylation is frequently identified in several genes, such as 
RASSF1A, p16INK4a, FHIT, MGMT, ECAD, DAPK, GSTP1, TIMP3, and RARβ [137]. Epigenetic 
changes, such as promoter hypermethylation, are reversible changes, and so a potential 
therapeutic target [137]. 
 
 
 
 

  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 – OBJECTIVES

29 
CHAPTER 2 – OBJECTIVES 
This work aimed to study preneoplastic lung lesions and carcinomas, focusing on: 
differentiation and diagnostic aspects, prognostic and factors with predictive therapeutic 
value. 
 
Firstly, adaptive and preneoplastic bronchial lesions were studied, namely respiratory 
epithelium basal hyperplasia, squamous metaplasia and dysplasia till carcinoma in situ (CIS).  
The aim of this part of the study was to acquire better knowledge of the evolution of 
preneoplastic bronchial lesions, according to the expression of markers of differentiation and 
proliferation and EGFR and HER2-neu as a potential biomarker for lung cancer risk assessment. 
This knowledge would be important to develop new and effective strategies for early diagnosis 
and insights into chemoprevention strategies and targeted therapy. 
Immunohistochemical antibodies (CK5/6, CK7, Chromogranin A, Ki67, p53, HER2 and EGFR) 
were applied in the study of preneoplastic lesions. The HER2 and EGFR gene copy number 
were assessed by FISH (fluorescent in situ hybridization). 
 
Taking into account the results obtained in the study of preneoplastic epidermoid carcinoma 
lesions and the increasing importance of targeted therapy, HER2 and EGFR protein expression, 
HER2 and EGFR gene copy number and HER2 and EGFR mutation status were studied in lung 
epidermoid carcinoma. The aim was to obtain a better understanding of the molecular 
pathology of epidermoid carcinoma concerning these genes with clinical and therapeutic 
implications, and to contribute to knowledge concerning the status of these genes studied by 
immunohistochemistry, FISH and PCR. 
 
Considering the increasing incidence of lung adenocarcinoma, recent developments in their 
classification and the growing evidence of the importance of pattern recognition with 
diagnostic, prognostic, and even therapeutic predictive value, a sample of lung 
adenocarcinomas was studied according to the expression of differentiation molecular 
markers, proliferation molecular markers, the expression of different gene products with 
implications for the signal transduction pathways, cell cycle control, and the apoptosis control, 
and with potential therapeutic implications, especially concerning targeted therapy. These 
adenocarcinomas were evaluated using a pattern-based approach, trying to identify 
differences according to patterns that could reflect different molecular pathways relevance’s 
according to adenocarcinoma patterns. The objectives were to validate a small differentiation 
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IHC panel, evaluate the protein expression of different genes according to different 
adenocarcinoma patterns, and correlate this expression with progression and drug resistance 
cell pathways, in order to understand bronchial-pulmonary adenocarcinoma carcinogenesis. 
Another objective was to verify possible differences of gene expression in adenocarcinoma 
taking account of variables such as gender, age, smoking and different tumour stages. The 
global intention of this project is to acquire knowledge that could be applied in the diagnosis 
and prognostic evaluation of bronchial-pulmonary adenocarcinoma and its subtypes in order 
to define individual treatment. 
 
In a fourth stage, EGFR and KRAS mutational status, EGFR and HER2 gene copy number and 
immunohistochemical EGFR and HER2 expression were studied in these adenocarcinomas, also 
taking account of adenocarcinoma patterns. The objectives of this part of the work were to 
evaluate EGFR and KRAS mutational status, EGFR and HER2 gene copy number and 
immunohistochemical EGFR and HER2 expression in lung adenocarcinomas according to the 
patterns/subtypes present, in order to better understand the value of pattern sub-typing, 
supported by an immunohistochemical set routinely used, in adenocarcinoma diagnosis and 
anti-EGFR / targeted therapy decision. 
 
In a fifth stage, it was studied FGFR1 expression and gene copy number in bronchial pulmonary 
carcinomas, knowing that FGFR1 is an oncogene that can potentially be targeted by tyrosine 
kinase inhibitors. This part of the work aimed to evaluate FGFR1 expression and gene copy 
number in adenocarcinomas, squamous cell lung carcinomas, pleomorphic carcinomas and 
adenosquamous carcinomas. EMT pathway was also explored in more complex lung 
carcinomas such as adenosquamous and pleomorphic carcinomas as well as adenocarcinomas, 
according to Vimentin and TTF1 expression, and in squamous cell carcinoma, joining CK7 
expression. The purpose was to identify differences and/or similarities in between these 
groups of lung tumours in order to characterize the histological types for targeted therapy. 
This work plan gave rise to a work flow with different methodologies reflected in several 
publications involving specific material and methods, results evaluation and discussion. The 
results section of this thesis will present several published or forthcoming articles, concerning 
especially the study of preneoplastic lesions, epidermoid lung carcinomas, and 
adenocarcinomas. Each publication contains material and methods, results and discussion of 
the data. 
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Data obtained during the PhD study period is summarized in the following six manuscripts and 
twelve published abstracts: 
Manuscript I – EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic 
lesions of bronchial epithelium: an immunohistochemical and genetic study. 
Virchows Arch (2011) 458:571–581. 
 
Manuscript II – Polysomy and amplification of chromosome 7 defined for EGFR gene in 
squamous cell carcinoma of the lung together with exons 19 and 21 wild type. 
Rev Port Pneumol 2010; XVI (3): 453-462. 
 
Manuscript III – Bronchial-Pulmonary Adenocarcinoma Subtyping Relates With Different 
Molecular Pathways. 
In publication in Revista Portuguesa de Pneumologia - Received 30 October 2013, accepted 
30 May 2014, available online 5 March 2015. 
doi:10.1016/j.rppnen.2014.05.006 
 
Manuscript IV – Lung adenocarcinoma: sustained subtyping with immunohistochemistry and 
EGFR, HER2 and KRAS mutational status. 
Rev Port Pneumol. 2015;21:113-25.  
doi: 10.1016/j.rppnen.2014.09.009. Epub 2015 Mar 11. 
 
Manuscript V – EGFR and KRAS mutations coexistence in lung adenocarcinomas. 
Diagnostic Pathology 2015, 1:13. 
http://www.diagnosticpathology.eu/content/index.php/dpath/article/view/13 
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Manuscript VI – Targeted therapy for FGFR1 may be independent of the histological type of 
bronchial-pulmonary carcinomas. 
Submited / undergoing revision – Virchows Archive. 
 
Abstract I – EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 AND P53 EXPRESSION IN 
PRENEOPLASTIC LESIONS OF BRONCHIAL EPITHELIUM. 
BMC Proceedings 2010, 4(Suppl 2):P64. 
The 16th International Charles Heidelberger Symposium on Cancer Research, Coimbra, 
Portugal, September 26-28, 2010. 
 
Abstract II – EGFR UNUSUAL MUTATION STATUS IN LUNG ADENOCARCINOMAS. 
BMC Proceedings 2010, 4(Suppl 2):P61. 
The 16th International Charles Heidelberger Symposium on Cancer Research, Coimbra, 
Portugal, September 26-28, 2010. 
 
 
Abstract III – KRAS AND EGFR MUTATIONS COEXISTING IN LUNG ADENOCARCINOMA. 
BMC Proceedings 2010, 4(Suppl 2):P57. 
The 16th International Charles Heidelberger Symposium on Cancer Research, Coimbra, 
Portugal, September 26-28, 2010. 
 
Abstract IV – EGFR and KRAS mutations in mixed type of Pulmonary Adencocarcinoma. 
Virchows Arch (2010) 457: 91-281. 
Intercongress Meeting of the European Society of Pathology, Krakow – Poland, 31st August - 
4th September, 2010. 
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Abstract V – KRAS Mutations in Lung Adenocarcinomas may be Relevant in Histological 
Patterns, EGFR Mutational Status and Male Smokers. 
Virchows Archiv 2011; Supplement 459: SI – S320.  
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
 
 
Abstract VI – TTF1 Negative Solid Pattern in Lung Adenocarcinomas May Reflect 
Morphogenesis.  
Virchows Archiv 2011; Supplement 459: SI – S320.  
 23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
 
 
Abstract VII – Lung Adenocarcinomas Subtyping is not Relevant for EGFR Mutations, Gene 
Copy Number and Protein Expression.  
Virchows Archiv 2011; Supplement 459: SI – S321.  
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
 
 
Abstract VIII – ALK Gene Rearrangment in EGFR and KRAS Positive Lung Adenocarcinomas. 
Virchows Archiv 2011; Supplement 459: SI – S320.  
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
 
 
Abstract IX – ALK EXPRESSION IN PULMONARY ADENOCARCINOMAS. 
Virchows Arch (2012) 461: S1-S332.  
24thEuropean Congress of Pathology, Prague, September 8 – 12, 2012. 
 
 
Abstract X – Bronchial-Pulmonary Carcinoma Cases with EGFR, ALK and MET Alterations. 
Rev Port Pneumol. 2013; 19(Esp Cong 4): 127-176. 
XXIX Congresso de Pneumologia, Albufeira-Portugal, October 25 – 27, 2013. 
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Abstract XI – EGFR Mutations, MET, EGFR Amplification and ALK Rearrangement 
Simultaneous in Five Bronchial-Pulmonary Adenocarcinomas.  
(2014) Pulmonary Pathology Society Biennial Meeting Abstracts. Archives of Pathology & 
Laboratory Medicine: May 2014, Vol. 138, No. 5, pp. 700-709. 
Biennial Pulmonary Pathology Society (PPS) Meeting, Grenoble, June 25-28, 2013. 
 
 
Abstract XII – Pulmonary Squamous Cell Carcinoma can harbor EGFR mutations. 
Rev Port Pneumol. 2014; 20(Esp Cong 3): 1-37. 
5º Congresso de Pneumologia do Centro, June 26-27, 2014. 
 
 
Data concerning material and methods, results and discussion will be addressed in the 
manuscripts and / or abstracts, concerning specifically the studies on preneoplastic bronchial 
epithelium lesions (Manuscript I and Abstract I), epidermoid carcinoma (Manuscripts II and VI 
and Abstract XII), and adenocarcinomas (Manuscripts III, IV, V and VI and Abstracts II-XI). 
The general discussion following the presentation of papers (Manuscripts and Abstracts) will 
deal with aspects covering all manuscripts, with reflections and conclusions. 
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CHAPTER 3 – EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic 
lesions of bronchial epithelium: an immunohistochemical and genetic study.    
ORIGINAL ARTICLE
EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53
expression in preneoplastic lesions of bronchial epithelium:
an immunohistochemical and genetic study
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Teresa Cabral & Ana Maria Alarcão & Ana Gomes &
Patrícia Couceiro & Lina Carvalho
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Abstract A prognostic interpretation of preneoplastic lesions
would have impact in bronchial carcinoma early diagnosis and
through the study of Erb-B family receptors as they have an
important role in lung carcinogenesis. The existence of drugs
as tyrosine kinase inhibitors stressed the importance of
studying gene alterations for selected chemoprevention
schemes and characterization of carcinogenesis. Bronchial
preneoplastic lesions were characterized by immunohisto-
chemistry using the antibodies LP34 (high weigh molecular
cytokeratin), CK7, chromogranin A, Ki67, p53, C-erbB-2 and
EGFR. HER2 and EGFR gene copy number was also
evaluated by fluorescent in situ hybridization in those
lesions. The expected results defined the origin cell for basal
cell hyperplasia and squamous metaplasia as adaptative
lesions and dysplasia. By known experiences and published
data, beyond the stem cell, the spectral evolution of
bronchial preneoplastic lesions was demonstrated by charac-
terizing basal cells (LP34) and their neoplastic potentiality.
Dysplasias showed a higher expression of EGFR, Ki67 and
p53 with a stepwise increase with the gravity of the
respective grading. C-erbB-2 immunohistochemical over-
expression was a rare event in preneoplastic lesions.
Polysomy was the main mechanism for EGFR and HER2/
neu higher gene copy number and together with increased
proliferation index (Ki67) will account to preview bronchial
carcinogenesis.
Keywords Bronchial squamous metaplasia .
EGFR, HER2/c-erB-2 . CK7 . LP34
Introduction
Lung cancer is the leading cause of death by malignancy in
developed countries and throughout the world. Environ-
mental and occupational exposures, such as polyaromatic
hydrocarbons, radon, asbestos, nickel, arsenic and chromi-
um, are important determinants of lung cancer risk, but
cigarette smoking is the main risk factor, accounting for
about 90% of the cases in men, 70% of the cases in women
and within today ex-smokers comprising nearly 50% of all
new lung cancer cases [1–5].
The overall 5-year survival rate for lung cancer patients
remains less than 15% [6], and the death rate for lung
cancer exceeds the combined total for breast, prostate and
colon cancer in developed countries [5]. The major reasons
for the poor prognosis for lung cancer are the lack of
effective screening and early diagnosis procedures, the
propensity for early metastasis and the inability of systemic
therapies to cure patients with widely metastatic disease [7].
Lung cancer is the result of a multi-step accumulation of
genetic and/or epigenetic alterations; therefore, a better
understanding of the molecular mechanism, by which these
alterations affect lung cancer pathogenesis, would provide
new and more effective strategies for chemoprevention,
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early diagnosis and targeted treatment [8]. The existence of
novel drugs against specific molecular targets like EGFR
and HER2/neu genes leads to the importance of defining
their expression as biomarkers in preneoplastic lesions.
The 1999/2004 WHO lung tumour classification recog-
nizes three types of preinvasive lesions: squamous dyspla-
sia and carcinoma in situ (CIS); atypical adenomatous
hyperplasia and diffuse idiopathic pulmonary neuroendo-
crine cell hyperplasia [9]. Respiratory epithelium adaptative
lesions include basal cell hyperplasia, squamous metapla-
sia, followed by dysplasia and CIS, which precede or
accompany microinvasive or invasive carcinoma. Hyper-
plasia and squamous metaplasia are considered reversible
lesions, while dysplasia and CIS are not [10–15].
Squamous metaplasia as a common adaptative lesion of
the bronchial mucosae, especially in smokers, represents a
precursor step in the development of invasive squamous
cell carcinoma, deserving an accurate study to define its
evolutionary potential to lung cancer, in order to be
determined in bronchial biopsies [10, 14, 16, 17].
Several molecular and genetic abnormalities have been
described in lung carcinogenesis, including activation of
proto-oncogenes and loss of tumour suppressor genes and
DNA repair genes. Proto-oncogenes can be activated by point
mutations, amplification, chromosomal rearrangement and
expression of a high gene copy number. [18–20]. Those
genomic and molecular abnormalities are early events in
lung carcinogenesis and can persist in bronchial lesions for
months or years and their persistence or regression have been
correlated with lesions' evolution [15, 21–30]. Molecular
changes are recognized not only in lung cancer, but also in
bronchial epithelium and parenchyma of current and former
smokers without the development of lung cancer [31, 32].
Epidermal growth factor receptor (EGFR; ErbB-1 gene)
and ErbB-2 (HER2/neu) belong to ErbB family, a family of
tyrosine kinase receptor proteins that includes also ErbB-3
(HER-3) and ErbB-4 (HER-4). The ErbB receptors are
composed of three major domains: an extracellular ligand
binding; a transmembranar segment and a cytoplasmic with
tyrosine kinase activity. ErbB receptor function begins upon
ligand binding and is followed by receptor homo (e.g. Erb-1/
Erb-1) or heterodimerization (e.g. Erb-1/Erb-2), activating
the tyrosine kinase domain of the receptor, which becomes
phosphorylated and acts as a docking site for downstream
signalling molecules and cytoplasmic messenger proteins
that then trigger a cascade of cytoplasmic and nuclear
pathways [15].
It has been suggested and supported by experimental
data that aberrant activation of the kinase activity of ErbB
receptors plays an important role in the neoplastic transfor-
mation and progression, prognosis, survival and resistance
to cytotoxic therapies [6, 7, 15, 33–38]. EGFR's high
expression is an early event in preneoplastic lesions, with
an increasing expression from normal mucosae to hyper-
plasia, metaplasia and dysplasia [6, 38–42]. EGFR is
overexpressed in 84% of squamous cell carcinoma, 65%
of adenocarcinomas and 68% of large cell lung carcinomas
[41]. As it seems, that ErbB2 is also highly expressed in
bronchial preneoplastic lesions and its overexpression is
less common in carcinomas (less than 35% of non-small
cell lung carcinomas (NSCLC), mainly adenocarcinomas)
[18, 41, 43]. The heterodimer EGFR/HER2-neu has been
shown to have a stronger proliferative effect than the
corresponding homodimers [38, 44–46]. Amplification and
polysomy of EGFR and HER2-neu and overexpressed
proteins have been related to survival in patients with
NSCLC (non- small cell lung cancer), but contradictory
results have been published [47–51]. New therapies have
also been developed recently directed to these two
molecular targets, some of them being applied in chemo-
prevention trials, stressing the necessity to understand their
expression in adaptative and preneoplastic lesions [5, 52–
56]. This study concerned bronchial preneoplastic lesions
observed in biopsies as basal cell hyperplasia, squamous
metaplasia and dysplasia. Using immunohistochemistry,
those lesions were characterized by antibodies applied
against LP34, CK7, chromogranin A, Ki67, p53, C-erbB-
2 and EGFR. HER2 and EGFR gene copy number was also
evaluated by fluorescent in situ hybridization (FISH), using
normal controls. The aim of the present study is to achieve
a better understanding of the spectral evolution of bronchial
adaptative and preneoplastic lesions, by recognizing the
expression of EGFR and HER2-neu as potential biomarkers
for lung cancer risk assessment. This knowledge would
help to provide new and more effective strategies for
chemoprevention, early diagnosis and targeted treatment.
Materials and methods
Material
A number of 67 bronchial biopsies were included in this study,
comprising 89 preneoplastic lesions, selected from recent data
base, by considering the preservation, number and dimension
of the small fragments obtained by bronchial fibroscopy and
represented 16 basal cell hyperplasia, 40 squamousmetaplasia
and 33 epidermoid dysplasia (7 mild dysplasia, 7 moderate
dysplasia, 4 severe dysplasia and 15 CIS) (Fig. 1a, b, c, d, e);
in 22 cases there was concomitancy of the lesions. The
population consisted of 57 men and 10 women, with
66.3 years as mean age (range 38–92).
Hyperplasia was defined when more than four basal cell
layers were observed. Squamous metaplasia was considered
when there was replacement of ciliated columnar epitheli-
um by pavimentous epithelium without atypia. Dysplasia
572 Virchows Arch (2011) 458:571–581
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was graded as mild, moderate and severe/CIS according to
the levels of atypia.
Biopsy products were routinely fixed in 4% neutral
buffered formalin immediately after bronchial fibroscopy.
They were processed and embedded in paraffin. One
paraffin block was chosen from each case, containing
several representative fragments. From each paraffin block,
several cuts 5-μm thick sections were made and put on
glass slides then stained with haematoxylin–eosin and
reviewed by two pathologists in order to ensure the optical
criteria for preneoplastic bronchial lesions according to the
1999/2004 histological WHO/IASLC classification of
preinvasive squamous lesions of the bronchi.
Methods
Immunohistochemistry
The imunnohistochemical analysis included seven different
antibodies: CK7 (Monoclonal Mouse Anti-human, OV-TL
12/30, Dako); LP34 (Monoclonal Mouse Anti-human,
Clone LP34, Dako); chromogranin A (Monoclonal Mouse
Fig. 1 Morphology and immunostaining: a Normal bronchial
epithelium, H&E, ×400. b Basal cell hyperplasia, H&E, ×400. c
Squamous metaplasia, H&E, ×400. d Moderate dysplasia, H&E, ×400.
e In situ carcinoma, H&E, ×400. f CK7 expression, normal
bronchial epithelium, ×400. g Basal cell hyperplasia, LP34, ×400.
h Ki67 3+/70%, ×400. i P53 2+/50%, ×400. j EGFR negative, normal
epithelium, ×400 k EGFR, 3+/60%, ×400. l C-erbB-2, 2+, ×1,000
Virchows Arch (2011) 458:571–581 573
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Anti-human, Clone DAK-A3, Dako); Ki67 (Monoclonal
Mouse Anti-human, Clone MIB-1, Dako); p53 (Monoclo-
nal Mouse Anti-human, Clone DO-7, Dako); C-erbB-2
(Policlonal Mouse Anti-human, Dako) and EGFR (Mono-
clonal Mouse Anti-human, Clone 31G7, Zymed Labora-
tories Inc.). The procedure was performed according to a
standard avidin-biotin-peroxidase complex. Three-
micrometer tissue sections were placed on coated slides
and allowed to dry overnight. After deparaffinization and
rehydration, antigen unmasking was performed using
Module PT (Lab Vision®) for citrate buffer for 25 min
at pH 6, 98°C for chromogranin A, p53, Ki67 and c-erbB-
2 antibodies. Antigen unmasking was performed with
Pronase E, for 10 min at room temperature for CK7, LP34
and EGFR antibodies. Endogenous peroxidase activity
was quenched using 15 min incubation in 3% diluted
hydrogen peroxide (H2O2). For blocking nonspecific
binding, Ultra V Block (Ultra Vision Kit®; TP-015-HL) was
applied to the sections and then they were incubated at room
temperature, with primary antibodies against CK7 at a dilution
of 1/50 for 30 min, LP34 at a dilution of 1/100 for 60 min,
chromogranin A at a dilution of 1/300 for 30 min, p53 at a
dilution of 1/40 for 30 min, Ki67 at a dilution of 1/50 for
30 min, c-erbB-2 at a dilution of 1/40 for 60 min and EGFR at
a dilution of 1/20 for 30 min. After washing with phosphate-
buffered saline, slides were incubated with biotin-labelled
secondary antibody (Lab Vision®) for 15 min. Primary
antibody binding was localized in tissues using peroxidase-
conjugated streptavidin (Lab Vision®) and 3,3-diaminobenzi-
dine tetrahydrochloride was used as the chromogen according
tomanufacturer's instructions. The slides were counterstained
with hematoxylin, dehydrated and mounted.
For each biopsy, external and the intrinsic positive
control were considered: basal cells for LP34 and columnar
ciliated cells for CK7 in normal bronchial epithelium;
carcinoid tumour sections for chromogranin A; sections of
a colonic tubulo-villous adenoma for p53; female breast
ductal carcinoma in situ for C-erbB-2 and sections of lung
adenocarcinoma with intense EGFR IHC positivity. Ki67
was validated by a small cell lung carcinoma.
LP34, CK7 and chromogranin A expression were
classified as negative if there was no expression or mild
focal expression or positive when there was moderate or
intense and diffuse expression. The cut off to classify a
lesion as positive for proliferative marker Ki67 was 10% in
at least two layers of positive nuclei above the epithelial
basal membrane, since it is normal to observe some
proliferative activity mainly in the basal cell layer.
A score established by other authors was applied to Ki67,
p53 and EGFR protein expression: 0-negative; 1-focal
positivity; 2-mild positivity; 3-moderate positivity; 4-intense
positivity. The intensity was multiplied by the percentage of
positive cells, thus defining a 0–200% score as negative or
low expression, 201–300% score as intermediate expression
and a 301–400% score as high expression [19].
The expression of C-erbB-2 was validated by membrane
staining and an identical score to the one used in breast
cancer was applied with some alterations because of the
limited number of cells observed. Each specimen was
scored semi-quantitatively according to the intensity of
membrane immunostaining in a 4-point scale: 0/negative -
absence of staining; + - weak staining and/or no homoge-
neous staining; ++ - moderate homogeneous membrane
staining; +++ - intense homogeneous membrane staining.
For the ++ and +++, we registered the number/percentage
of stained cells. Cytoplasmic staining was not considered
when present.
Fluorescence in situ hybridization (FISH)
Sections of formalin-fixed paraffin-embedded specimens, 4-
μm thick, were incubated at 65°C for 24 h, deparaffinized in
two xylene washes for 10 min and dehydrated in ethanol. The
slides were then incubated at 120°C for 4 min with 10 mM
citrate buffer (ph 6.0), followed by saline sodium citrate buffer
(2×SCC pH 7.0) washes. Sections were digested with
proteinase K (0.25 mg/ml in 2×SCC, Sigma, pH 7.0) for
5 min at 37°C, followed by new 2×SCCwash and post-fixation
with 1% formalin for 10 min at room temperature. The slides
were later on dehydrated in ethanol series (70–90–100%) for
2 min. Dual-colour FISH assays for HER2 were performed by
using Qbiogene HER2/neu (17q21)/Alphasatellite 17 dual
colour probe, and for EGFR, the Vysis, Inc. USA LSI EGFR
Spectrum Orange/CEP 7 Spectrum Green probe was used.
Ten-microliter probe set was applied to the selected area of the
slides and the hybridization areas were covered with a glass
cover slip and sealed with rubber cement. The slides were
incubated at 90°C for 6 min for co-denaturation and at 37°C
for 12–18 h for hybridization in a humidified chamber. Post-
hybridization washes were performed with 50% formamide/
2×SCC (pH 7.0) at 46°C for 5 min, followed by 2×SSC at
46°C for 2 min. After dehydratation in ethanol series, 4′, 6′-
diamidino-2-phenylindole (DAPI; 0.15 mg/ml in Vectashield
mounting medium, Vector Laboratories, Bulingame, CA,
USA) was applied for chromatin counterstaining.
Microscopic analysis was performed on a Nikon Eclipse
80i bright field and epifluorescent microscope equipped
with LUCIA cytogenetics software. Fluorescence signals
were scored using single-band filters for DAPI, FITC,
Texas Red and triple-band pass filter (DAPI, FITC and
Texas Red). Images were recorded with a Nikon digital
DMX 1200 F camera in monochromatic layers, which were
subsequently merged by Nikon ACT-1 capture software.
The reference slide (stained with haematoxylin–eosin)
usually contained normal bronchial epithelium adjacent to
the adaptative and preneoplastic lesions and at least 100 non-
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overlaping interphase nuclei were scored in each fragment for
both HER2 and chromosome17 centromer signals and for
EGFR and chromosome7 centromer signals, following
scoring guidelines and constant adjustments of microscope
focus when signals were located at different levels.
Two independent observers performed analysis in a
blinded study and scored results, restricted to the selected
lesions and bronchial epithelium in each case, with
reproducible results.
Six major FISH patterns were identified: disomy (≤2
gene copies per nucleus in >90% of cells); low trisomy (≤2
gene copies per nucleus in ≥40% of cells, 3 gene copies in
10–40% of cells, ≥4 gene copies in <10% of cells); high
trisomy (≤2 gene copies per nucleus in ≥40% of cells, 3
gene copies in ≥40% of cells, ≥4 gene copies in <10% of
cells); low polysomy (≥4 gene copies per nucleus in 10–
40% of cells); high polysomy (≥4 gene copies per nucleus
in ≥40% of cells) and gene amplification (defined by
presence of tight EGFR gene clusters and a ratio of EGFR
gene to chromosome of ≥2 or ≥15 copies of EGFR per cell
in ≥10% of analysed cells), according to a FISH scoring
System defined by Cappuzzo et al. [57]. Amplification and
high polysomy were considered as FISH-positive results.
Statistical analysis
Comparisons were performed using bilateral chi-squared
tests or Fisher exact test when needed, because of the small
number of lesions in some categories. Anova test was
applied to compare the markers expression's percentage.
Results
Differentiation markers
Basal cell hyperplasia positive LP34 cells in the lower cell
layers revealed clear cut to squamous metaplasia staining
up to the top cell layer, by loss of CK7 expression (Table 1,
Fig. 1f, g). Accordingly, dysplasias showed always LP34
positivity and CK7 negativity.
Chromogranin A expression was negative in all the cases
(Table 1).
Caliciform cell hyperplasia, when present, was negative
for LP34 (only the basal cell layer remained positive) and
maintained the expression for CK7.
Proliferation (Ki67) and apoptotic (p53) markers
Significant differences of Ki67 expression were found
between basal cell hyperplasia and squamous metaplasia
group and dysplasia group cases (p=0.001). Ki67 expression
was higher in dysplasia (p=0.0007). There was also found a
stepwise increment of expression from basal cell hyper-
plasias, to squamous metaplasia and dysplasia (p<0.0001).
The intense expression of Ki67 (intense positive cases) was
shown to have a statistical significant increase from basal
cell hyperplasia, to squamous metaplasia and dysplasia (p=
0.0002). (Tables 2 and 3, Fig. 1h). Intense positive cases were
observed in 19 (57.6%) dysplasias, 9 (22.5%) metaplasias and
one basal cell hyperplasia (6.25%). There were no significant
differences between the three grades of dysplasia. Despite the
intense positive cases observed, moderate expression of Ki67
was the second predominant type of expression in dysplasia
(11 cases, 33.3%). Weak expression of Ki67 was mainly
observed for basal cell hyperplasia (8 cases, 50%) and
squamous metaplasia (13 cases, 32.5%).
An increasing expression for p53 in all the three types of
lesions was observed (p<0.0001). P53 expression was
significantly higher in dysplasia when compared with basal
cell hyperplasias and metaplasias (p=0.0007). Intense
positive cases were also more frequent in dysplasia (p=
0.0001). In 10 basal cell hyperplasias (62.5%) and 22
squamous metaplasias (55%), it was possible to observe a
weak p53 expression. An intense expression of p53 was
observed in 20 cases (60.6%) of dysplasia (Tables 2 and 3,
Fig. 1i).
EGFR and C-erbB-2/HER2 protein and gene expression
EGFR immunohistochemical expression was significantly
higher in dysplasias when compared with other preneo-
LP34 CK7 Chromogranin A
Positive Negative Positive Negative Positive Negative
Basal cell hyperplasia n=16 16 0 0 16 0 16
100% 0% 0% 100% 0% 100%
Squamous Metaplasia n=40 40 0 0 40 0 40
100% 0% 0% 100% 0% 100%
Dysplasia n=33 33 0 0 33 0 33
100% 0% 0% 100% 0% 100%
Table 1 LP34, CK7 and
chromogranin A expression
in preneoplastic lesions
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plastic lesions (p=0.009) (Tables 2 and 3, Fig. 1j, k, Fig. 2).
EGFR IHC expression increased between the three
groups of lesions (p=0.0005). The intensity of the
expression was higher in the group of dysplasia followed
by squamous metaplasia, with 18 (54.5%) dysplasias
showing moderate expression and 3 cases (9.1%) intense
expression, while 14 (35%) squamous metaplasia pre-
sented moderate expression and 1 (2.5%) intense expres-
sion (p=0.005). Basal cell hyperplasia showed mainly a
low EGFR expression, counting ten (62.5%) cases.
Statistical differences between the different grades of
dysplasia were not found (Fig. 2). C-erbB-2 protein
overexpression was clearly observed in only one severe
dysplasia (Tables 2 and 3, Fig. 1l), without statistical
differences between the three groups of lesions or
according to the severity of the dysplasia (p=0.14). C-erbB-2
protein expression was less frequent than EGFR.
EGFR and HER2 gene increased copy number was more
often due to polysomy than to amplification. Among the
four cases with intense EGFR protein expression, three had
high polysomy and one showed disomy.
The number of FISH EGFR positive cases were higher
in the group of dysplasia (p=0.0002) (Fig. 3). Statistical
significant correlation between EGFR IHC expression and
FISH EGFR results was determined when the intensity of
IHQ expression (positive intense vs. non-intense positive
cases) was considered (p=0.0092) (Fig. 4).
HER2 FISH positive cases (n=4) were due to high
polysomy. In one case (n=1), high trisomy was observed.
All high polysomy cases were identified in CIS cases, and
the high trisomy case was identified in a basal cell
hyperplasia. These cases were IHC negative. The IHC-
positive C-erbB-2 case showed low trisomy and was
considered FISH HER2 negative (Fig. 5a, b, c).
Ki 67 p53 C-ErbB-2 EGFR
No. (%) No. (%) No. (%) No. (%)
Basal cell hyperplasia (n=16) Negative 1 6.25 1 6.25 15 93.75 5 31.25
+ 9 56.25 10 62.5 1 6.25 9 43.75
++ 5 31.25 5 31.25 0 0 1 6.25
+++ 1 6.25 0 0 0 0 1 6.25
Squamous metaplasia (n=40) Negative 8 20 5 12.5 39 97.5 6 15
+ 18 45 22 55 0 0 13 32.5
++ 9 22.5 12 30 1 2.5 14 35
+++ 5 12.5 1 2.5 0 0 7 17.5
Dysplasia (n=33) Negative 0 0 1 3 27 81.8 4 12.1
+ 3 9.1 8 24.2 5 15.2 7 21.3
++ 17 55.5 9 27.3 1 3 15 45.5
+++ 13 39.4 15 45.5 0 0 4 12.1
Table 2 Ki67, p53, C-erbB-2
and EGFR intensity of
expression in preneoplastic
lesions
Ki 67 p53 C-ErbB-2 EGFR
No. (%) No. (%) No. (%) No. (%)
Basal cell hyperplasia (n=16) Neg 2 12.5 1 6.25 15 93.75 5 31.25
Low pos 8 50 10 62.5 1 6.25 10 62.5
Mod pos 5 31.25 2 12.5 0 0 1 6.25
Pos int 1 6.25 3 18.75 0 0 0 0
Squamous metaplasia (n=40) Neg 13 32.5 5 12.5 39 97.5 6 15
Low pos 13 32.5 22 55 0 0 19 47.5
Mod pos 5 12.5 4 10 1 2.5 14 35
Pos int 9 22.5 9 22.5 0 0 1 2.5
Dysplasia (n=33) Neg 0 0 1 3 27 81.8 4 12.2
Low pos 3 9.1 8 24.2 5 15.2 8 24.2
Mod pos 11 33.3 4 12.2 1 3 18 54.5
Pos int 19 57.6 20 60.6 0 0 3 9.1
Table 3 Ki67, p53, c-erbB-2
and EGFR expression in pre-
neoplastic lesions considering
intensity and percentage of cells
with expression
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Discussion
As lung carcinogenesis is a multistep process, preneoplastic
or preinvasive bronchial lesions' evolution to bronchial
carcinoma depends upon the molecular and genetic abnor-
malities accumulated in time. Those abnormalities increase
from the normal bronchial epithelium through basal cell
hyperplasia, squamous metaplasia and low-grade to high-
grade dysplasia. Certain proteins and genes play key roles
in lung carcinogenesis and their aberrant expression in that
process makes them as potential biomarkers susceptible to
discriminate a subpopulation of patients with particularly
active mutagenesis, progressive cancerization process and
at very high risk to develop lung cancer [58].
LP34, CK7, chromogranin A, Ki67, p53, EGFR and C-
erbB2 were the seven biomarkers chosen for this study as
their abnormal expression is related with the oncogenic
process. The first three were used successfully as differen-
tiation markers of the preneoplastic lesions.
A basal cell origin for basal hyperplasia, squamous
metaplasia and dysplasia was clearly defined, based on
LP34 and CK7 expression. Immunohistochemical differen-
tiation markers like LP34, CK7 and chromogranin A
demonstrated useful to discriminate preneoplastic lesions
from other proliferative lesions like caliciform cell hyper-
plasia or neuroendocrine cell hyperplasia. As expected,
basal cell hyperplasia and squamous metaplasia are always
LP34-positive and CK7 and chromogranin A-negative,
indicating basal cell origin and conditioning squamous cell
carcinoma as a basal cell carcinoma. In contrast, caliciform
cell hyperplasia maintains cytoplasmic CK7 positivity cells
and inconstant LP34 membrane positivity, reflecting an
origin in cylindrical cells of the upper cell layer of the
respiratory epithelium in bronchial adenocarcinoma carci-
nogenesis. Chromogranin A, a neuroendocrine marker, was
constantly negative in this study, emphasizing that neuro-
endocrine cell hyperplasia has a different cell commitment.
Ki67 expression stepwise increment reflects the increas-
ing proliferative index observed in the spectrum of preneo-
plastic lesions. The statistical higher expression observed in
dysplasia group compared to basal cell hyperplasia and
squamous metaplasia defines two groups of lesions accord-
ing to their proliferative index. As other authors observed,
the intensity of Ki67 expression is also higher in dysplasia.
This way, we reinforce the utility of Ki67 as a biomarker,
namely for dysplasia, as it appears as a group characterized
by high proliferative index, subscribing the literature and
other authors' study of preneoplastic lesions [22–26, 59].
P53, the “guardian” maintaining the integrity of the
genome by participating in the DNA damage checkpoints
in the cell cycle, regulating cellular proliferation and
apoptosis [20], has been detected in preneoplastic lesions
of the lung, suggesting that it occurs early during lung
carcinogenesis [14, 18, 20] as the obtained results con-
firmed. P53 expression was significantly higher in dyspla-
sia when compared with hyperplasia and metaplasia, and
the intensity of expression was also higher in the dysplasia
group, supporting p53 accumulation involvement in the
development of squamous cell lung cancer and fixing p53
as a remarkable biomarker in lung carcinogenesis.
There are many studies concerning EGFR, C-erbB-2,
Ki67 and p53 expression in lung cancer. However, there are
Fig. 2 (MS Excell) Immunohistochemical EGFR expression between
the preneoplastic lesions Fig. 4 (MS Excell) Correlation between immunohistochemical EGFR
expression and FISH results
Fig. 3 (MS Excell) EGFR FISH results according to preneoplastic
lesions
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fewer results validating these markers in preneoplastic
lesions and most of them used only immunochemistry
techniques. By analysing the expression of those biomarkers,
using not only immunohistochemistry but also feasible
molecular techniques, such as FISH and correlating the
results obtained by the two different techniques, bronchial
preneoplastic lesions achieve prognostic significance.
EGFR immunohistochemical increased expression in
preneoplastic lesions, increasing from basal cell hyperplasia
to dysplasia, had been demonstrated [6, 7, 21, 38–42, 55, 60].
Meert et al. [21] also demonstrated not only an increasing
EGFR rate from normal bronchial epithelium to CIS and
microinvasive tumours, but also a statistically significant cut
off between mild dysplasia and severe dysplasia. Although
the greater expression has been seen in dysplasia, statistical
differences between the different grades of dysplasia were
not demonstrated (probably because the number of cases of
dysplasia was limited).
EGFR high gene copy number was due more frequently
to polysomy than to amplification. FISH-positive EGFR
cases are present in all types of preneoplastic lesions and
were higher in dysplasia group. Polysomy appears as an
early event in the sequence of hyperplasia–metaplasia–
dysplasia. The higher frequency of polysomy in preneo-
plastic lesions is reflected in the high frequency of this
event in squamous cell carcinomas, constituting the earliest
molecular event in lung carcinogenesis [17, 22, 41].
EGFR protein was overexpressed in all lesions with an
increased gene copy number. There was statistical significant
correlation between EGFR immunohistochemical expres-
sion and FISH EGFR results, when considering the intensity
of IHC expression [17]. Therefore, it was demonstrated that
protein expression does reflect high gene copy number, like
polysomy and amplification. Although EGFR gene ampli-
fication is implicated as one mechanism for EGFR over-
expression, it does not seem to be the main one [61].
Despite an increasing expression of EGFR and Ki67
along the spectrum of preneoplastic lesions, no correlation
between the two markers was found. Meert et al. recently
described that low-grade lesions showed no EGFR or Ki67
expression contrasting with high-grade lesions. EGFR
overexpression is associated with cell proliferation, making
EGFR an early marker of malignant transformation in lung
carcinogenesis [21, 38, 59].
C-erbB-2 immunohistochemical overexpression is less
frequent than EGFR overexpression, supporting the minor
role of C-erbB-2 in squamous cell carcinogenesis when
compared with EGFR [17, 62]. In our study, only one case
of severe dysplasia showed C-erbB-2-positive immunohis-
tochemical expression and polysomy was observed in 70%
of the cells. C-erB-2 FISH-positive cases were due to high
polysomy, showing that amplification is less frequent as a
high gene copy number event. No statistical significant
correlation was obtained between C-erbB-2 gene and
protein expression.
C-erB-2 does not seem to be involved in the first steps of
lung carcinogenesis [16]. For Piyathilake et al., the
expression of C-erbB-2 was significantly higher in squa-
mous cell carcinoma and associated precancerous lesions
than in normal epithelium and hyperplastic lesions, but no
stepwise expression of C-erbB-2 was observed, suggesting
its lack of importance in the squamous cell lung carcino-
genesis [38]. HER2/neu increased copy number is observed
in approximately 35% of adenocarcinomas and slightly less
Fig. 5 a Dual-colour FISH assay with EGFR (red) and chromosome
7 (green), balanced polysomy, ×1,000. b Dual-colour FISH assay with
EGFR (red) and chromosome 7 (green), amplification, ×1,000. c
Dual-colour FISH assay with HER2neu (red) and chromosome 17
(green), amplification, ×1,000
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frequently in squamous cell carcinomas [18], assuming
more importance in the development of lung adenocarci-
nomas. The increased copy number of HER2/neu in
NSCLC is most often attributable to chromosome duplica-
tion and polysomy [50], rather than amplification [18].
Although EGFR and Ki67 expression increases from
normal epithelium to preinvasive lesions together, this was
not seen for C-erbB-2. Therefore, any correlation between
EGFR and Ki67 expressions and C-erbB-2 expression was
established, like other studies also registered [21, 41, 63–
66]. Interestingly, other studies revealed that EGFR/HER2/
neu heterodimerization expression is capable to induce a
stronger and more sustained proliferative signal than EGFR
homodimers [60, 62].
The need to accurate detection of the EGFR and HER2/
neu gene copy number and protein overexpression, reflect-
ing their importance as biomarkers in squamous cell
pathogenesis, has become even more important because
despite recent advances in lung cancer treatments, improve-
ment in survival has only been modest, showing that
effective therapeutic and early detection approaches are still
lacking [38]. Selection of patients with preneoplastic
lesions expressing selected biomarkers is the way to
provide new and more effective strategies for early
diagnosis, a posterior closer follow-up and eventually
chemoprevention and targeted treatment with better safety
profiles. A variety of new approaches that target selected
biomarkers in lung carcinogenesis are in clinical develop-
ment or have already been approved for second and third
line lung cancer treatment [5, 52–56, 67].
Our comparison between gene copy number and protein
expression contributes to define which are the most reliable
methods to be used in patient selection. Since our study
includes a large number of preneoplastic lesions in a
different population analysed by two different techniques
(IHC and FISH), the results obtained reinforce other results
published before, some of them centred only in one
molecular marker and/or have used a single technique,
which measures either the protein level or the gene
expression. By identifying dysplasia as a group of preneo-
plastic lesions, chemoprevention targeted schemes can be
delineated to select individual patients, considering protein
expression, gene copy number and gene mutational status
with repercussions in drug sensitivity.
Conclusions
We conclude that squamous cell carcinoma preneoplastic
lesions studied have a basal cell origin, as demonstrated by
the unbalance between LP34 and CK7. The differentiation
markers, LP34, CK7 and chromogranin A, successfully
discriminate preneoplastic lesions origin.
Dysplasias showed a higher expression of EGFR, Ki67 and
p53 with a stepwise expression with the gravity of the
preneoplastic lesions, reflecting their importance as potential
biomarkers of preinvasive lesions of the bronchial epithelium
and may be used to identify patients with a higher risk of
developing squamous cell lung carcinoma. C-erbB-2 immu-
nohistochemical overexpression is a rare event in bronchial
preneoplastic lesions, emphasizing the minor role of C-erbB-2
as a biomarker in squamous cell carcinogenesis.
EGFR and HER2/neu high gene copy number was
present in preneoplastic lesions, with a higher EGFR gene
copy number in dysplasias. EGFR and HER2/neu high gene
copy number was due to polysomy more often than to
amplification, reinforcing that amplification is not the main
mechanism for protein overexpression. Although HER2/neu
does not seem to be involved in the early steps of squamous
cell lung carcinogenesis, HER2/neu gene copy number is
important because this gene is a HER family member and
an important heterodimerizarion partner for EGFR.
Biological/genetic markers associated with several mo-
lecular and genetic abnormalities, such as Ki67, p53, EGFR
and HER2/neu, need to be validated as potential and useful
preneoplastic bronchial lesion biomarkers. Risk assessment
should be based not only on smoking consumption and on
histopathology of bronchial lesions, but also on the basis of
in situ molecular biomarkers [58]. Therefore, in the future,
the recognition of those biomarkers will allow a targeted
screening and a posterior closer follow-up to select patients
for chemoprevention schemes and will have a positive
impact on survival.
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Resumo
Objectivo: O receptor do factor de crescimento epidér-
mico (EGFR) está sobreexpresso na maioria dos carci-
nomas do pulmão de não pequenas células (CPNPC) e 
é um dos principais alvos específicos dos inibidores da 
tirosina cinase (TKI) utilizados para o tratamento do 
CPNPC avançado. Apesar disto, há um considerável 
número de factores biológicos que também estão asso-
ciados à resposta dos EGFR-TKIs. Este estudo teve 
como principal objectivo a pesquisa de mutações somá-
ticas e amplificação do EGFR em casos de carcinoma 
epidermóide do pulmão. Material e métodos: Secções 
Abstract
Purpose: The epidermal growth factor receptor 
(EGFR) is overexpressed in the majority of non-
small-cell lung cancers (NSCLC) and is a major tar-
get specific EGFR tyrosine kinase inhibitors (TKIs) 
developed and used for the treatment of advanced 
NSCLC. A number of biological factors are also as-
sociated with EGFR-TKIs responsiveness. This study 
was focused on EGFR somatic mutations and ampli-
fications in squamous cell lung cancer. Material and 
methods: Representative sections of squamous cell 
carcinoma were selected from 54 surgical specimens 
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representativas de carcinoma epidermóide foram selec-
cionadas de 54 casos em que o tecido estava fixado em 
formal e incluído em parafina, sendo depois submeti-
dos à construção de TMA. A determinação da expres-
são proteica do EGFR foi feita por imunoistoquímica 
(IHQ) (Zymed, laboratórios). A hibridização in situ de 
fluorescência (FISH) foi realizada com a sonda EGFR 
LSI / CEP 7 (Vysis; Abbott Molecular, EUA). O ADN 
genómico foi extraído de 48 casos, amplificado por re-
acção em cadeia da polimerase (PCR) para pesquisa de 
mutações nos exões 19 (deleções) e 21 (mutações pon-
tuais). Todos os casos expressaram positividade para a 
citoqueratina de alto peso molecular e foi observada ne-
gatividade para CK7, CD56 e cromogranina. Resulta-
dos: A sobreexpressão proteica do EGFR foi identifica-
da em 49 casos, pela aplicação do score de Hirsh/
Cappuzzo (2005). A pesquisa de alterações génicas no 
cromossoma 7 e do gene EGFR foram analisadas por 
FISH e de acordo com o método de Cappuzzo (2005), 
foi identificada alta polissomia em 31 casos e amplifica-
ção em 7 casos. Por electroforese capilar, foram detecta-
das no exão 19 do EGFR: deleções em heterozigotia em 
3 dos 48 casos estudados e o exão 21 apresentou-se 
sempre na sua forma wild-type, quando estudado por 
enzimas de restrição. Conclusões: A detecção de dele-
ções e mutações pontuais no EGFR mostrou ser um 
evento raro no carcinoma epidermóide do pulmão. 
Apesar de a presença de mutações no EGFR ser um in-
dicador molecular e de sensibilidade eficaz em doentes 
com CPNPC avançado, submetidos ao tratamento 
com EGFR-TKIs, é a determinação de amplificações e 
de polissomias no gene EGFR que melhor traduz a efi-
cácia do tratamento nos doentes com carcinoma epi-
dermóide, quando isolado do grupo de CPNPC. 
 
Rev Port Pneumol 2010; XVI (3): 453-462
Palavras-chave: Carcinoma do pulmão, carcinoma 
epidermóide, tecido incluído em parafina, EGFR, 
amplificação, polissomia.
from formalin-fixed paraffin-embedded tissues and 
submitted to TMA construction. Determination of 
EGFR protein expression was done by immuno-
histochemistry(IHC) (Zymed, Laboratories). Fluo-
rescence in situ hybridization (FISH) was performed 
with LSI EGFR/CEP 7 (Vysis; Abbott Molecular, 
USA). Genomic DNA was extracted from 48 cases 
and exon 19 was amplified by polymerase chain reac-
tion (PCR) for search deletions and point mutations 
for exon 21. All cases expressed high weigh cytokeratin 
and were observed negativity for CK7, CD56 and 
chromogranin. Results: EGFR protein overexpres-
sion was identified in 49 cases, by the application of 
Hirsh’s scoring system. The chromosome 7 and EGFR 
gene were analyzed by FISH and scored according to 
Cappuzzo’s method that showed high polysomy in 31 
cases and amplification in 7 cases. Deletion in exon 
19 of EGFR was detected in 3 cases of 48 samples; 
the exon 21 of EGFR was expressed in its wild type 
by RFLP in all cases. Conclusions: Detection of 
common EGFR deletion and mutation showed to be 
a rare event in Squamous cell carcinoma of the lung. 
While EGFR mutation is the most effective molecu-
lar predictor or sensitivity in patients with advanced 
NSCLC submitted to EGFR-TKIs treatment, ampli-
fication and polysomy is the most effective molecular 
predictor for EGFR-TKIs responsiveness in squamous 
cell carcinoma, when valida ted isolated from the 
group of NSCLC.
Rev Port Pneumol 2010; XVI (3): 453-462
Key-words: Lung cancer, epidermoid carcinoma, 
paraffin-embedded tissue, EGFR, gene amplification, 
gene polysomy.
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Introduction
Lung cancer is one of the most common 
human cancers and the leading cause of 
cancer death world-wide1,2.
Non-small cell lung cancer (NSCLC) com-
prises approximately 85% of all cases divi-
ded into squamous-cell carcinoma (SCC), 
adenocarcinoma (AC), large cells carcino-
mas and others3-5.
The treatment of lung cancer is based on 
the stage of the cancer, and on patients per-
formance status: for patients with early stage 
disease (stage I or II) surgical resection is 
considered the primary therapeutic choice. 
However, that majority of NSCLC cases 
have reached locally advanced (stage III) or 
metastatic stages (stage IV) at the time of 
diagnosis and chemotherapy is usually re-
commended as first line therapy.
Surgical resection is considered to be a cura-
tive treatment during earlier stage disease, 
but 5-year survival after surgical resection 
remains less than optimal, ranging from 
67% for pT1N0 patients to 23% for pa-
tients with ipsilateral mediastinal lymph 
node involvement3-6.
Receptor and non-receptor tyrosine and 
serine/threonine kinases have emerged as 
promising targets for specific drug develop-
ment because overexpression or aberrant 
activation of these kinases often play an im-
portant role in the molecular pathogenesis 
of solid tumours. Further, the structural 
heterogeneity of these kinases has permitted 
development of small compounds which is 
a specific way inhibit their activity.
Epidermal growth factor receptor (EGFR), 
a 170 kDa tyrosine kinase (TK), is a mem-
ber of the human epidermal receptor (HER) 
family that consists of four transmembrane 
tyrosine kinase receptors, EGFR (HER1, 
erbB-1), HER2 (erbB-2, HER/neu), HER3 
and HER4. Upon ligands binding, the re-
ceptors homo or hetero-dimerize in between 
or either other growth factors. Subsequent-
ly, activation of receptor intrinsic tyrosine 
kinase activity occurs together either down-
stream signalling cascades, mainly including 
Ras-Raf-MAP-kinase pathway, PI3K-Akt 
pathway, and STAT pathway. All these have 
strong stimulatory effect on cell prolifera-
tion, differentiation, survival, angiogenesis 
and migration7,8.
EGFR has emerged as a critical tumorigenic 
factor in the development and progression 
of NSCLC. EGFR and erbB-2 are expressed 
in many solid tumours and their overexpres-
sion is associated with poor prognosis.
Activating mutations of EGFR are related to 
increased response rate and survival in pa-
tients treated with EGFR tyrosine kinase in-
hibitors (TKIs)9. Specific EGFR tyrosine ki-
nase inhibitors (TKIs) have been developed 
and used clinically in the treatment of ad-
vanced NSCLC. They disrupt EGFR signal-
ling by competing with adenosine triphos-
phate (ATP) for binding sites at tyrosine 
kinase domain, and thus inhibiting the phos-
phorylation and activation of EGFRs and 
the downstream signalling network10.
Tyrosine kinase inhibitors after first line 
chemotherapy are used to complement con-
ventional chemotherapy and several studies 
are required to define molecular characteris-
tics, different in adenocarcinoma and 
squamous cell carcinoma, to predict the res-
ponse to those drugs11.
Somatic mutation is the mutation that oc-
curs only in somatic cells, which are in con-
trast to germ cells. A large number of so-
matic mutations have been identified in the 
EGFR gene in NSCLC. In general, these 
Carcinoma epidermóide do pulmão: polissomia e amplificação do cromossoma 7 
e do gene EGRF com forma wild type nos exões 19 e 21
Patrícia Couceiro, Vítor Sousa, Ana Alarcão, Maria Silva, Lina Carvalho
Pneumologia 16-3 - Miolo - 3ª PROVA.indd   Sec2:455 01-07-2010   16:24:10
 CHAPTER 4 – MANUSCRIPT II 
56 
R e v i s t a  P o r t u g u e s a  d e  P n e u m o l o g i a456
Vol XVI  N.º 3  Maio/Junho  2010
mutations can be included into three major 
types: in-frame deletion, insertion, and mis-
sense mutation. Most of these mutations are 
located in the tyrosine kinase coding do-
main (exons 18-21) of the EGFR gene. The 
amino acids 746-750 encoded by exon 19 
and amino acid 858 encoded by exon 21 are 
two mutation hotspots, which accounts for 
over 80% of all the detected mutations12,15.
A considerable number of retrospective 
studies have reported that two activating 
mutations, small in-frame deletion in exon 
19 and substitution of leucine for arginine 
at amino acid 858 in exon 21 (L858R), 
have a striking correlation with EGFR-TKI 
sensivity.
Both activating mutations are able to en-
hance kinase activity of EGFR and the acti-
vation of its downstream signaling, and play 
a pivotal role in supporting NSCLC cell 
survival. When the specific EGFR-TKIs are 
applied, the excessive survival signals that 
cancer cells are “addicted to” are counter-
atcted and a clear apoptosis occurs14.
The present study intended to clarify the sta-
tus of EGFR gene by FISH, PCR and its im-
munohistochemical expression in squamous 
cell carcinoma of the lung.
Material and methods
Sample selection
A cohort of 54 formalin-fixed paraffin-em-
bedded samples, adequate for analysis were 
included in this retrospective study, concern-
ing sections of squamous cell carcinoma se-
lected from surgical specimens. In Table I is 
resumed the age and gender of the patients.
Slides of tumor samples stained with hema-
toxylin-eosin were independently reviewed 
by two pathologists and representative areas 
were marked. Core tissue biopsy speciemens 
(3mm in diameter) in triplicate were ob-
tained from individual paraffin-embedded 
samples (donor blocks) and arranged in a 
new recipient paraffin block (tissue array 
block) using a punch-extractor pen (Histo-
pat, Histopathology, Ltd.). Each tissue array 
block contain 12 specimens, which allowed 
all 162 specimens (triplicate speciemens of 
54 cases) to be contained in 13 array blocks. 
This TMA construction was used for FISH 
and immunohistochemical analysis.
Immumohistochemistry
Three μm sections of TMA were placed on 
coated slides and were allowed to dry over-
night. After deparaffinization and rehydra-
tion, antigen unmasking was performed us-
ing pronase E for 10 minutes. Endogenous 
peroxidase activity was quenched using 15 
minutes incubation in 3% diluted hydrogen 
peroxide (H2O2). For blocking nonspecific 
binding of secondary antibody, Ultra V 
Block (Ultra Vision Kit; TP-015-HL; Lab-
Vision) was applied to the sections and then 
the sections were incubated at room tem-
perature with primary anitbodies against 
EGFR (clone 31G7; Zymed Laboratories) 
at a dilution of 1:20 for 30 minutes. After 
washing with phosphate-buffered saline 
(PBS) the slides were incubated with biotin-
labeled secondary antibody for 30 minutes. 
Primary antibody biding was located in tis-
Table I – Patients characteristics
Female (7) Male (47)
Age (years) median 65,8 66,9
Age (years) range 54-73 48-84
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sues using peroxidase-conjugated streptavi-
din (LabVision). 3,3-diaminobenzidine tet-
rahydrochloride (DAB) was used as the 
chromogen, according to manufacturer’s in-
structions. The slides were counterstained 
with hematoxylin, dehydrated and mount-
ed. In parallel we used known positive and 
negative controls.
IHC staining for EGFR antibody was scored 
according to Hirsch: intensity and percent-
age of cells. The staining was read as follow:
Grade + Score Intensity/positivity
0 <10 + IHC negative
1 50% cells 10-100 1 – Weak Æ IHC low positive
2 75% cells 101-200 2 – Moderate Æ IHC moderate positive
3 >75% cells 201-300 3 – Strong Æ IHC intense positive
Fluorescence in situ hybridization
In situ hybridization is a sensitive method 
that is generally used to detect specific gene 
sequences in tissue sections or cell prepara-
tions by hybridizing the complementary 
strand of a nucleotide probe to the sequence 
of interest.
Dual-color FISH analysis was performed on 
paraffin-embedded tissue blocks on the cas-
es studied, using the Vysis LSI EGFR/CEP 
7 probe assay (Vysis; Abbott Molecular, 
USA). In brief, sections of 4 μm thickness 
from the tissue microarray blocks were used, 
they were baked overnight at 56°C, deparaf-
finized in xylol, rehydrated in 100%, 70% 
ethanol and bidestilled water. Slides were 
then submitted to a pre-treatment in a pres-
sure cooker with 10mM citric acid-triso-
dium salt buffer pH6 for 4 minutes. Washed 
in 2× SSC salts (sodium chloride and so-
dium citrate) pH 7 for 5 minutes at room 
temperature. Slides were immersed for 15 
minutes in proteinase K solution at 37°C, 
they were then rinsed in 2x SSC pH7 for 5 
minutes at room temperature. The slides 
were then dehydrated in 70%, 90% and 
100% ethanol then air dried. Ten microli-
ters of probe mixture were applied on the 
target areas and a 22mmx22mm glass cover-
slip was placed over the probe.
Coverslips were sealed with rubber cement 
and codenatured at 83°C for 5 minutes and 
incubated overnight at 37°C in a humidity 
chamber. Post-hybridization washes in buf-
fer (50% formamide 2x SSC pH7) at 46°C 
and washed with 2x SSC pH7. Slides were 
air-dried in the dark and counterstained 
with DAPI.
Analysis was performed using Nikon Eclipse 
80i and DXM 1200F Workstation equipped 
with Nikon filter set with single-band exi-
tors for rhodamine, fluorescein isothiocya-
nate, DAPI.
Overlapping cells were excluded from ana-
lysis. Two signals were counted as adjacent 
or fused only if they were separated by less 
than one domain.
One hundred spindel cells interphase nuclei 
with strong and well delineated signals were 
examined by two different individuals. A 
split signal in 5% or more of spindle cells 
was required for a result to be classified as 
positive.
DNA preparation and molecular analysis 
of the EGFR gene
Polymerase Chain Reaction (PCR) – is a 
method that allows logarithmic amplifica-
tion of short DNA sequences within a lon-
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ger DNA molecule. Briefly, genomic DNA 
was extracted from serial 5-μm archival pa-
raffin-embeded tissue, containing a repre-
sentative portion of each tumor block, using 
the QIAmp DNA Mini Kit (Qiagen, IZA-
SA, Portugal). One hundred nanograms 
(ng) of DNA were amplified in a 50 μl reac-
tion solution containing 5 μl of 10x buffer 
(Roche, Portugal), 2,5 mM MgCl2, 0,2 μM 
of each complementary primer, 200 μM de-
oxynucleoside triphosphate and 1 unit of 
DNA polymerase (Roche, Portugal). Ampli-
fications were performed using a 5 minutes 
initial denaturation at 95ºC; follwed by 40 
cycles 30 seconds at 95ºC, 1 minute at 60ºC 
1 minute at 72ºC and a 10 minutes of final 
extension at 72ºC. EGFR gene (exons 19 
and 21) mutations were determinated using 
the intron-based primers according to a 
published method6. We performed muta-
tional analysis of exon 19 deletion and 
L858R point mutation of the EGFR gene, 
as previously described7. Briefly, exon 19 de-
letion was determinated by common frag-
ment analysis using PCR with an FAM-la-
beled primer set, and the products were 
electrophoresed on ABI PRISM 3100 (Ap-
plied Biosystems) and all electropherograms 
were reanalysed by visual inspection to check 
for the mutations. The L858R mutation was 
performed using also MJ MiniOpticon (Bio-
Rad), and its products were then detected by 
restriction fragment length polymorphism 
(RFLP) analysis. The restriction enzyme 
MscI was used to digest the TGGCCA se-
quence in the amplicon of the wild-type al-
lele. In contrast, mutant type (L858R) was 
not digested because of the base substitution 
of T to G at the first base of TGGCCA. On 
the other hand, a new FauI restriction site, 
CCCGC, that can be used to distinguish 
L858R mutant allele from wild-type. The 
PCR products were digested with the restric-
tion enzymes MscI and FauI and run on 3% 
agarose gel, and the existence of this muta-
tion was accessed. The Fig. 4 presents the 
predicted gel-electrophoresis patterns for 
PCR-RFLP samples.
Statistical analysis
Statistical analyses of categorical variables 
were performed using bilateral Chi-squared 
tests or Fisher exact test as appropriate. To 
compare percentage of markers expression 
ANOVA test was applied.
Results
Patient characteristics
This study included 47 male and 7 female 
patients with a median age of 66 years. All 
of them had a history of smoking. Stages 
were diagnosed I (52.8%), II (31.6%) and 
III (15.6%) (Table I).
EGFR expression 
by immunohistochemistry
Immunohistochemical EGFR protein overex-
pression was identified in 49 cases, by the ap-
plication of Hirsh’s scoring system (Table II).
Table II – EGFR protein expression detected by IHC in 
squamous cell carcinoma of the lung
Results Immunohistochemistry
IHC + Low Mod Int14 14 17
IHC - 9
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Table III – Comparision of detected EGFR copy number using FISH and IHC in Squamous cell carcinoma of the lung
TNM status Patients EGFR protein expression IMC
EGFR gene expression 
FISH Cappuzzo
N % Positive n (%) Negative n (%) Positive n (%) Negative n (%)
T1NOMx 14 26% 11 (79%) 3 (21%) 7 (50%) 7 (50%)
T1N1Mx 4 7% 4 (100%) 0 4 (100%) 0
T2N0Mx 19 35% 16 (84%) 3 (16%) 16 (84%) 3 (16%)
T2N1Mx 4 7% 4 (199%) 0 1 (25%) 3 (75%)
T2N2Mx 2 4% 1 (50%) 1 (50%) 1 (50%) 1 (50%)
T3N0Mx 8 15% 7 (100%) 1 (50%) 4 (50%) 4 (50%)
T3N1Mx 2 4% 1 (50%) 1 (50%) 2 (100%) 0
T4N0Mx 1 2% 1 (100%) 0 1 (100%) 0
Table IV – EGFR molecular alterations scored according Cappuzzo et al, 2005 criteria
Results
FISH
Disomy Low trisomy High trisomy Low polysomy HighPolysomy
Ampli  cation 
EGFR / CEP 7
IHC + 5 1 1 6 25 7
IHC - 1 1 1 – 6 –
TOTAL 6 2 2 6 31 7
Table V – Relationship between the results obtained in IHC 
and FISH of 54 screened patients
Results FISH NEG FISH POS TOTAL
IHC NEG 3 6 9
IHC LOW POS 8 7 15
IHC MOD POS 4 10 14
IHC INT POS 3 13 16
TOTAL 18: 3 / 15 36: 6 / 30 54
EGFR mutations determinated 
by FISH and PCR
The chromosome 7 and EGFR gene were 
analyzed by FISH and scored according to 
Cappuzzo’s (2005) method that showed in 
31 cases high polysomy and in 7 cases am-
plification (Table III and Fig. 5).
Through capillary electrophoresis, deletion 
in exon 19 of EGFR was detected in 3 cases 
of 48 samples; the exon 21 of EGFR was 
expressed in its wild type by RFLP in all 
cases (Figs. 1-4).
Correlation between EGFR expression 
and EGFR mutations
(Table V).
2 1
45
Wt
Wt/Del 15bp
Wt/Del 18bp
Fig. 1 – Capillary electrophoresis – Exon 19 of EGFR
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Discussion/Conclusions
EGFR mutation screening could be num-
ber one test to provide the most direct and 
valuable information to help clinicians to 
make treatment decision when dealing with 
NSCLC in general1.
Meanwhile somatic mutations of EGFR gene 
are found in about 2-8% of USA non-small-
cell lung cancer patients because of consider-
ing together all histological types of NSCLC.
In the current study – all smokers: exon 19 
deletion was found in 3/48 (6.25%) of Por-
tuguese derived lung epidermoid carcino-
mas and in exon 21 – any L858R mutation 
in the 48 cases studied was identified. In-
frame deletions in exon 19 and in exon 21 
mutations L858R are the EGFR mutations 
most commonly identified and most clearly 
associated with TKI responsiveness.
Low number of EGFR gene copies per cell, 
including disomic and trisomic patterns, 
did not influence the level of protein expres-
sion, whereas a high gene copy number, 
clustered amplification or high polysomy, 
correlated with protein level.
EGFR protein overexpression in all tumours 
with gene amplification is the mechanism for 
overexpression. Balanced disomy for chro-
mosome 7 and EGFR gene while expressing 
high protein expression might be controlled 
by other mechanisms, the complex interac-
tion between gene and protein levels.
Identifying a panel of predictive markers is 
very important for selection of advanced 
NSCLC patients for EGFR-TKI therapy. 
Although several important demographic 
and clinical factors are associated with treat-
ment response, EGFR somatic mutations 
are still the most effective predictor for 
EGFR-TKI sensitivity in lung cancer histo-
logical types.
Fig. 2 – In–frame deletion of exon 19 (del E746-A750): Representative nucleotide se-
quence of the EGFR gene in tumor speciemens, the nucleotide sequence of heterozygous 
in–frame deletions in exon 19 by direct sequencing (double peaks)
5
43
Wt
No PCR ampli  cation
Fig. 3 – RFLP – Exon 21 of EGFR
Fig. 4 – Agarose gel – Exon 21 of EGFR
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Our study is the first that concerning only 
cases of squamous cell carcinoma of the 
lung in surgical stages, after reviewing the 
published medical literature which only in-
cludes cases of non-small-cell lung Cancer 
in advanced stages with higher expressions 
of the parameters here included.
However, the results obtained showed that 
squamous cell lung carcinoma in surgical stag-
es expressed EGFR protein and high polysomy 
of chromosome 7 in 46.3% and amplification 
in 12.9% of the cases. Only in 3 cases we have 
detected deletions in exon 19.
The presence of high polysomy, amplifica-
tion and deletions in exon 19 of EGFR gene 
have implications on tumorigenesis process 
due to his increased enzymatic activity be-
come a TKIs therapeutic target.
These conclusions have to be correlated 
with follow-up of these patients to define 
potential recurrence related with the results 
obtained.
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Introduction
Tobacco,  environmental  and  genetic  factors  and  several  lung
diseases contribute  to  lung  cancer  carcinogenesis.  Lung  can-
cer is  one  of the  most common  cancer  diagnosed,  and  has
also the  highest  mortality  rate due  to the advanced  stages
at time  of diagnosis,  and  when  the options  for  treatment
have to be  understood  as  personalized  therapy.1-8
Bronchial-pulmonary  carcinomas  consist  of  small  cell  lung
cancer (SCLC),  squamous  cell  carcinoma  (SCC),  adenocarci-
noma, large  cell  carcinoma  and  sarcomatoid/pleomorphic
carcinomas.8 Adenocarcinoma  is  the  most  common  type  in
non-smokers and  its  incidence  has  increased  in  recent  years,
developing after  terminal  respiratory  unit  (TRU)  but also
recognized in  respiratory  epithelium.8--10 Adenocarcinoma
pure patterns  are  recognized  [acinar, papillary,  micropapil-
lary, BA (bronchioloalveolar/lepidic/AIS-adenocarcinoma  in
situ), solid  with  mucin  production]  but mixed  type pre-
dominates. Differences  between  the subtype/patterns  of
adenocarcinoma should  be taken  into  account  to  improve
diagnosis, prognosis  and  as  an enhancement  in therapy
selection.8,10
Cytokeratin  7 (CK7), high  weight  molecular  cytokeratins
(HWMC) like  CK5/6,  CK20,  chromogranin  A  and  TTF1  are
currently used in  lung  cancer  diagnosis.11,12 Ki67  is  a  cell
proliferation marker  with  prognostic  value.13--15 In  the  apo-
ptosis pathway, p53  induces  Bax  transcription  and  reduces
bcl2. Bcl2/Bax  ratio  is  negative  in  lung  carcinomas.16 Inac-
tivation of  RB  pathway  is  considered  a  requirement  for
lung carcinogenesis.16 Adenomatous  polyposis  coli  (APC)
gene is  involved  in  the canonical  Wnt/-catenin  signal
transduction. APC  is  mutated  in liver,  colorectal  adeno-
mas and  lung  tumors.17 Cyclins  D  (D1,  D2, and  D3)  are
activators of cyclin-dependent  kinases  cdk4  and  cdk6,  to
translate growth  signals  into  cell  cycle  progression,  lead-
ing to proliferation.18,19 Cyclin  D1  overexpression  and  pRB
inactivation indicates  a  poor  prognosis.20
Bcl2  as  an  anti-apoptotic  protein  has a  more  impor-
tant role  in  neuroendocrine  (NE)  lung  cancer  than
in other  bronchial-pulmonary  carcinomas.21 Excision
repair cross-complementing  1  (ERCC1)  genetic  polymor-
phisms may  affect patient’s response  to platinum-based
chemotherapy.22,23 However,  another  study concluded  that
patients with  a  bronchial-pulmonary  carcinoma  with  high
ERCC1 expression  have a  better  prognosis  than  those  with
low expression.24 Multidrug  Resistance  Protein 1  (MRP-1)
and lung  resistance-related  protein  (LRP)  may  confer
resistance to cytotoxic  and  antiviral  drugs.25-31
EGFR  and  HER2  play  a  central  role  in  tumorigenesis.32,33
Targeting  those  receptors  provides  a  unique  approach  for
treating EGFR/HER2  expressing  cancers.34,35 The  most com-
mon alteration  of HER2  is overexpression/amplification;
mutations  are  less frequent.33,35,36 The  activated  receptors
trigger Ras-Raf-MEK  (mitogen-activated  and  extracellular
signal regulated  kinase),  ERK1  and  ERK2  (extracellular-signal
regulated kinase  1  and  2) pathways  leading  to cell  growth,
mTOR (mammalian  target  of rapamycin)  pathway  leading
to protein  synthesis,  and  PI3K-AKT  (phosphatidylnositol-2
kinase Akt)  pathway  sustaining  cell survival.36
The  objectives  of this  work  were to  validate  a  small
differentiation IHC panel, evaluate  protein  expression  of
different  genes  according  to different  adenocarcinoma  pat-
terns,  and  correlate  this expression  with  cell  pathways
of progression  and  drug  resistance,  in  order  to under-
stand bronchial-pulmonary  adenocarcinoma  carcinogenesis.
Another objective  was to verify  possible  differences  of  gene
expression in  adenocarcinoma  taking  into  account  variables
such as  gender, age,  smoking  and  different  tumor stages.
The global  intention  of  this  project  is  to acquire  knowl-
edge which  can be  applied  in the  diagnosis  and  prognosis
evaluation of bronchial-pulmonary  adenocarcinoma  and  its
subtypes in  order  to  define  individual  treatment.
Materials  and methods
Materials
Surgical  samples  of bronchial-pulmonary  adenocarcinomas
(n =  45) covering  all subtypes  recognized  by  WHO/2004  were
randomly selected  and  staged  by  the 2010  TNM system;  the
ERS/ATS proposal  was also  applied.  At  least two sections
of each  tumor  and  sections  of  lymph  node metastasis  were
selected (Table  1).12,37
Methods
CK7,  TTF1,  CK20,  CK  5/6/18  (LP34),  chromogranin  A,
Ki67, P53,  RB,  BCL2,  cyclin  D1,  APC,  ERCC1,  LRP,  MRP-1,
EGFR, and  HER2  expressions  were evaluated  by  immuno-
histochemistry (IHC).  IHC  was  performed  on  formalin-fixed,
paraffin-embedded tissue  samples  in  automatic  immunos-
tainer (Autostainer  360  --  LabVision®). Streptavidin  biotin
protocol was  applied  according  to the  manufactures  indica-
tions for each antibody. Three-micrometer  tissue  sections
were placed  on  coated  slides  and  allowed  to  dry  overnight.
After deparaffinization  and  rehydration,  antigen  retrieval
was performed  according  to Table  2. Endogenous  peroxi-
dase activity  was  quenched  using  15 min  incubation  in  3%
diluted hydrogen  peroxide  (H2O2). For blocking  non-specific
binding, Ultra  V  Block  (Ultra  Vision  Kit®;  TP-015-HL)  was
applied to  the  sections  and  then  they  were  incubated
at room  temperature,  with  primary  antibodies  according
to Table  2.  After  washing  with  phosphate-buffered  saline
(PBS), slides  were  incubated  with  biotin-labeled  secondary
antibody (LabVision®) for 15 min.  Primary  antibody  bind-
ing was localized  in  tissues  using  peroxidase-conjugated
streptavidin  (LabVision®) and  3,3-diaminobenzidine  tetrahy-
drochloride (DAB)  was  used as  the  chromogen,  according  to
manufacturer’s instructions.  The  slides  were  counterstained
with hematoxylin,  dehydrated  and  mounted.  In  parallel,
known positive  (Table  2) and  negative  controls  were  used.
Three-micrometer  tissue  sections  were placed on coated
slides and allowed  to dry  overnight.  IHC  scoring  was applied
independently by  two  pathologists  who  registered  the
intensity of  expression  (1  --  low  expression,  2  --  interme-
diate expression  and  3  -- high  expression)  and  percentage
of stained  cells.  For statistical  analyses  we  grouped  the
immunohistochemistry results  in  4  categories.  For each  case
we  multiplied  the  intensity  of expression  by  the percentage
of staining  cells  and  we  used  this  score  for  the  formation  of
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Figure  1  (A)  Expression  (++)  of  APC  in  BA  pattern,  200×;  (B)  Expression  (+++)  of BCL2  in  papillary  pattern,  200×;  (C)  BA  pattern
with Cyclin  D1  expression,  400×;  (D)  Cyclin  D1  expression  in solid  pattern,  200×;  (E)  EGFR  expression  (+++)  in acinar  pattern,  200×;
(F)  EGFR  expression  (+++)  in solid  pattern,  200×;  (G)  ERCC1  expression  (++)  in BA  pattern,  200×;  (H)  ERCC1  expression  (++)  in solid
pattern,  200×;  (I)  HER2  expression  (++)  in  acinar  pattern,  400×;  (J)  Ki67  expression  (+++)  in lymph  node  metastasis,  200×;  (L) Ki67
expression  (+++)  in  acinar  pattern,  400×;  (M) LRP expression  (+++)  in acinar  pattern,  400×;  (N)  MRP-1  expression  (+++)  in  solid
pattern,  200x;  (O)  RB  expression  (++)  in  papillary  pattern,  200×;  and  (P) P53  expression  (+++)  in micropapillary  pattern,  200×.
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Figure  2  Dendrogram  for  the  hierarchical  clustering  analysis
of transcripts  according  to  their  expression  values,  using  Single
linkage algorithm,  Euclidean  distances,  targeting  the  various
patterns and normal  tissue.
was higher  in adenocarcinomas  of smokers  and  ex-smoker
patients (p  = 0.0034  and  p  = 0.0064).
TTF1, Ki67, APC,  RB,  P53,  BCL2,  ERCC1  and  EGFR  showed
significantly different  expressions  according  to the stage  of
the tumor.  TTF1 expression  showed  differences  between
stage IA  and  IIIA,  being  higher  in stage  IA  (p  =  0.02).  Ki67
was higher  in  IIIA  compared  to IA  and  IIA  (p  =  0.02  and
p =  0.02).  APC expression  was  higher  in IIA  and  IIIA  com-
pared to IA  (p = 0.065 and  p =  0.025).  RB  expression  was
higher in stage  IB  tumors  compared  to  stage  IA  (p = 0.04).
P53 expression  was higher in  IIA,  IB  and  IIIA  compared  to  IA
(p =  0.01;  p =  0.03;  p =  0.01).  BCL2  expression  was higher  for
IB compared  to IA  (p =  0.039).  ERCC1  was  higher  in stage
IA compared  to  IIA  (p  = 0.02)  and  in  IIIA  compared  to IIA
BAC
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Figure  3  The  correlation  of  the  patterns  with  the  advanced
PCA factor  analysis.
(p = 0.01).  EGFR  expression  was  lower  in  stage  IB  compared
to IA (p  =  0.032).
To  sum  up,  almost  all patterns  showed  differences  of
expression in  relation  to  normal  tissues  with  some excep-
tions for  cyclin  D1 (papillary  and  micropapillary  patterns),
for EGFR  membrane  staining  (papillary  and  micropapil-
lary patterns),  for ERCC1  (in  micropapillary, solid and
BA/lepidic patterns),  for  RB  (in  acinar, papillary  and
solid patterns)  and  for  TTF1  (in  papillary  and  solid  pat-
terns).
Solid pattern  demonstrated  lower  HER2  expression  com-
pared to acinar, papillary,  micropapillary  and  BA/lepidic
patterns. Papillary  pattern  had  lower  ERCC1  expression  than
solid and  BA/lepidic  patterns.  Solid  pattern  showed  lower
TTF1 expression  than  BA/lepidic  pattern.
Discussion
Non-BA/lepidic  adenocarcinomas  are most often  periph-
eral tumors  with  different  growth  patterns  considered
mixed type according  to WHO classification,  with  at
least two  individual  patterns;  solid  or acinar  patterns
are the most frequent  in the central  tumoral  bulk  and
BA/lepidic at the periphery. Acinar  has been  described
as the most common  pure  subtype and  the  most  com-
mon in  the mixed  type.  Papillary  pattern  was  present  in
10% of the adenocarcinomas,  often  difficult  to  differen-
tiate from  BA/lepidic,  which  has  important  therapeutic
strategies’ implications.9 Micropapillary  pattern  is cha-
racterized by  small  papillary  tufts  growing  from  alveolar
septa or floating  within  alveolar  spaces  lacking  fibrovas-
cular cores  and  is  usually  observed  with  papillary  and
mixed patterns;  they  are more  aggressive  due  to their
increased capacity  for metastasize,  indicating  unfavor-
able prognosis.9 Solid  pattern  with  mucin  production  has
been reported  in  15% of mixed-type  adenocarcinomas.9,10
BA/lepidic  pattern  shows  tumor cell  growth  along  alveo-
lar septa  and  aerogeneous  spread  through  the lung.  It is
frequently diagnosed  in  former  and  non-smoking  women.
BA/lepidic is  classified  as  non-mucinous,  mucinous  or
mixed.9,10,38
Markers  of  differentiation
CK20,  HWMC  and  chromogranin  A were  negative  in  all  our
samples and  CK7 and  TTF1  were positive,  which  means  mor-
phology almost always  sustains  bronchial-pulmonary  adeno-
carcinomas’ diagnosis  when  mucin  is  not  present.  These
results corroborated  those  that  have been  described  in  the
literature. CK7 is  positive  in  90--100% and  CK20  is  positive
in only 7--10%  of primary  lung  adenocarcinomas.39 Chromo-
granin A  is not  expressed  in  an  ordinary  adenocarcinoma.40
TTF1  is a  useful  marker  for  lung  adenocarcinoma  and  is
also expressed  in thyroid  normal  tissue  and  tumors.22 The
use of TTF1,  as  a  differentiation  marker, is  useful  not
only for  diagnostic  purpose  but especially  to  differentiate
between different  histological  types of bronchial  and  TRU
adenocarcinomas.
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Genetic  expression  in  each  pattern  of
bronchial-pulmonary  adenocarcinoma
Acinar  pattern
Starting with  membrane  proteins  that  play  a  central  role
in the  control  of cellular  proliferation,  differentiation,
apoptosis and  angiogenesis,  EGFR and  HER2  had  a  higher
expression in  acinar  pattern  than  in normal  epithelium/lung
cells, highlighting  the  importance  of AKT/mTOR,  PI3K and
MAPK pathways,  essential  for  oncogenic  transformation  and
tumor maintenance.41 Blockage  of  both  results in  apoptosis
and tumor  shrinkage.42,43 AKT,  by  inhibiting  GSK-3,  changes
canonical Wnt  pathway, releasing  -catenin,  and  leading  to
angiogenesis and  proliferation.44
TTF1 positivity  was statistically  higher  in the adenocar-
cinomas (with  acinar  pattern)  compared  to  normal  tissue.
While the  majority  of the adenocarcinomas  expresses  TTF1,
this marker  is misunderstood,  because  its  positivity  is  associ-
ated inversely  with  proliferation  but it  is  correlated  with  P53
expression and  HER2/neu  involved  in lung  cancer.45 TTF1,
NKX2-8 and  PAX9  are  very  important  in  initiation  and  pro-
gression of  lung  cancer. It  is  said  that  MAPKinase,  JAK/STAT
and Wnt are  important  in activation  of TTF1  and  NKX8,  con-
nected with  EGFR  and  Her2.46
The expression  of cyclin  D1 was  higher  in  tumoral  than
in normal  tissue  and  RB  expression  had  no  statistical  dif-
ference when  compared  to  normal  tissue.  This  fact  may
indicate a  tendency  to proliferate,  because  once  cyclin  D1 is
in high  concentration,  it  could  phosphorylate  more  RB  pro-
tein and  release  E2F, involved  in  the  regulation  of genes  with
implications in  cell  cycle  progression  (G1  to S phase).43,47
One  of  the genes  that  correlate  with  E2F  is  Ki67, still  a
good marker  for  proliferative  index.48 We obtained  statis-
tical significant  higher  expression  of Ki67  in  all  patterns  of
adenocarcinoma, indicating  active  proliferative  activity.49
Another  overexpressed  gene  in  this  pattern  was  P53  and
some studies  indicate  that  ‘‘a  low  level  of  p53  leads  to
transient growth  arrest  and  cell  survival,  whereas  a  high
level promotes  irreversible  apoptosis’’,  and  P53  levels  may
have oscillations,  and  it has  to  be explored  as  a  target  for
therapy.50 ERCC1  is  downregulated  in  acinar  pattern,  may  be
indicating that  DNA  repair  pathway  is not  activated  in  the
acinar pattern.  ERCC1  is  associated  with  radio  resistance,  so
it is important  for treatment  choice.51 High  BCL2  expression
may favor  cell  cycle  arrest.
LRP  and  MRP1  were also  overexpressed  in  our  samples,  as
has been  described  in lung  cancer.52,53 As  mentioned  these
genes can lead  to chemotherapy  resistance.  This  fact  should
be taken  into  consideration  when  assessing  prognosis  and
treatment issues.
APC  was also  overexpressed  in the acinar  pattern,
and being involved  in  -catenin  degradation  is  important
in progression,  with  GSK-3  and  Axin  downregulating  -
catenin (leading  to -catenin  degradation).54 Our  findings
also suggest  that  -catenin  may  be  downregulated,  already
described in  lung  cancer, which  is  related  to  cell  invasion
and metastasis.55 -Catenin  is  connected  to cytoskeleton
and cadherins  and  regulates  E-  or N-cadherin-mediated
cell adhesion.  Notch activation  (that  inactivates  -catenin)
may repress E-cadherin,  leading  to tumor  growth  and
metastasis.56 So,  overexpression  of APC  leads  to -catenin
degradation  that  weakens  cell  adhesion  promoting  tumor
growth and  metastasis.
In  relation  to the acinar  pattern  the  genes  analyzed
expressions could  lead to cell  proliferation  and  survival,
angiogenesis and  metastasis.
Papillary pattern
This  pattern  showed  some  differences  compared  to acinar
pattern. There  were no  differences  of expression  for  cyclin
D1 and  TTF1,  compared  with  normal  tissue.  Since  cyclin  D1
level is  not  upregulated  as  well  as  RB  gene,  the  concen-
tration of  active  E2F  must  be regular.  However  Ki67  was
overexpressed, in  contrast  to previous  findings.21 So  other
pathways could  explain  cellular  proliferation.  There  was
higher expression  of EGFR but  just  in  cytosol  compartment;
membrane EGFR had  the same  level  of expression  as  normal
tissue, so  we  can conclude  that  activity  of  EGFR  is normal.
Thus, all pathways  that  this  gene  regulates  are  functioning
normally or if  activated,  this  activation  is  not  induced  by
EGFR.41,57,58
Papillary  pattern  proliferation  properties  could  in  part  be
explained by  APC  upregulation  when  compared  to normal
tissue.
Micropapillary pattern
Micropapillary pattern  is  characterized  by  small  papillary
tufts and  is  considered  an  aggressive  adenocarcinoma,  more
than papillary  pattern.59--61 There  were  three  differences
with papillary  patterns  concerning  expression  of  ERCC1,  RB
and TTF1.  RB  expression  was downregulated  in  micropap-
illary, being  almost non-existent.  Some  authors  said  that
downregulation of RB  leads  to the progression  of cell  cycle.62
Micropapillary  pattern  had  a  basal level  of  ERCC1,  this  indi-
cating that  DNA  repair  may  occur  with  NER  activation.  TTF1
was overexpressed  in this pattern  and,  according  with  what
has been  said  before,  this  fact  indicates  lung  cancer  progres-
sion and  development  after  the  terminal  respiratory  unit.
These considerations  are  consistent  with  our  results  because
downregulation of  RB  and  TTF1  overexpression  are  responsi-
ble for  cell  cycle  progression  and  basal  level  of ERCC1  allows
DNA repair. This  last  consideration  is  very  important  to keep
in mind  in treating  lung  cancer.
Solid pattern
Genetic  expression  in  this  pattern  is  identical  to  acinar
pattern with  only two  differences  for  ERCC1  and  TTF1
expressions. These  showed  no  differences  compared  to nor-
mal tissue  in  solid  pattern,  whereas  in  acinar  pattern  there
was a  higher  expression  for  TTF1  and  downregulation  for
ERCC1. A  lower  TTF1  expression  reflects  a  lower  differenti-
ation of this  pattern  and  eventually  means  a  more  aggressive
behavior since in  general  less differentiated  tumors  are
more aggressive.  Higher  EGFR  expression  could  be  the reflex
of EGFR mutations  and/or  overexpression  activating  sev-
eral pathways  involved  in  cell  cycle  control,  proliferation
and even  metastization.  EGFR  overexpression  is also  associ-
ated with poor  prognosis.33,63 Solid  pattern  has more  ERCC1
expression than acinar  and  this  aspect  is  very  important
because ERCC1  repairs  DNA  and  confers  resistance  to some
drugs.51
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BA/lepidic  pattern
BA pattern,  called  lepidic  in ATS/ERS  proposed  classification
can be difficult  to distinguish  morphologically  from  papil-
lary pattern.12 Cyclin  D1 had  higher expression  in BA/lepidic
pattern and  a  basal level  in  papillary  pattern.  This  fact
and knowing  that  RB  was not  overexpressed,  enhances  the
idea that  this  pathway  leads  to cell  progression.  As  TTF1
is related  with  tumor  progression  and  is  overexpressed,
unlike in  papillary  pattern,  and  ERCC1  has  a  basal  level  in
BA/lepidic pattern  and  is  downregulated  in  papillary  pat-
tern, this  may  explain  chemical  resistance.
By  evaluating  the expression  of  these  13 genes,
BA/lepidic pattern  has  more  cell  progression  pathways
activated than  papillary  pattern.  This  finding  proves  that
they are  biologically  different.  The  differences  could  be
explained by  the origin  in TRU with  the  different  activated
pathways, with  probable  implication  in  the prognosis  and
treatment, knowing  that  different  pathways  are targets  for
therapeutic approach.
Metastasis  analysis
Metastasis  formation  is a complex  process  with  several  path-
ways activated  leading  to  loss  of cellular  adhesion,  increased
motility and  invasiveness.55 Acinar  pattern  metastasis  had
cyclin D1  over-expression,  statistically  different  between
primary and  metastatic  tumor. This  gene  is  involved  in  cell
progression that  might  be  helping  cell  survival  in  circulation
and colonization.55
Gender, age,  smoking  and  tumor staging
ERCC1  expression  was higher  in  females,  correlating  in some
studies to a  better  prognosis.64 However  ERCC1  may  confer
resistance to cisplatin.65
Lung  adenocarcinoma  is  more  frequently  diagnosed  in
patients over  60  years  and  it is  infrequent  before  age 40
and generally  more  aggressive.66 All  our  samples  were  taken
from patients  older  than  the age  of 40. There  were  no  dif-
ference in  the  expression  of  the  markers  studied  between
the group  under  and  over  60 years.
Concerning  smoking  history, HER2  expression  was  higher
in non-smokers  than  in  ex-smokers.  Ki67  expression  was
higher in  tumors  of  smokers  and  ex-smoker  patients  than
in non-smokers,  indicating  a  higher  proliferative  rate  and
more aggressive/mitotically  active  tumors.
Women  diagnosed  with  adenocarcinoma  were  more  fre-
quently non-smokers,  reflecting  the cultural  tobacco  habits
and some  of  those  adenocarcinomas  belonging  to the  group
of adenocarcinomas  diagnosed  in  women,  non-smokers  and
young that  could  harbor  EGFR mutations.67 Adenocarcino-
mas diagnosed  in  women  patients  were  more  frequently
diagnosed at  stages  IA  and  IB  reflecting  somehow  a  less
aggressive behavior  demonstrated  also  by  a  lower  prolifera-
tive index  in these  stages.  Tobacco  habits  could  also  explain
the activation  of different  pathways  and  genetic  alterations
in these  cases.  Our  results  also  demonstrated  a  relation
between higher  Ki67  expression  and  smoking  habits.
Many  gene  products  have  their  expression  altered  when
correlating with  stage,  such  as  APC,  BCL2,  EGFR,  ERCC1,
Ki67, P53,  RB  and  TTF1,  showing  that  gene  expression  is  a
dynamic  and  unforeseen  process.  From  stage  IA  to  IB we
observed lower  Bcl2  and  EGFR  expressions  and  RB  higher
expression. From  stage  IB  to  IIA  we  observed  higher  Bcl2 and
lower ERCC1  expressions.  IIIA  stage  showed  higher  ERCC1
and Ki67 expressions.  From  IA and  IB to IIA  we  observed
also higher  APC and  Bcl2  expressions.  In  advanced  stages
we observed  especially  higher Ki67, APC  and  ERCC1  expres-
sions and lower  TTF1  expression,  the  last  reflecting  a  lower
differentiation and  even  a  non-TRU  adenocarcinoma  with  a
more aggressive  behavior. Ki67 higher expression  in higher
stages was an  expected  result as  it  reflects  higher  prolif-
eration index  and  thus  aggressive  behavior. APC mutations
were described  in  several  tumors.17 Taking  into  account  our
results, it seems  that  APC genetic  and  pathways  changes  are
important to  consider  in  advanced  stages  of adenocarcino-
mas.
One of the most  important  molecule  in  this  study  was
P53 because  it was higher  expressed  in  all  patterns  and  is
involved in  several  pathways  and  mechanisms  in  normal  cell
cycle,  carcinogenesis  and  DNA  repair  with  obvious  thera-
peutic implications.  Some  authors  relate  P53  with  MRP1,
because their  parallel  increase  is  frequent.  It was  demon-
strated that  P53  wild-type  suppressed  MRP1  promoter. These
hypotheses are  corroborated  by  our  data,  because  we  always
obtained high expression  of MRP1 and P53.  According  to
these authors  P53  was  mutated  in  all  patterns.68
RB expression  was  lower  in  micropapillary  pattern,  which
also explained  a  more  aggressive  phenotype  because  free
E2F activates  transcription  of genes  related  with  tumor pro-
gression.
TTF1 was  connected  with  P53  and  HER2  in  lung  can-
cer and some authors  relate  this  protein  with  initiation
and progression  in  lung  carcinogenesis.19,23 The relation
between TTF1  and  HER2  was  observed  between  solid  and
BA/lepidic patterns,  because  both  gene  expression  was
higher in  BA/lepidic  pattern  than  in solid.
Conclusions
Female  adenocarcinoma  patients  were  more  frequently  non-
smokers  and  diagnosed  in earlier  stages,  with  higher  ERCC1
expression involved  in DNA  repair.
Advanced  stages  (IIA  and  IIIA)  of adenocarcinomas
showed higher  Ki67, APC,  ERCC1  expressions  and  lower  TTF1
expression reflecting  a  more  aggressive,  mitotically  active
and less  differentiated  adenocarcinoma  and  eventually  a
non-TRU adenocarcinoma.
There was  generally  higher  expression  of  the  products  of
genes studied  in  the adenocarcinomas  compared  to normal
adjacent cells  reinforcing  their  importance  in  lung  adeno-
carcinoma carcinogenesis.
There  were two  specific  gene  expressions  with  differ-
ences between  patterns,  HER2  and  TTF1  that  interfere  with
gene transcription.  Papillary  and  solid  patterns  revealed
less TTF1  expression,  identical  to normal  tissue  exhibiting
a non-TRU/bronchial  phenotype.  At the other  end acinar,
BA/lepidic and  micropapillary  showed  higher TTF1  expres-
sion. Solid  pattern  revealed  also  lower  HER2  and  higher  EGFR
and  ERCC1  (this  compared  to papillary)  expression.  Papillary
showed higher HER2  and  lower  ERCC1  expressions.  Adeno-
carcinomas showed  higher  TTF1 expression  (type  TRU) in
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acinar,  BA/lepidic  and  micropapillary  patterns,  micropapil-
lary with  higher  RB  expression,  acinar  with  lower  ERCC1  and
higher EGFR.  Ciclin  D1 seems  to have more  importance  in
acinar and  BA/lepidic  patterns  than  in  micropapillary.
ERCC1  protein  expression  in  micropapillary, solid  and
BA/lepidic patterns  indicates  DNA  repair  and  in acinar  and
papillary patterns  there  was lower  expression.  BCL2  was
overexpressed in all  patterns,  suggesting  that  there  is  inhi-
bition of apoptosis.  MRP-1and  LRP  were overexpressed  in  all
patterns and  it  is  important  to  further  analyze  these proteins
for a  better  understanding  of  the response  to therapy.
By hierarchical  clustering  test  we  highlight  papillary
pattern as  the  most  different  pattern  followed  by  solid
pattern; acinar  and  BA/lepidic  patterns  are most  alike.
Using PCA analysis  we  realized  that  acinar, micropapillary
and BA/lepidic  patterns  are the  most alike,  so  we  made
three clusters  of patterns:  papillary,  solid  and  micropapil-
lary/acinar/lepidic  (BA).
Furthers  studies  are  needed  in  order  to  interpret  these
results regarding  therapeutic  response  in  advanced  staged
bronchial-pulmonary carcinomas.
Ethical disclosures
Protection  of  human  and  animal  subjects.  The  authors
declare that  no  experiments  were  performed  on  humans  or
animals for this  study.
Confidentiality of  data. The authors  declare  that  they  have
followed the protocols  of  their work  center  on  the publica-
tion of patient  data.
Right to  privacy  and  informed  consent.  The  authors
declare that  no patient  data  appear  in this  article.
Funding
Funded  by  a  grant  from  CIMAGO,  Faculty  of Medicine,  Uni-
versity of Coimbra,  Portugal.
Conflicts of  interest
The  authors  declare  that  they  have  no  conflicts  of interest.
References
1. Haegebarth A, Clevers H. Wnt signaling, lgr5, and stem cells in
the intestine and skin. Am J  Pathol. 2009;174:715--21. PubMed
PMID: 19197002. Pubmed Central PMCID: 2665733.
2.  Lodish HJED, Berk A, Kaiser CA, Lodish HF,  Darnell J, Scott MP,
et al.  Molecular cell biology. 5th ed. New York: W.H. Freeman
& Co Ltd.; 2003.
3. Lee PN, Forey BA, Coombs KJ.  Systematic review with meta-
analysis of  the epidemiological evidence in  the 1900s relating
smoking to lung cancer. BMC Cancer. 2012;12:385. PubMed
PMID: 22943444. Pubmed Central PMCID: 3505152.
4.  Massion PP, Carbone DP. The molecular basis of  lung can-
cer:  molecular abnormalities and therapeutic implications.
Respir  Res. 2003;4:12. PubMed PMID: 14641911. Pubmed Central
PMCID: 314397.
5. Peto R,  Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smok-
ing, smoking cessation, and lung cancer in the UK since 1950:
combination of  national statistics with two case--control stud-
ies. BMJ. 2000;321:323--9. PubMed PMID: 10926586. Pubmed
Central  PMCID: 27446.
6. Siegel R,  Naishadham D, Jemal A.  Cancer statistics, 2013. CA
Cancer J  Clin. 2013;63:11--30. PubMed PMID: 23335087.
7. Tomashefski JF Jr, Cagle PT, Farver CF, Fraire AE. In: Tomashefski
JF Jr, editor. Dail and Hammar’s pulmonary pathology. 3rd ed.
New York: Springer; 2008.
8. Wistuba II, Gazdar AF.  Lung cancer preneoplasia. Annu Rev
Pathol. 2006;1:331--48. PubMed PMID: 18039118.
9.  Tomashefski JF,  Cagle PT, Farver CF, Fraire AE. Dail and Ham-
mar’s pulmonary pathology. 3rd ed. New York: Springer; 2008.
10. Travis WD, Brambilla E, Müller-Hermelink HK,  Harris CC. Pathol-
ogy genetics of tumours of the lung, pleura, thymus and heart.
In: Tumours L, editor. WHO. Lyon: IARC Press; 2004.
11. Travis WD, Brambilla E, Noguchi M,  Nicholson AG, Geisinger
K, Yatabe Y, et al. Diagnosis of  lung cancer in small biop-
sies and cytology: implications of  the 2011 International
Association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society classification. Arch Pathol
Lab Med. 2013;137:668--84. PubMed PMID: 22970842.
12.  Travis WD, Brambilla E, Noguchi M,  Nicholson AG, Geisinger KR,
Yatabe Y, et al. International association for the study of lung
cancer/american thoracic society/european respiratory society
international multidisciplinary classification of  lung adenocar-
cinoma. J  Thorac Oncol: Off Publ Int Assoc Study Lung Cancer.
2011;6:244-85. PubMed PMID: 21252716.
13.  Neves LR, Oshima CT, Artigiani-Neto R, Yanaguibashi G,
Lourenco LG, Forones NM. Ki67 and p53 in gastrointestinal stro-
mal tumors----GIST. Arq Gastroenterol. 2009;46:116--20. PubMed
PMID: 19578612.
14. Scholzen T, Gerdes J. The Ki-67 protein: from the known and
the unknown. J Cell Physiol. 2000;182:311--22. PubMed PMID:
10653597.
15.  Woo T,  Okudela K, Yazawa T,  Wada N, Ogawa N, Ishiwa N, et al.
Prognostic value of KRAS mutations and Ki-67 expression in stage
I lung adenocarcinomas. Lung Cancer. 2009;65:355--62. PubMed
PMID: 19162366.
16. Mori S,  Ito G, Usami N,  Yoshioka H, Ueda Y, Kodama Y, et al.
p53 apoptotic pathway molecules are frequently and simul-
taneously altered in nonsmall cell lung  carcinoma. Cancer.
2004;100:1673--82. PubMed PMID: 15073856.
17.  Gotz R.  Inter-cellular adhesion disruption and the RAS/RAF and
beta-catenin signalling in lung  cancer progression. Cancer Cell
Int. 2008;8:7. PubMed PMID: 18492263. Pubmed Central PMCID:
2427011.
18.  Gong Y, Somwar R, Politi K, Balak M,  Chmielecki J, Jiang X,
et al.  Induction of BIM  is essential for apoptosis triggered by
EGFR kinase inhibitors in  mutant EGFR-dependent lung adeno-
carcinomas. PLoS Med. 2007;4:e294. PubMed PMID: 17927446.
Pubmed Central PMCID: 2001209.
19.  Adjei AA. Blocking oncogenic Ras signaling for cancer therapy.
J Natl Cancer Inst. 2001;93:1062--74. PubMed PMID: 11459867.
20. Myong NH. Cyclin D1 overexpression, p16 loss, and pRb inacti-
vation play a key role in pulmonary carcinogenesis and have a
prognostic implication for the long-term survival in  non-small
cell  lung carcinoma patients. Cancer Res Treat: Off J Korean
Cancer Assoc. 2008;40:45--52. PubMed PMID: 19688048. Pubmed
Central PMCID: 2697490.
21. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern
of E2F1 expression in human lung tumours: E2F1 is upregu-
lated in small cell lung carcinoma. Oncogene. 2001;20:1678--87.
PubMed  PMID: 11313916.
22. Schettino C, Bareschino MA, Maione P, Rossi A, Ciardiello F,
Gridelli C. The potential role of pharmacogenomic and genomic
in the adjuvant treatment of  early stage non-small cell lung can-
cer. Curr Genomics. 2008;9:252--62. PubMed PMID: 19452042.
Pubmed Central PMCID: 2682934.
  CHAPTER 5 – MANUSCRIPT III 
75 
 
Please  cite  this  article  in  press  as:  Sousa  V,  et al. Rev  Port Pneumol.  2015.
http://dx.doi.org/10.1016/j.rppnen.2014.05.006
ARTICLE IN PRESS+ModelRPPNEN-1034; No. of Pages 12
Bronchial-pulmonary  adenocarcinoma  subtyping  11
23. Kalikaki A, Kanaki M,  Vassalou H, Souglakos J, Voutsina A,
Georgoulias V, et al. DNA repair gene polymorphisms predict
favorable clinical outcome in advanced non-small-cell lung can-
cer. Clin Lung Cancer. 2009;10:118--23. PubMed PMID: 19362955.
24.  Simon GR, Sharma S,  Cantor A, Smith P,  Bepler G. ERCC1
expression is a predictor of survival in resected patients with
non-small cell lung  cancer. Chest. 2005;127:978--83. PubMed
PMID: 15764785.
25. Deeley RG, Cole SP. Substrate recognition and transport
by  multidrug resistance protein 1 (ABCC1). FEBS Lett.
2006;580:1103--11. PubMed PMID: 16387301.
26.  Konig J, Hartel M, Nies AT, Martignoni ME, Guo J, Buchler MW,
et al. Expression and localization of  human multidrug resistance
protein (ABCC) family members in  pancreatic carcinoma. Int J
Cancer. 2005;115:359--67. PubMed PMID: 15688370.
27.  Berger W,  Setinek U, Hollaus P,  Zidek T,  Steiner E, Elbling L, et al.
Multidrug resistance markers P-glycoprotein, multidrug resis-
tance protein 1, and lung  resistance protein in non-small cell
lung cancer: prognostic implications. J Cancer Res Clin Oncol.
2005;131:355--63. PubMed PMID: 15856298.
28.  Bouhamyia L, Chantot-Bastaraud S,  Zaidi S, Roynard P,  Prengel
C, Bernaudin JF, et al.  Immunolocalization and cell expres-
sion of  lung resistance-related protein (LRP) in normal and
tumoral human respiratory cells. J  Histochem Cytochem: Off
J Histochem Soc. 2007;55:773--82. PubMed PMID: 17438350.
29. Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, Andre F,
et al.  Multidrug resistance proteins do not predict benefit of
adjuvant chemotherapy in  patients with completely resected
non-small cell lung cancer: International Adjuvant Lung Cancer
Trial Biologic Program. Clin Cancer Res: Off J Am Assoc Cancer
Res. 2007;13:3892--8. PubMed PMID: 17606722.
30.  Fridman E, Skarda J, Pinthus JH, Ramon J,  Mor Y. Expression of
multidrug resistance-related protein (MRP-1), lung resistance-
related protein (LRP) and topoisomerase-II (TOPO-II) in Wilms’
tumor: immunohistochemical study using TMA methodology,
vol.  152. Olomouc, Czechoslovakia: Biomedical Papers of the
Medical Faculty of the University Palacky; 2008. p.  47--51.
PubMed  PMID: 18795074.
31. Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z,  Cec-
chetto M, et  al. Role of  drug transporters and drug accumulation
in the temporal acquisition of drug resistance. BMC Cancer.
2008;8:318. PubMed PMID: 18980695. Pubmed Central PMCID:
2596802.
32.  Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M,
Lee H, et al. Somatic mutations of the HER2 kinase domain in
lung adenocarcinomas. Cancer Res. 2005;65:1642--6. PubMed
PMID: 15753357.
33. Wu  SG, Chang YL, Hsu YC, Wu JY,  Yang CH, Yu  CJ,  et al. Good
response to gefitinib in lung adenocarcinoma of complex epider-
mal growth factor receptor (EGFR) mutations with the classical
mutation pattern. Oncologist. 2008;13:1276--84. PubMed PMID:
19060236.
34.  Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS
mutations in patients with adenocarcinoma of  the lung. Korean
J Intern Med. 2009;24:48--54. PubMed PMID: 19270482. Pubmed
Central PMCID: 2687655.
35. Jo UH, Han SG, Seo JH, Park KH, Lee JW, Lee HJ, et  al. The
genetic polymorphisms of HER-2 and the risk of  lung cancer in
a Korean population. BMC Cancer. 2008;8:359. PubMed PMID:
19055823. Pubmed Central PMCID: 2661000.
36.  Katzel JA, Fanucchi MP, Li Z. Recent advances of novel tar-
geted therapy in  non-small cell lung cancer. J  Hematol Oncol.
2009;2:2. PubMed PMID: 19159467. Pubmed Central PMCID:
2637898.
37.  Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL,  Trotti A.
AJCC cancer staging manual. New York: Springer; 2010.
38. Zell JA, Ou SH, Ziogas A, Anton-Culver H. Epidemiology of bron-
chioloalveolar carcinoma: improvement in survival after release
of the 1999 WHO classification of lung  tumors. J Clin Oncol: Off J
Am Soc Clin Oncol. 2005;23:8396--405. PubMed PMID: 16293870.
39.  Ikeda S, Fujimori M,  Shibata S,  Okajima M, Ishizaki Y, Kurihara T,
et al. Combined immunohistochemistry of beta-catenin, cyto-
keratin 7, and cytokeratin 20 is useful in discriminating primary
lung adenocarcinomas from metastatic colorectal cancer. BMC
Cancer. 2006;6:31. PubMed PMID: 16451736. Pubmed Central
PMCID: PMC1373659.
40. Pelosi G, Pasini F, Sonzogni A, Maffini F, Maisonneuve P,  Iannucci
A, et al.  Prognostic implications of neuroendocrine differentia-
tion  and hormone production in patients with Stage I  nonsmall
cell lung carcinoma. Cancer. 2003;97:2487--97. PubMed PMID:
12733148.
41.  Matsuzawa Y, Kiuchi Y, Toyomura K, Matsumoto I, Nakamura H,
Fujino H, et al. Activation of cytosolic phospholipase A2alpha by
epidermal growth factor (EGF) and phorbol ester in  HeLa cells:
different effects of  inhibitors for EGF receptor, protein kinase
C, Src,  and C-Raf. J  Pharmacol Sci. 2009;111:182--92. PubMed
PMID: 19783865.
42. Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T,  Mauri FA,
et al. AKT/mTOR pathway activation and BCL-2 family pro-
teins modulate the sensitivity of  human small cell lung cancer
cells to RAD001. Clin Cancer Res: Off J Am Assoc Cancer Res.
2009;15:1277--87. PubMed PMID: 19228731.
43.  Sos ML,  Fischer S,  Ullrich R, Peifer M, Heuckmann JM, Koker
M, et  al.  Identifying genotype-dependent efficacy of single and
combined PI3K- and MAPK-pathway inhibition in cancer. Proc
Natl Acad Sci U S  A. 2009;106:18351--6. PubMed PMID: 19805051.
Pubmed Central PMCID:2757399.
44. Kubba LA, McCluggage WG, Liu J, Malpica A, Euscher ED,  Silva
EG, et  al. Thyroid transcription factor-1 expression in  ovar-
ian epithelial neoplasms. Mod Pathol. 2008;21:485--90. PubMed
PMID: 18246044.
45. Barlesi F, Pinot  D, Legoffic A, Doddoli C, Chetaille B, Torre JP,
et al. Positive thyroid transcription factor 1  staining strongly
correlates with survival of patients with adenocarcinoma of
the lung. Br J  Cancer. 2005;93:450--2. PubMed PMID: 16052216.
Pubmed Central PMCID: 2361585.
46.  Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Steven-
son M, et  al. Characterizing the developmental pathways TTF-1,
NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A.
2009;106:5312--7. PubMed PMID: 19279207. Pubmed Central
PMCID: 2664027.
47. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in  2000:
epidemiology, prevention, and early detection. Lancet Oncol.
2003;4:45--55. PubMed PMID: 12517539.
48.  Su YC, Hsu YC, Chai CY.  Role of  TTF-1, CK20, and CK7 immuno-
histochemistry for diagnosis of primary and secondary lung
adenocarcinoma. Kaohsiung J Med Sci. 2006;22:14--9. PubMed
PMID: 16570563.
49. Francesconi CM, Hutcheon AE, Chung EH, Dalbone AC, Joyce NC,
Zieske JD. Expression patterns of retinoblastoma and E2F family
proteins during corneal development. Investig Ophthalmol Vis
Sci. 2000;41:1054--62. PubMed PMID: 10752941.
50.  Zhang XP, Liu F, Wang W.  Coordination between
cell  cycle progression and cell fate decision by the
p53  and E2F1 pathways in  response to DNA dam-
age.  J  Biol Chem. 2010;285:31571--80. PubMed PMID:
20685653.  Pubmed Central PMCID: 2951231.
51.  Hwang IG, Ahn MJ, Park  BB, Ahn YC, Han J, Lee S, et al.
ERCC1 expression as a prognostic marker in  N2(+) nonsmall-cell
lung cancer patients treated with platinum-based neoadjuvant
concurrent chemoradiotherapy. Cancer. 2008;113:1379-86.
PubMed  PMID: 18623378.
52. Kang HK, Lee E, Pyo H, Lim SJ. Cyclooxygenase-independent
down-regulation of multidrug resistance-associated protein-1
expression by celecoxib in  human lung cancer cells. Mol Cancer
Ther. 2005;4:1358--63. PubMed PMID: 16170027.
 CHAPTER 5 – MANUSCRIPT III 
76 
                                                                                                                                                                                                   
 
 
 
 
 
Please  cite  this  article  in  press  as:  Sousa  V,  et  al.  Rev Port  Pneumol.  2015.
http://dx.doi.org/10.1016/j.rppnen.2014.05.006
ARTICLE IN PRESS+ModelRPPNEN-1034; No. of  Pages 12
12  V.  Sousa et  al.
53. Rolff J, Dorn C, Merk J, Fichtner I. Response of  patient-derived
non-small  cell lung cancer xenografts to classical and targeted
therapies is not  related to multidrug resistance markers. J
Oncol. 2009;2009:814140. PubMed PMID: 19547715. Pubmed
Central PMCID: 2696640.
54. Farr GH 3rd, Ferkey DM, Yost C, Pierce SB, Weaver C, Kimelman
D. Interaction among GSK-3, GBP, axin, and APC in  Xeno-
pus axis specification. J  Cell Biol. 2000;148:691--702.
PubMed PMID: 10684251. Pubmed Central PMCID:
2169372.
55. Wu X, Zhu Y, Yan H, Liu B, Li Y, Zhou Q, et  al. Isothiocyanates
induce  oxidative stress and suppress the metastasis poten-
tial of human non-small cell lung cancer cells. BMC Cancer.
2010;10:269. PubMed PMID: 20534110. Pubmed Central PMCID:
2891640.
56.  Panelos J, Batistatou A, Paglierani M, Zioga A, Maio V, Santi
R, et  al.  Expression of  Notch-1 and alteration of  the E-
cadherin/beta-catenin cell adhesion complex are observed
in primary cutaneous neuroendocrine carcinoma (Merkel
cell carcinoma). Mod Pathol. 2009;22:959--68. PubMed PMID:
19396152.
57.  Fakih M,  Vincent M.  Adverse events associated with anti-EGFR
therapies for the treatment of  metastatic colorectal cancer.
Curr Oncol. 2010;17 Suppl. 1:S18--30. PubMed PMID: 20680104.
Pubmed Central PMCID: 2901793.
58.  Fakih M,  Wong R. Efficacy of  the monoclonal antibody EGFR
inhibitors for the treatment of  metastatic colorectal cancer.
Curr Oncol. 2010;17 Suppl. 1:S3--17. PubMed PMID: 20680105.
Pubmed Central PMCID: 2901794.
59.  Borczuk AC.  Micropapillary histology: a frequent morphology of
mutation-associated lung  adenocarcinoma? Am J  Clin Pathol.
2009;131:615--7. PubMed PMID: 19369618.
60.  Prior JO,  Stupp R, Christodoulou M, Letovanec I.
Micropapillary pattern in lung adenocarcinoma: aspect
on 18F-fluorodeoxyglucose positron emission tomography/
computed  tomography imaging. Interact Cardiovasc Thorac
Surg. 2010;10:144--5. PubMed PMID:19875512.
61.  De Oliveira Duarte Achcar R,  Nikiforova MN, Yousem SA.
Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF
mutational profile. Am  J Clin Pathol. 2009;131:694--700.
PubMed PMID: 19369630.
62. Moulager M, Corellou F, Verge V, Escande ML,  Bouget FY. Inte-
gration of light signals by the retinoblastoma pathway in the
control of S phase entry in  the picophytoplanktonic cell Ostreo-
coccus. PLoS Genet. 2010;6:e1000957. PubMed PMID: 20502677.
Pubmed Central PMCID: 2873908.
63.  Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, et al. Rational
optimization of  a bispecific ligand trap  targeting EGF recep-
tor family ligands. Mol Med. 2009;15:11--20. PubMed PMID:
19048033. Pubmed Central PMCID: 2592073.
64.  Zheng Z, Li X,  Schell MJ, Chen T, Boulware D, Robinson L, et  al.
Thymidylate synthase in situ protein expression and survival in
stage I  nonsmall-cell lung  cancer. Cancer. 2008;112:2765--73.
PubMed  PMID: 18442042.
65. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi
S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms
with  response and survival in gemcitabine/cisplatin-treated
advanced non-small cell lung  cancer patients. Clin Cancer Res:
Off J Am  Assoc Cancer Res. 2008;14:1797--803. PubMed PMID:
18347182.
66.  Qian J, Zou Y, Rahman JS, Lu B, Massion PP. Synergy between
phosphatidylinositol  3-kinase/Akt pathway and Bcl-xL in  the
control of apoptosis in adenocarcinoma cells of  the lung. Mol
Cancer Ther. 2009;8:101--9. PubMed PMID: 19139118. Pubmed
Central PMCID: 3110728.
67. Dacic S, Shuai Y, Yousem S, Ohori P,  Nikiforova M.  Clinicopatho-
logical  predictors of EGFR/KRAS mutational status in primary
lung adenocarcinomas. Mod Pathol. 2010;23:159--68. PubMed
PMID: 19855375.
68. Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, Hait WN.
Regulation of expression of the multidrug resistance protein
MRP1 by p53 in  human prostate cancer cells. J  Clin Inves-
tig.  2000;105:1261--7. PubMed PMID: 10792001. Pubmed Central
PMCID: 315445.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 – MANUSCRIPT IV 
Lung adenocarcinoma: sustained subtyping with immunohistochemistry and EGFR, HER2 and 
KRAS mutational status.

  
79 
CHAPTER 6 – Lung adenocarcinoma: sustained subtyping with immunohistochemistry and 
EGFR, HER2 and KRAS mutational status. 
 Rev Port Pneumol. 2015;21(3):113--125
www.revportpneumol.org
ORIGINAL ARTICLE
Lung  adenocarcinoma:  Sustained  subtyping  with
immunohistochemistry and EGFR,  HER2  and KRAS
mutational status
Vitor Sousaa,b,∗,  Carolina Rodriguesa, Maria Silvaa, Ana Maria Alarcãoa, Lina Carvalhoa,b
a IAP-FMUC-Institute  of  Pathology,  Faculty  of  Medicine,  University  of  Coimbra,  Coimbra,  Portugal
b Pathology  Institute,  Coimbra  University  Hospital,  Coimbra,  Portugal
Received 18  March  2014;  accepted  1 September  2014
Available  online  11 March  2015
KEYWORDS
Lung;
EGFR;
KRAS;
HER2;
Immunohistochemistry;
Adenocarcinomas
Abstract  Pulmonary  adenocarcinomas  are  still  in  the  process  of  achieving  morphological,
immunohistochemical and genetic  standardization.  The  ATS/ERS/IASLC  proposed  classification
for  lung  adenocarcinomas  supports  the  value  of  the  identification  of  histological  patterns,
specifically in  biopsies.
Thirty pulmonary  adenocarcinomas  were  subjected  to  immunohistochemical  study  (CK7,  CK5,
6,  18,  CK20,  TTF1,  CD56,  HER2,  EGFR  and  Ki-67),  FISH  and PCR  followed  by  sequencing  and
fragment  analysis  for  EGFR,  HER2  and  KRAS.
Solid  pattern  showed  lower  TTF1  and  higher  Ki-67  expression.  TTF1  expression  was  higher
in  non-mucinous  lepidic  and micropapillary  patterns  when  compared  to  acinar  and  solid  and
acinar,  solid  and mucinous  respectively.  Higher  Ki67  expression  was  present  in  lepidic  and  solid
patterns  compared  to  mucinous.  EGFR  membranous  staining  had  increasing  expression  from
non-mucinous  lepidic/BA  pattern  to  solid  pattern  and  micropapillary  until  acinar  pattern.  EGFR
mutations,  mainly  in  exon  19,  were  more  frequent  in  females,  together  with  non-smoking  status,
while  KRAS  exon  2 mutations  were  statistically  more  frequent  in  males,  especially  in  solid
pattern.  FISH  EGFR  copy  was  correlated  gross,  with  mutations.  HER2  copy  number  was  raised
in  female  tumours  without  mutations,  in  all  cases.  Although  EGFR  and  KRAS  mutations  are
generally  considered  mutually  exclusive,  in  rare  cases  they  can  coexist  as  it  happened  in  one  of
this series,  and  was  represented  in  acinar  pattern  with  rates  of  42.9%  and 17.9%,  respectively.
EGFR  mutations  were  more  frequent  in  lepidic/BA  and acinar  patterns.  Some  cases  showed
different  EGFR  mutations.
The differences  identified  between  the  adenocarcinoma  patterns  reinforce  the  need  to
carefully  identify  the  patterns  present,  with  implications  in  diagnosis  and in  pathogenic  under-
standing.  EGFR  and  KRAS  mutational  status  can  be  determined  in  biopsies  representing  bronchial
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pulmonary  carcinomas  because  when  a  mutation  is  present  it  is  generally  present  in  all  the
histological  patterns.
© 2014  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
Introduction
There  are  1.3  million  deaths  from  lung  cancer  annually
worldwide and  it  is  the  leading  cause  of cancer-
related mortality  in USA,  Japan  and  Western-countries.1--4
Bronchial-pulmonary  carcinomas  were  classified  as  small
cell lung  cancer  (SCLC)  and  non-small  cell  lung  can-
cer (NSCLC),  representing  13%  and  85%  of  lung  cancers
respectively. Squamous  cell carcinoma  (SQCC)  and  ade-
nocarcinoma (ADC)  subdivision  become  mandatory  due  to
personalized therapy  and NSCLC  designation  should  not  be
reported.5,6
Bronchial-pulmonary  adenocarcinomas  are malignant
epithelial tumours  with  glandular  differentiation,  and/or
mucin production,  acinar,  papillary,  micropapillary,  bron-
chioloalveolar (BA)/lepidic,  or  solid  with  mucin  growth
patterns, complementing  the  morphological  spectrum  of
mixed-type adenocarcinoma.  The  incidence  differs  with
gender and  population,  being  roughly  28% in men  and  42%
in women.  Recently  a  new classification  was  proposed  by
ATS/ERS/IASLC. This  new  classification  recognizes  several
patterns such as  lepidic  instead  of  BA,  acinar,  papillary,
solid, and micropapillary.  It  also  recognizes  mucinous  adeno-
carcinomas including  the former  mucinous  BA  carcinoma
and colloid  carcinoma.  It  also  highlighted  the  need  for  an
assertive diagnosis  specially  in biopsy  material,  supported
by immunohistochemical  study,  with  clinical,  prognostic  and
therapeutic implications.5--8
The  transmembrane  tyrosine  kinase  epidermal  growth
factor receptor  (EGFR)  belonging  to  the EGFR  family  of
receptor tyrosine  kinases  (TKs)  called  the  HER  or  ErbB  fam-
ily (consisting  of  four  members  --  EGFR  (HER1/ErbB1),  HER2
(ErbB2), HER3  (ErbB3)  and  HER4  (ErbB4))9,10 may  be  over-
expressed and  this  correlates  with  poor  prognosis,  with
aggressive disease  and  decreased  survival.3,11--14
KRAS  mutations  are associated  with  poor  prognosis,
reported since 1990,  occurring  in  codon  12,  occasion-
ally at  codon  13  and  rarely  at  codon  61.10,15,16 According
to the  current  data,  EGFR  and  KRAS  mutations  are
mutually exclusive10,17,18; the  explanation  is related  to
KRAS-MAPK pathway  inserts  in the downstream  signalling
pathway of  EGF.10 This  mutation  appears  in  30% of  Cau-
casian patients  with  lung  cancer  and  10%  of East  Asian
adenocarcinomas.16,18,19 KRAS  mutations  are more  frequent
in smokers  and  are  related  to  poor  prognosis.10,16,17 Lung
cancers with  KRAS  mutations  are  resistant  to  EGFR-TKIs  and
Yatabe confirmed  in  his  study  that none  of the  lung  cancers
with KRAS  mutation  achieved  clinical  response.10,20
Due  to  what  has  been  said,  the EGFR-MAPK  signal
transduction pathway  is important  to  understand  the role
of individual  somatic  changes  in  tumours,  predicting  the
response to  EGFR-TKIs.  EGFR  status  is then  a  favourable
predictive  factor  in  the  case  of  sensitizing  mutations.
Despite the positive  response  observed  in up to  70% of
patients, different  data  concluded  that not every  patient
benefitted from  treatment  with  TKIs,  probably  due to
mutations in the downstream  effectors  of  EGFR  signalling,
more frequently  KRAS  gene.  Mutations  in this intermediate
transduction pathway  may  also  select  patients;  as  KRAS  acts
downstream of  EGFR  receptor,  its somatic  changes  can  lead
to a  non-response  to  EGFR-TKIs  as  response  rate  to  anti-
EGFR therapy  is  less  than  3%  in  patients  with  KRAS  mutant
tumours as opposed  to  20%  in  NSCLC  with  wild-type  KRAS.
The  objectives  of this  work  are to  evaluate  EGFR  and
KRAS mutational  status,  EGFR  and  HER2  gene  copy  num-
ber and  immunohistochemical  EGFR  and  HER2  expression  in
lung adenocarcinomas  according  to  the  patterns/subtypes
present, in order  to  understand  the  value  of  pattern  recog-
nition, supported  by  an  immunohistochemical  set  used  in
routine, in adenocarcinoma  diagnosis  and  anti-EGFR  therapy
decision.
Materials and methods
Materials
A series  of  30  bronchial-pulmonary  adenocarcinomas  classi-
fied according  with  WHO  2004  histological  classification  and
the new ATS/ERS/IASLC  classification  were  selected  from
the archive  of  the  Pathology  Service  of  Coimbra  University
Hospital.
The patterns  present  were  registered  (namely  lep-
idic/BA, acinar,  papillary,  micropapillary,  solid  and muci-
nous). Metastases  were  also  registered  by  patterns.  Clinical
data like  age,  gender,  smoking  habits  and  stage  were also
registered.
Ethical  standards
The principles  of  Helsinki  Declaration  were  respected  and
the study  was  developed  according  to  the  Faculty  of
Medicine of  the University  of  Coimbra.
Ethical  Committee  rules  for  PhD  theses  were  followed.
Immunohistochemistry  (IHC)
Representative  sections  of the adenocarcinomas  and  their
patterns were  submitted  to  IHC  (CK7,  TTF1,  CK5/6,
CD56 and  CK20)  to  validate  the  pure  condition  of
bronchial-pulmonary  adenocarcinomas  mainly  to validate
solid pattern.  Ki67-MIB1  antibody  was used  to  character-
ize proliferation  index.  C-erbB-1/EGFR  and  c-erbB-2/HER2
were applied  to  evaluate  protein  expression  of  these
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molecules.  Endogenous  peroxidase  activity  was quenched
using 15 min  incubation  in 3%  diluted  hydrogen  peroxide
(H2O2).  For  blocking  nonspecific  binding  with  primary  anti-
bodies we  used  Ultra  V  Block  (Ultra  Vision  Kit; TP-125-UB;
Lab Vision  Corporation;  Fremont  CA;  USA).  Primary  anti-
bodies against  CK7 (clone  OV-TL12/30;  DakoCytomation,
Glostrup, Denmark)  at  a  dilution  of 1/50  for 30  min,  Cyto-
keratin 5,6,18  (clone  LP34;  Novocastra  Laboratories  Ltd,
Newcastle, United  Kingdom)  at a  dilution  of  1/100  for
60 min,  TTF1  (clone  8G7G3/1;  DakoCytomation,  Glostrup,
Denmark) at  a  dilution  of  1/100  for  60 min,  CD56  (clone
CD564; Novocastra  Laboratories  Ltd,  Newcastle,  United
Kingdom) at  a  dilution  of  1:75  for  60 min,  CK20  (clone
KS20.8; DakoCytomation,  Glostrup,  Denmark)  at  a  dilution
of 1/50  for  30  min,  Ki67  (clone  MIB-1;  DakoCytomation,
Glostrup, Denmark)  at a dilution  of  1/50  for  30  min,  c-
erbB-2 (Polyclonal;  DakoCytomation,  Glostrup,  Denmark)  at
a dilution  of  1/200  for  30 min,  and  c-erB-1  (clone  31G7;
Invitrogen, Camarillo,  California,  USA)  at  a  dilution  of 1:20
for 30  min  were  applied  to  the cells  and  incubated  at  room
temperature. They  were  washed  with  phosphate-buffered
saline (PBS)  (Ultra  Vision;  TP-125-PB;  Lab  Vision  Corpora-
tion; Fremont  CA;  USA);  and  after this,  for 15 min,  slides
were incubated  with  biotin-labelled  secondary  antibody
(Ultra Vision  Kit;  TP-125-BN;  Lab  Vision  Corporation;  Fre-
mont CA;  USA).  Primary  antibody  binding  was  localized
in tissues  using  peroxidase-conjugated  streptavidin  (Ultra
Vision Kit;  TP-125-HR;  Lab  Vision  Corporation;  Fremont  CA;
USA) and  3,3-diaminobenzidine  tetrahydrochloride  (DAB)
(RE7190-K; Novocastra  Laboratories  Ltd,  Newcastle,  United
Kingdom) was  used  as  chromogen,  according  to  manufac-
turer’s instructions.  Pretreatment  was  done  with  Pronase,
10′ for  CK7,  CK5,6,18,  CK20  and  c-erbB-1,  with  MW  --micro
wave, PH6,  20′ for Ki67  and  c-erbB-2  and  with  MW,  EDTA,
40′ for  TTF1  and  CD56. Haematoxylin  was  used  to  counter-
stain the  slides  which  were  then  dehydrated  and  mounted.
In parallel,  known  positive  and  negative  controls  were
used.
The intensity  of  the staining  was graded  semi-
quantitatively on  a  four  point scale  (0;1+,2+,3+).  The
percentage of  immunostained  cells  was  also  registered.  A
final score  was  obtained  multiplying  the intensity  by  the  per-
centage of  cells  with immunohistochemical  expression  and
the cut  off considered  was  10%  positive  cells.
Fluorescent  in  situ hybridization  -- FISH
The  Vysis  LSI  EGFR/CEP7  probe  assay (Vysis; Abbott  Molecu-
lar, USA)  was  applied  to  tumour  sections  of 4  m thickness,
baked overnight  at  56 ◦C,  deparaffinized  in  xylol,  rehy-
drated in  100%,  70%  ethanol  and  bidistilled  water.  A  pressure
cooker with  10  mM  citric  acid-trisodium  salt  buffer  pH  6,
for 4  min,  was used  to  submit  slides  to  a  pre-treatment.
They were  washed  in 2×  SSC  salts  (sodium  chloride  and
sodium citrate)  pH  7 for 5  min  at  room  temperature.  At
15 min  slides  were  immersed  in proteinase  K  solution  at
37 ◦C  and  then,  they  were rinsed  in  2× SSC  pH  7 for 5 min
at room  temperature.  The slides  were  then  dehydrated
in 70%,  90% and  100%  ethanol,  and  then  air  dried.  Ten
microliters of  probe  mixture  were  applied  on  the target
areas  and  a  22  mm ×  22 mm glass  coverslip  was placed  over
probe.
After being  sealed  with  rubber  cement  and  codenatura-
tion at  83 ◦C for  5  min,  coverslips  were  incubated  overnight
at 37 ◦C in a  humidity  chamber.  Post-hybridization  they  had
washes in  buffer  (50%  formamide  2×  SCC pH  7)  at  46 ◦C and
were also  washed  with  2×  SCC pH  7.  Slides  were  air-dried
in the dark  and  counterstained  with  DAPI.
FISH  was  used  to  analyze  the  chromosome  7  and  EGFR
gene, and they  were  scored according  to  Cappuzzo’s  (2005)
method. Positive  FISH  cases  showed  high  polysomy  or
amplification and  the  same  procedure  was  followed  to HER-
2 probe  (HER-2/Neu  (17q12)/SE17;  Kreatech  diagnostics;
Amsterdam). Positive  and  negative  FISH  cases  were  accord-
ing to  Varella-Garcia  et al.21
The microscopic  analyses  were  done  in a  Nikon  Eclipse
80i of  brilliant  field  and  epifluorescent  microscope  (LUCIA
cytogenetics software).  Images  were  captured  and  reg-
istered with  a  digital  camera  (Nikon  DXM  1220F),  in
monochromatic images/layers  posterior  joint  in  one  single
image. This  process  was assisted  by  Nikon  ACT-1  capture
software.
Overlapping cells  were  excluded  from  analysis.  Two  sig-
nals were counted  as adjacent  or  fused only  if  they  were
separated by  less  than  one  domain.  Two  different  individ-
uals examined  one  hundred  spindle  cells  interphase  nuclei
with strong  and  well-delineated  signals.
Fluorescent  signals  were  observed  and quantified  with  a
score previously  defined  using  DAPI,  FITC,  Texas  Red  (unique
band) and  triple  band  (DAPI,  FITC  and  Texas  Red)  filters.
PCR, sequencing  and  fragment  analysis
Genomic  DNA  was  extracted  from  5  m section  of paraffin-
embedded tissue  after manual  microdissection  of  all
independent patterns  separation  as  supported  in  Table  1.
For that,  the QIAmp  DNA  Mini  Kit  (Qiagen,  IZAZA,  Germany),
was used.  One hundred  nanograms  (ng)  of  DNA  were  ampli-
fied in  a 50  l reaction  solution  containing  5  l  of  10×  buffer
(Roche, Germany),  2.5 mM  MgCl2, 0.2  M  of  each  comple-
mentary primer,  200  M deoxynucleoside  triphosphate  and
one unit  of DNA  polymerase  (Roche,  Germany).  A  5  min
initial denaturation  at  95 ◦C was  used  to  perform  the  ampli-
fications; this was  followed  by  40 cycles,  30  s at  95 ◦C, 1  min
at 60 ◦C  (for  exon 19)  or  57 ◦C  (for  exon 21),  1  min  at  72 ◦C
and 10  min  of final  extension  at  72 ◦C.
The EGFR  gene  mutations  located  at exons  19  and  21 were
determined using  the  intron-based  primers  according  to  the
published method.22 Mutational  analysis  of  exon  19 dele-
tion L858R  point  mutation  of  the  EGFR  gene  was explored,
as described.23 The  determination  of  exon  19  deletion  was
made by  common  fragment  analysis  using  PCR  with  an  FAM-
labelled primer  set,  and  the  products  were  electrophoresed
on ABI  PRISM  3100  (Applied  Biosystems®)  and all  eletro-
pherograms were  reanalyzed  by  visual  inspection  in order
to check  for  mutations.  To  evaluate  the L858R  mutation
MyCycler (Bio-Rad)  was also  used  and  its products  were  then
studied by  direct  sequencing.
The  same  procedure  was applied  to  KRAS  except  for
amplification, which  we performed  using  a  5 min  initial
denaturation at 95 ◦C,  followed  by  40  cycles,  30  s at  95 ◦C,
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Table  1  Clinical  and  pathological  characteristics  of  adenocarcinomas.
Case  Gender  Age  Smoking  habits  TNM  classification  Stage  Histologic  patterns  Metastasis
1  M  73 Non-smoker  T1a  N0  Mx  IA  Acinar,  Lepidic/BA
2 F  71 Non-smoker  T1a  N0  Mx  IA  Lepidic/BA,  Acinar
3 M  69 Smoker  T4  N0  MX  IIIA  Lepidic/BA,  Acinar,
Papillary
4 M  75 Non-smoker  T1a  N2  Mx  IIIA  Acinar,  Solid  Acinar,  Solid
5 F  53 Non-smoker  T1a  N0  Mx  IA  Acinar,  Lepidic/BA
6 F  62 Ex-smoker  T1a  N2  Mx  IIIA  Acinar,  Solid  Acinar,  Solid
7 F  74 Non-smoker  T1a  N0  Mx  IB Acinar,  Solid,  Lepidic/BA
8 F  68 Non-smoker  T2a  N0  Mx  IB Acinar,  Solid,
Micropapillary  Mucinous
9 F  50 Non-smoker  T1b  N2  Mx  IIIA  Acinar,  Solid Acinar
10 F  57 Smoker  T2a  N0  Mx  IB Acinar,  Solid
11 M  51 Non-smoker  T1a  N1  Mx  IIA  Acinar,  Lepidic/BA  Acinar.  Solid
12 F  75 Non-smoker  T2a  N0  Mx  IB Acinar,  Solid,
Micropapillary
13 M  85 Ex-smoker  T1a  N0  Mx  IA  Acinar,  Lepidic/BA
Papillary
14 F  63 Smoker  T1a  N2  Mx  IB Acinar,  Lepidic/BA
Micropapillary,  Papillary
Acinar,  Solid
15 F  55 Smoker  T1a  N0  Mx  IA  Acinar,  solid
16 F  67 Smoker  T1a  N0  Mx  IA  Lepidic/BA,  Acinar,
Micropapillary
17 M  48 Smoker  T1a  N0  Mx  IA  Acinar,  Solid,  Lepidic/BA
18 M  71 Non-smoker  T2a  N1  Mx  IIA  Acinar,  Papillay,
Micropapillary
Acinar
19 F  80 Non-smoker  T1b  N0  Mx  IA  Acinar,  Micropapillary
20 F  68 Non-smoker  T2a  N1  Mx  IIA  Acinar,  Lepidic/BA
Micropapillary
Acinar,
Micropapillary
21 M  48 Non-smoker  T2b  N1  MX  IIA  Lepidic/BA,  Acinar,  Acinar
22 F  67 Non-smoker  T2a  N0  Mx  IB Acinar,  Mucinous
23 M  76 Ex-smoker  T1b  N0  Mx  IA  Lepidic/BA,  Acinar,
Mucinous
24 F  56 Non-smoker  T1a  N0  MX  IA  Lepidic/BA,  Acinar,
Micropapillary,  Papillary
25 M  64 Smoker  T2b  N0  Mx  IIA  Acinar,  Papillary
26 F  71 Non-smoker  T2a  N0  MX  IB Lepidic/BA,  Acinar,  Solid
27 F  50 Smoker  T2a  N0  MX  IB Lepidic/BA,  Solid
28 F  80 Non-smoker  T1a  N0  Mx  IA  Solid
29 M  56 Smoker  T1a  N0  MX  IA  Lepidic/BA,  Acinar
30 F  56 Non-smoker  T1a  N0  Mx  IA  Lepidic/BA,  Acinar
1  min  at  53 ◦C, 1  min  at  72 ◦C  and  a  10  min  of  final  extension
at 72 ◦C.
The  same  procedure  was applied  to  HER2  except  for
amplification, which  we  performed  using  a  1  min  initial
denaturation at 95 ◦C; followed  by  35  cycles,  30  s at  95 ◦C,
1 min  at  64 ◦C, 1  min  at  72 ◦C and 10  min  of  final  extension
at 72 ◦C.
Statistical  analyses
PASW  Statistics,  version  18, to  do  the statistical  analysis
of the  information  was  applied.  To do  the characterization
of the  sample  we  calculated  mean  and  standard  devi-
ation for  quantitative  variables  and  we  determined  the
absolute and  relative  frequencies  for qualitative  variables.
We made  several  comparisons  between  nominal  variables
(gender,  smoking  habits,  mutations)  using  Chi-square  test,
Fisher’s Exact  test and  ANOVA.  Immunohistochemistry,  FISH
and  Mutational  (PCR)  results’  concordances  were  calcu-
lated by  kappa  coefficient.  Correlation  coefficient  r  was  also
calculated (Spearman  test).  The  comparison  between  the
existence of  different  types  of  mutation  and  age  was  real-
ized with  Mann--Whitney’s  test.  A  significance  level  of  5%
(p ≤ 0.05)  was considered.
Results
Patterns  and clinical  data
Table  1 shows  29  cases  of  mixed-type  adenocarcinomas
with registration  of  decreasing  percentage  of  the  identified
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Figure  1  Case  21:  2+  CK20  expression;  acinar  pattern.  200×.
patterns:  28  (93.4%)  cases  with acinar  pattern,  18  (60%)
cases with  non-mucinous  lepidic/BA  pattern,  12  (40%)  cases
with solid  pattern,  8  (26.7%)  cases  with  micropapillary
pattern, 6  (20%)  cases  with  papillary  pattern  and  3  (10%)
cases with  mucinous  pattern.  Case 28 was  the only  where
only one  pattern  was present  (solid  pattern).  Two  patterns
were represented  in 16  cases  (7  cases  had  acinar  and  lep-
idic/BA non-mucinous  patterns,  5 cases  had  acinar  and  solid
patterns, 1  case  had  acinar  and  papillary  patterns,  1  case
had acinar  and micropapillary  patterns,  1  case  had  acinar
and mucinous  glandular  patterns  and  1  case  had  lepidic/BA
and solid  patterns);  13 cases  showed  3 or  more  histological
patterns and  of  these,  the most  frequent  association  was
acinar, lepidic/BA  non-mucinous  and  solid  patterns  (n  =  3),
followed  by  acinar,  lepidic/BA  non-mucinous  and micropap-
illary patterns  (n =  2),  acinar,  lepidic/BA  non-mucinous
and papillary  patterns  (n =  2) and  acinar,  lepidic/BA
non-mucinous, papillary  and  micropapillary  patterns  (n = 2).
In  this  series,  19 (63.3%)  cases  belonged  to  female  gender,
11 (36.7%)  cases  to  masculine  gender,  18  (60%)  cases  had  no
smoking habits,  9 (30%)  cases  belonged  to smoker  patients
and 3  (10%)  cases  to  ex-smoker  patients  (Table  1);  of  18  non-
smoking patients  (admitting  passive  smoking),  there  were  13
females. It  is  important  to  notice  that histological  patterns
present in lymph  node metastasis  belonged  to  acinar,  solid
and micropapillary  morphology  (pN1/2--8  cases).
Immunohistochemistry
All  histological  types  and  patterns  identified  were  CK  5,6,18
and CD56  negative  without  statistical  significant  differences
(p >  0.05).  Normal  epithelial  basal  cells  were  all  positive  for
CK5,6,18 as internal  control;  lymph  node metastasis  did  not
express  these antibodies.
As with  normal  parenchyma,  equivalent  results  were seen
after the  application  of CK20  except:  in two  cases  of  mixed-
type adenocarcinoma,  where  acinar  and  lepidic/BA  patterns
had a  2+  expression  (moderate  intensity)  in  50%  of  the  cells;
in a  third  case,  the  mucinous  glandular  pattern  had  CK20
weak expression  (1+)  in 10%  of  the neoplastic  cells  (Fig.  1).
These three  cases  expressed  CK7  3+  and  TTF1  3+ (Fig.  1).
Lymph node  metastasis  had no  CK20  expression.
Figure  2  Case  6:  CK7  intense  expression  (3+)  in  solid  pattern.
200×.
Mucinous  pattern  showed  lower  expression  of  CK7
than normal  pulmonary  epithelial  cells  and  respira-
tory cylindrical  epithelial  cells  (p  =  0.09);  acinar  pattern
(p = 0.0584),  lepidic/BA  pattern  (p  = 0.0822),  micropapil-
lary pattern  (p  =  0.086)  and  solid  pattern  (p  = 0.0661)  had
higher expression  of  CK7  than  mucinous  glandular  pattern
(Fig. 2).
Considering mucinous  pattern,  one  case  had  no  CK7
expression; CK7  expression  was moderately  intense  (2+)  in
50% of  the  cells  in another  case  and a  third  case,  had  intense
(3+) expression  in 80%  of  the cells.
TTF1  expression  was positive  in normal  alveolar  septae
cells as expected;  it  was  negative  in 6 acinar  pattern  cases,
in 2  of the  non-mucinous  lepidic/BA  pattern  cases,  in  1
papillary pattern  case  and  in 2 solid  pattern  cases.  Overall
expression, taking  into  account  the  intensity  and  the per-
centage of positive  cells,  for  TTF1  higher  expression  was
seen in lepidic/BA  pattern  (p  = 0.002)  and  in micropapil-
lary pattern  (p  =  0.005),  when compared  to  normal  alveolar
septae. In mucinous  patterns,  expression  was  lower when
compared to  normal  tissues  (p  = 0.0192).  There  were  no
differences between  normal  tissue  and papillary  pattern
(p = 0.315)  and lepidic/BA  pattern  had  higher  expression
than acinar  pattern  (p  =  0.059)  and  solid  pattern  (p  =  0.0115).
Micropapillary pattern  had  higher  expression  when com-
pared to  acinar  (p =  0.0413),  solid  (p  =  0.009)  and  mucinous
(p = 0.0225)  patterns.
Adenocarcinomas  showed  higher  proliferative  index,  vali-
dated by  Ki67  expression,  than  normal  tissues  (p  < 0.05).  Ki67
expression was  also  higher  in lepidic/BA  (non-mucinous)  pat-
tern  when  compared  to  mucinous  pattern  (p =  0.0845)  and  in
solid compared  to  mucinous  patterns  (p  =  0.0817).  Basal  cells
in respiratory  epithelium  expressed  Ki67  in  50%  of  cells.
We  did  not  find  membrane  staining/expression  for CerbB2
in any cases  of  the  studied  adenocarcinomas.  Cytoplas-
matic expression  was  seen  in all  patterns  and  in  normal
tissues adjacent  to  the  neoplasias,  with  significant  statisti-
cal differences  between  alveolar  septae  and  acinar  patterns
(p < 0.0001),  lepidic/BA  pattern  (p <  0.0001),  papillary  pat-
tern (p  =  0.004),  micropapillary  pattern  (p  < 0.0001),  solid
pattern (p  = 0.0006)  and  mucinous  pattern  (p  =  0.0073).
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Figure  3  Case  7:  ErbB-2  3+ cytoplasmatic  expression;  solid
pattern. ErbB-2,  400×.
Solid  pattern  had  lower expression  than  acinar
(p =  0.0034),  lepidic/BA  (p =  0.004),  papillary  (p  =  0.0334)
and micropapillary  patterns  (p  = 0.0089)  (Figs.  3  and  4).
EGFR membrane  immunostaining  was revealed  in aci-
nar pattern  of  5  adenocarcinomas  as  moderate  (2+)  and
in 4  cases  as  intense  (3+).  We  did  not  find  membrane
expression in papillary  pattern.  In  micropapillary  pattern,
one case  showed  2+ membrane  expression  and  3  cases
3+. Non-mucinous  lepidic/BA  pattern  showed  2+  membrane
expression in 2  cases  and  3+  in  one case.  Solid  pattern
showed 2  cases  with  2+  positivity  and 3 cases  with  3+ mem-
brane expressions.  Mucinous  pattern  was  negative  in all
studied adenocarcinomas.
Pulmonary parenchyma  also  expressed  membranous
EGFR in  epithelial  cells  but  at  a  very  low  rate  when com-
pared to  adenocarcinomas  (p  =  0.0029).  Higher  expression
was verified  in  solid  pattern  (p  =  0.097)  and  in  micropapillary
pattern (p =  0.0457)  when  compared  to  lepidic/BA  pattern
(Fig. 5).
Considering immunohistochemical  expression  between
primary adenocarcinomas  patterns  and lymph  node
Figure  4  Case  8:  ErbB-2  3+ cytoplasmatic  expression;
micropapillary  pattern.  ErbB-2,  400×.
Figure  5  Case  12:  Intense  (3+)  EGFR  expression;  acinar  pat-
tern. EGFR,  200×.
metastasis  there  was  no  statistical  significance  for CK7,
CK20, CK  5,6,18,  CD56,  TTF1 and  Ki67  proliferative  index.
CerbB2  was not  expressed  as  membrane  staining  in
the metastatic  (some  cytoplasmatic  expression  was seen)
malignant cells.  There  were  no statistical  significant  dif-
ferences between  primitive  patterns  in  adenocarcinomas
and respective  metastasis  (p  =  0.3711)  for the cytoplasmatic
stain previously  described.
Taking  into  account  membrane  expression  of EGFR  there
were no  differences  between  the adenocarcinomas’  pat-
terns and  the  lymph  node metastasis  (p =  0.108).
HER2,  EGFR  and  KRAS  mutational  status
HER2  mutations
HER2  exon  20 mutation  was  absent  in  30  cases  of  adenocar-
cinomas. All  the patterns  were  wild-type  (WT).
EGFR mutations
EGFR  exon  21  point  mutation  occurred  in  8  cases  of the
30 adenocarcinomas  studied:  in 6 cases,  the mutation  was
present in all  the patterns  of the  adenocarcinoma,  in 2  cases
the mutation  was  present  in  the acinar  pattern  and  the  other
patterns were  WT  (lepidic/BA  and solid  and  lepidic/BA  pat-
terns, respectively).
A group  of  10  adenocarcinomas  showed  exon 19  dele-
tions: 6  with  mutations  in all  patterns;  one  case with
mutation in lepidic/BA  pattern  and  acinar  pattern  WT;  the
remaining 3 cases  had  mutations  present  in one pattern
(namely two  cases  in  acinar  and  one  case  in  lepidic/BA  pat-
terns).
EGFR mutations  were  present  in  42.9%  of  acinar  pattern.
EGFR mutations  were  more  frequent  in lepidic/BA  and  acinar
patterns (p  = 0.008).
Deletion  of  9pb  (DEL  9pb)  was  present  in 5 cases,  deletion
15pb (DEL 15pb)  in 4 cases,  DEL 18pb  in 2 cases  and  DEL 12pb
in one  case.
One singular  case  showed  3  types  of  deletion,  mainly  DEL
19pb, 15pb  and  18pb  in  the  acinar  pattern  and  DEL  15pb in
solid and  micropapillary  patterns.
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Table  2  EGFR  exon  19 mutations  (n.p.  -- not present  this  pattern;  n.d.  -- not determined).
Case  Lepidic/BA  Acinar  Solid  Micropapillary  Mucinous
7  n.d.  DEL  9  pb  n.d.  n.p.  n.p.
8  n.p.  DEL  9,15,18  pb  DEL  15  pb  DEL  15 pb  n.d.
9  n.p.  DEL  9  pb  n.d.  n.p.  n.p.
12  n.p.  DEL  15  pb  DEL  15  pb  n.d.  n.p.
16  DEL  12  pb  DEL  12  pb  n.p.  DEL  12 pb  n.p.
19  n.p.  DEL  15  pb  n.p.  DEL  15 pb  n.p.
20  DEL  15  pb DEL 15  pb n.p. n.p.  n.p.
24  DEL  9 pb DEL 9  pb n.p.  DEL  9 pb n.p.
26  DEL  18  pb n.d. n.p.  n.p.  n.p.
30  DEL  9 pb  WT  n.p.  n.p.  n.p.
Table  3  EGFR  exon  21 mutations  (n.p.  -- not present  in  pattern;  n.d.  --  not  determined).
Case  Lepidic/BA  Acinar  Papillary  Solid  Micropapillary  Mucinous
1  L858R  L858R  n.p.  n.p.  n.p.  n.p.
7  n.d.  L858R  n.p.  n.d.  n.p.  n.p.
14  n.d.  L858R  L858R  n.p.  n.d.  n.p.
18  n.p.  L858R  L858R  n.p.  n.d.  n.p.
23  L858R  L858R  n.p.  n.p.  n.p.  n.d.
24  L858R  L858R  n.d.  n.p.  L858R  n.p.
26  WT  L858R  n.p.  WT  n.p.  n.p.
30  WT  L858R  n.p.  n.p.  n.p.  n.p.
In  4  adenocarcinomas,  coexisting  L858R  exon 21  point
mutations and  exon  19  deletions  were  seen.  In two  of  these
cases the  L858R  and  Del9pb  mutations  were  present  in
all patterns  (acinar,  lepidic/BA  and  solid  patterns  in one
case and  in acinar  pattern  in another  case).  In one  case,
L858R exon  21  point  mutation  was seen  in  acinar  pattern
and exon  19  deletion  (DEL  18pb)  in lepidic/BA  pattern.  In
another case  exon  19  deletion  (DEL 9pb)  in lepidic/BA  pat-
tern and  L858R  exon 21  point  mutation  in  acinar  pattern
were observed.  Tables  2 and  3  explain the  obtained  muta-
tional status.
The obtained  results  showed  that  for EGFR,  exon 19
mutations were  present  in  the  different  histological  pat-
terns of the  same  tumour.  In  cases  8  and  30, lepidic/BA,
acinar, solid  and  micropapillary  patterns  expressed  different
mutations: in  case  8,  solid  and  micropapillary  patterns  only
expressed DEL 15pb,  acinar  pattern  also  expressed  DEL  9pb
and DEL  18pb simultaneously  and  case  30  expressed  differ-
ences between  lepidic/BA  and  acinar  patterns,  as the  first
one expressed  DEL 9pb  and  the  second  one  was WT.
In  case  26,  lepidic/BA  pattern  had  DEL  18pb  while  the
acinar pattern  was  undetermined.
After  applying  the Mann--Whitney  test,  patient’s  age
was not  statistically  related  with  the  existence  of EGFR
mutations (neither  EGFR-Exon  19 nor  EGFR-Exon  21  muta-
tions) with  p  =  0.156.  EGFR  mutations  were  more  frequent
in female  patients  (p  = 0.004).
There  was a  statistical  relationship  between  EGFR  muta-
tions and  female  gender  (p =  0.001)  (Chi-Square  Tests).
The estimated  risk obtained  Odds  ratio  for  sex =  6.286
(95% confidence  interval  between  1.918  and  20.603)  for
females.
KRAS  mutations
Of  the  30  adenocarcinomas  studied  5 cases  had  exon  2  point
mutations, 3 of  them  of the  type  G12  V  (Valine)  and  2  of  the
type G12C  (Cystein).
For  the cases  with KRAS  mutation,  4  had  no EGFR  muta-
tions with  the  exception  of  one  case  that  had  also  exon 21
EGFR mutation  and  these  mutations  were  present  in the  two
patterns (lepidic/BA  and acinar)  of  this mixed-type  adeno-
carcinoma.
In relation  to  KRAS  exon 2  wild  type,  the  mean  age
was 66.35  years  with  a  95%  Confidence  Interval  for  mean
between 64.12  and  68.59  years,  with  a  minimum  of 50 and
a maximum  of 80  years;  for  KRAS  exon 2  mutated,  the
mean age  was 62.60 years  with  a  95% Confidence  Interval
for mean  between  51.16  and  74.04  years  and  with  a min-
imum of  48  and a  maximum  of 85  years.  After  applying
the Mann--Whitney  test,  no  statistical  relevance  was found
between the relation  of  KRAS-exon  2  and the  age  of  the
individuals (for  WT  and  mutated)  as  p  =  0.401  (Table  4).
KRAS mutations  were  statistically  related  with  male  gen-
der (p  =  0.001).  (Fisher’s  Exact  Test).
The  relationship  between  smoking  habits  and  KRAS
mutations was  statistically  relevant  (p  =  0.014)  with  higher
incidence in smokers.
EGFR  and  HER2  copy  number  -- FISH
For  EGFR  copy  number,  12  FISH  positive  cases  (either  high
polysomy or amplification)  (Figs.  6 and  7) and  18  FISH neg-
ative cases  were  demonstrated.  The  positive  cases  showed
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Table  4  KRAS  exon  2 mutations  (n.p.  -- not present  in  this  pattern;  n.d.  --  not  determined).
Case  Lepidic/BA  Acinar  Papillary  Solid  Mucinous
13  n.d.  G12C  G12C  n.p.  n.p.
17  n.d.  G12V  n.p.  G12V  n.p.
21  G12V  G12V  n.p.  n.p.  n.p.
23  G12V
(EGFR
L858R)
G12V
(EGFR
L858R)
n.p.  n.p.  n.d.
29  G12C  G12C  n.p.  n.p.  n.p.
Figure  6  Case  7:  FISH  positive  for  EGFR/chromosome  7 cen-
tromere. Gene  high  polysomy;  EGFR  --  red  signal,  chromosome
7-green. 1000×.
positivity  in  all  the  patterns  present.  In the 12  FISH pos-
itive cases,  3 were  EGFR  WT  and  9  had  EGFR  mutations.
On the  other  hand,  of  the  18  FISH negative  cases,  13  were
EGFR WT  and  5 had  EGFR  mutations  with  concordance  K
Test of  k  = 0.4595  (moderate  agreement).  These  results were
consistent  in  all  patterns  of  each  tumour.
When  considering  the  K  Test  for concordance  between
FISH results  and  each mutational  type  (exons  21  and  19)
the concordance  was only  considered  as fair  (k  =  0.2857  and
k = 0.2647,  respectively).
The  concordance  (K  Test) between  mutational  status  and
EGFR immunohistochemical  expression  (positive/negative)
was considered  fair (k = 0.2556).  The  concordance  (K test)
Figure  7  Case  12:  EGFR/chromosome  7.  Gene  amplification;
FISH positive.  EGFR/chromosome  7 centromere.  EGFR  --  red
signal, chromosome  7-green.  1000×.
between  FISH  status  and  IHC  results  were  also  considered  as
fair (k =  0.2635).
Correlation  coefficient  between  immunohistochemical
EGFR expression  and  mutational  status was  considered  not
quite  significant  (p  =  0.0561)  with  r  = 0.3525.  Correlation
coefficient between  EGFR  mutational  status  and  FISH status
(r =  0.5303)  was considered  very  significant  (p =  0.0026).  No
correlation was  identified  between  EGFR  protein  expression
and FISH  status.
HER-2 FISH  positive  (mainly  by  polysomy)  cases  were
identified in 10  cases  corresponding  mainly  to  women  and
20 cases  were  HER-2  FISH  negative  (Table  5  concise  HER2
and EGFR  positive  cases).  It  was relevant  that FISH  nega-
tive adenocarcinomas  had  also  FISH  negative  lymph  node
metastasis. In  FISH  positive  adenocarcinomas,  where  lymph
nodes metastases  were present,  they  were  HER2  FISH
negative.
Discussion
The predictive  importance  of  making  accurate  and  more
specific diagnosis  of  bronchial-pulmonary  carcinoma,  in
biopsies, especially  differentiating  adenocarcinomas  from
squamous cell  carcinoma  and  other  histological  types  was
searched by  applying  a  panel  of  antibodies  (CK7,  TTF1,
CK 5,6,18,  CK20  and  CD56) to  establish  the  diagnosis  of
primary adenocarcinomas  towards  other  pulmonary  histo-
logical types  and metastatic  adenocarcinomas,  following
the proposed  classification  for  lung  adenocarcinomas.8 IHC
was made  to  validate  the  pure  condition  of  bronchial-
pulmonary adenocarcinomas  mainly  to  validate  solid  pattern
and establish  differential  diagnosis,  as well  as  character-
ize proliferation  index  (Ki67-MIB1  antibody).  We  tried  also
to identify  differences  of  expression  between  the  patterns
studied in  order  to  understand  and  validate  the  importance
of differentiating  patterns.  All  morphological  patterns  were
registered  for each adenocarcinoma  and  revealed  negativity
for CK5,6,18  and  for CD56,  excluding  squamous  and  neu-
roendocrine differentiations,  as  shown  by  other  authors.24--26
CD56  is  useful  for  excluding  neuroendocrine  differentiation,
thus confirming  that we are  dealing  with pure  adenocarci-
nomas, not  combined  adenocarcinomas.
High  importance  has  been  given  to  CKs  family,  formed
by more  than  30  polypeptides,  distributed  by  tissue  and
differentiation-specific weights,  allowing  phenotyping  by
combining particularly  CK7,  CK20  and  epidermoid/basal
cells high  weight  CKs  to  determine  origin  of  cell  types  or
tissue.25--32
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Table  5  EGFR  and  HER2  FISH  Positive  Results.
Case  Pattern  EGFR  Estrat  HER2  Estrat
11  Lepidic/BA
Acinar
Pos
Pos
HP
HP
Neg
Neg
Dis
Dis
333 Papillary
Lepidic/BA
Acinar
Pos
Neg
Pos
HP
LP
HP
Pos
Pos
Pos
HP
HP
HP
66 Solid
Acinar
Pos
n.d.
HP
n.d.
Pos
n.d.
HP
n.d.
777 Solid
Acinar
Lepidic/BA
Pos
Pos
n.d.
HP
HP
n.d.
Pos
Pos
n.d.
HP
HP
n.d.
8888 Acinar
Solid
Micropapillary
Mucinous
Pos
Pos
Pos
n.d.
HP
HP
HP
n.d.
Pos
Neg
Pos
n.d.
HP
BP
HP
n.d.
1111 Acinar
Lepidic/BA
Neg
n.d.
Tris
n.d.
Pos
n.d.
Amp
n.d.
121212 Solid
Acinar
Micropapillary
Pos
Pos
Pos
Amp
Amp
Amp
Neg
Neg
Neg
Tris
Tris
Tris
141414 Papillary
Acinar
Lepidic/BA
Pos
Pos
n.d.
Amp
Amp
n.d.
Pos
Pos
n.d.
HP
HP
n.d.
1919 Micropapillary
Acinar
Pos
Pos
HP
HP
Neg
Neg
Tris
Tris
202020 Lepidic/BA
Acinar
Micropapillary
Pos
Pos
n.d.
HP
HP
n.d.
Neg
Neg
n.d.
Tris
Tris
n.d.
232323 Lepidic/BA
Acinar
Mucinous
Pos
Pos
n.d.
HP
HP
n.d.
Pos
Pos
n.d.
HP
HP
n.d.
262626 Acinar
Solid
Lepidic/BA
Neg
Neg
n.d.
Tris
Dis
n.d.
Pos
Pos
n.d.
HP
HP
n.d.
2727 Solid
Lepidic/BA
Pos
n.d.
HP
n.d.
Pos
n.d.
HP
n.d.
3030 Lepidic/BA
Acinar
Pos
Pos
HP
HP
Pos
Pos
HP
HP
Estrat. -- Estratification for FISH results; DIS  --  Disomy; LP --  Low  polysomy; Tris -- Trisomy; HP -- High polysomy; AMP --  Amplification;
n.d.  -- not determined.
All  morphological  registered  patterns  comprising  this
series of lung  adenocarcinomas  expressed  CK7  positivity,
without differences  (p  >  0.05),  and  predominant  negativity
for CK20,  like  other  series  published  in the  literature.8,27,33,34
CK20  was  expressed  in 3  cases  of  primary  lung  adenocarci-
noma, with  expression  of  CK7  and  TTF1.
Mucinous  glandular  pattern  showed  lower  expression
of CK7  than  the  other  patterns  and  one  mucinous  pat-
tern had CK20  1+ expression  in 10%  of  the cells  and
2 mixed  adenocarcinomas  showed  2+ expression  in 50%
of the  cells  in  both  acinar  and  lepidic/BA  patterns.  At
this point  it  is  relevant  to  make  a  comment  about  the
recently proposed  classification  for  lung adenocarcinomas.8
This  classification  proposes  the replacement  of  BA --
bronchiolo-alveolar pattern  carcinoma  designation  for  lep-
idic. When  dealing  with  classical  non-mucinous  BAC,  this
histological type  concerns  TRU  (terminal  respiratory  unit)
cells,  pool of  adult  stem  cells  in  the lung  where  pneu-
mocytes type  II  and  Clara cells  malignant  counterparts
are recognized;  the  proposed  lepidic  pattern  seems  to
mean going  for a morphologic  description  undervaluing
carcinogenesis. Mucinous  pulmonary  adenocarcinoma  cells
exhibiting positivity  for  intestinal  immunohistochemical
markers,  like  CK20,  MUC2 and  COX2,  fail  to  express
TTF135 and  with  bronchial  origin  may  comprise  either
bronchial adenocarcinomas  or  intestinal  type  bronchial
adenocarcinomas.  At  this point,  the  new proposed  lung  ade-
nocarcinoma classification  may  contain  a  future  relevant
importance by  gathering  together  all  mucinous  types  of
bronchial-pulmonary adenocarcinomas  under  the mucinous
adenocarcinoma umbrella,  eliminating  the  BAC  mucinous
type and  again,  giving  life  to  BA pattern  referring  to
the lepidic  non-mucinous  type.  Predictive  subtypes  will
be described  to  clarify  origin  and  prognosis,  between
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glandular  and  non-glandular  mucinous  bronchial-pulmonary
adenocarcinomas.36
Also  thyroid  transcription  factor-1  (TTF-1),  tissue-
specific transcriptional  factor,  identifies  epithelial  respi-
ratory cells  involved  in  the regulation  of  surfactant  as
pneumocytes type  II and  Clara  cell  secretory  protein  gene
expression and  distinguishes  primary  lung  adenocarcinoma
from metastasis  of  colorectal  cancer.  With  the  exception
of papillary  and  solid  patterns,  all  the other  patterns  had
intense expression  suggesting  that  some  patterns  showing
decreased expression  of  TTF1  can  explain  a  small  num-
ber of  cases  developing  in pure  CK7 positive  (bronchial)
cells.27,28 It is  a  classical  concern  of pathologists  to  report
a parameter  related  with  tumour  proliferation  index  and
Ki67-MIB1 as  a  nuclear  proliferation  associated  antigen
expressed in cell  cycle  (G1,S,G2  and  M)  but  not  in the
resting phase,  G0,  which  provides  information  about  the
portion of  active  cells  in the  cell  cycle.37,38 Ki-67  expres-
sion by  immunohistochemistry  can  be a  prognostic  marker
allowing the  prediction  of  post-operative  survival  in  differ-
ent types  of  cancer.  High  expression  of Ki-67  (cut-off  above
10) is  associated  with  worse  survival  in adenocarcinomas.30
Solid  pattern  expressed  higher  levels  of  Ki-67  when  com-
pared to  micropapillary  (p  = 0.0219),  acinar  (p  = 0.0731)  and
mucinous (p  =  0.068)  patterns  and we can  hypothesize  that
solid pattern  can  have  a  worse  biological  behaviour,  either
reflecting an  higher  proliferation  index  or  a  particular  differ-
ential origin  or as already  referred,  bronchial  development
when without  expression  of  either  TTF1 and  high weight
molecular cytokeratin  (CK  5,  6/CK5,  6,  18).
Membrane  expression  of  C-erbB-2  as  observed  in breast
carcinomas is  absent  in lung  adenocarcinomas  and  has  been
reported as  cytoplasmatic  since early  90s,  in all  morpholog-
ical patterns.  Solid pattern  showed  lower  expression  than
acinar, papillary  and  micropapillary  patterns  raising  again  a
question of  prediction  and  specific  genetic  pathways  worth
exploring.
In the  literature,  there are  numerous  references  for
immunohistochemistry and  genetic  studies  in  lung  adeno-
carcinomas and  especially  under  the  old nomenclature  of
NSCLC. The  importance  of this  work lies  in the fact  that
we compared  IHC  expression  between  the different  patterns
of lung  adenocarcinomas  to  identify  differences  and  rele-
vance between  them,  pioneering  the searching  of  EGFR  and
KRAS mutations  together  with  EGFR  and  HER2  copy  number
also in  between  the  different  morphological  patterns  of  lung
adenocarcinomas.
In the  submitted  population  we did  not find  correlations
between age and  mutation  status,  namely  for  EGFR  and
KRAS mutations.  However  EGFR  mutations  were  more  fre-
quent in  women  and  KRAS  mutations  in  men.  Gender  and
smoking habits  have  been  significantly  related  with  EGFR
mutations.2,3,30,39
The  commonly  reported  EGFR  mutation  rate  by  PCR
sequencing and  fragment  analyses  in lung  adenocarcinomas
is around  20%.40 Mutations  are  found  in the  first  four  exons  of
the TK  domain  of  the  EGFR  gene.  Short-mutations,  in-frame
deletions in  exon  19  or  point  mutations  resulting  in  a  sub-
stitution of  arginine  for leucine  at amino  acid  858 (L858R),
constitute roughly  90% of EGFR  mutations4,41;  45%  are exon
19 mutations,  41% are exon 21 mutations  and  the remaining
10% are  exon  18  and  20  mutations  (approximately  4%  of  exon
18  and  5%  of  exon 20)  --  firstly  described  as more  frequent
in females,  non-smokers,  adenocarcinomas  and  Japanese
patients.3,5,41 More  than 70%  of NSCLC  with  EGFR  mutations
are responsive  to  EGFR-TKIs  while  only  10%  of  tumours  with-
out EGFR  mutations  are responders.4
In our  study, we  had a  rate  of  EGFR  mutations  of 46%
gathering all  patterns.  Female  patients  had  a  57.9%  rate  and
male patients  had  a  27.3%  rate  (5  cases  in 25) (p =  0.001).
Female lung  cancer  patients  have  6  times  more  risk  (Odds
Ratio =  6.286)  of  having  EGFR  mutation  than  male  patients.
Shigematsu and Gazdar  defined  an  EGFR  superior  mutational
rate in women  (49%)  than  in male  patients  (19%).  A  reference
in this study  is  made  to  two other  studies,  based  on  Japanese
subjects, where  over  50%  of  female  patients  with  lung can-
cer had  higher  expression  of  EGFR  mutations.  Although  high,
our  EGFR  mutation  rate  is  not  unique.  It  may  reflect  the
exhaustive sampling  covering  all  the  patterns  present,  popu-
lation features,  and  the selected  population  may  have  more
advanced surgical  cases.  Tumour  heterogeneity  and  genetic
instability (leading  to the  accumulation  of  genetic  events)
could explain  the EGFR  mutation  rate  observed  as  well  as
the presence  of  different  mutations.
We  also tried  to  find  the same  relationship  for  the  iso-
lated mutations  in exons  19  and  21.  For  exon 19,  female
patients had  a  rate  of  52.6%  (10 in a  total  of  19  females)
while male  patients  had  a  rate  of  0%  (0  in a  total  of  11  males),
(p =  0.000).  For  EGFR  exon 21,  we  found  no significant  dif-
ferences (p =  0.835)  between  female  and  male  patients  as
female lung  cancer  had  a  mutation  rate  of  26.3%  while  male
patients had  a  rate  of 27.3%.  Also,  EGFR  exon 21  mutations
were however  more  frequent  in women  than  in men.
EGFR  mutations  were  described  as  more  frequent  in
never smokers  and  the  same  was  true  in  our  study  where
p =  0.004  (EGFR  mutation  was present  in  60% of  non-smokers
and only  in  23.1%  of  smokers).  So, EGFR  mutations  are
still associated  with  female  gender  and never  smoking
status. Despite  EGFR  mutations  being  more  prevalent  in  non-
smokers  we  cannot  be sure  that  smoking  can  prevent  EGFR
mutations. These  findings  only  suggest  that  carcinogens  con-
tained in  tobacco  smoke  are  probably  not  correlated  with
the presence  of  EGFR  mutations  which  might  be caused
by another  type  of  carcinogens  than  higher  numbers’  EGFR
copies.42
Some  consider  that FISH  EGFR  and  HER2  copy  num-
bers may  be used  when  DNA  quantity  is  not  sufficient  for
EGFR mutation  search  as  they  showed  some  degree  of  TKI
responses.3,19,39,42--44
HER2  has  strong  kinase  activity.3,12--14 Mutations  also
occur in the same  region  (3′ of  the  C-helix)  in exon  20
just as EGFR  in-frame  duplications/insertions,  present  in a
very small  fraction  of adenocarcinomas  of  non-smokers  and
females, (the same  as  EGFR  mutations) 10,19; the  majority
are insertion  mutations  in exon  20  and  the existence  of  HER2
mutations confers  resistance  to  EGFR-TKIs  but make  tumours
sensitive to  HER2  target  therapies.3,10,19,45--47 In our  study  we
did not  find  HER2  mutations,  indicating  lesser  importance  of
HER2 in lung adenocarcinomas’  carcinogenesis.
When  comparing  KRAS  exon 2  mutations  and  gender,  we
found that  male  lung  cancer  had  significantly  more  incidence
of mutation  than  female  cases  (p  = 0.000).  Male  patients  had
a rate  of 45.5%  (5  in  11  male  patients)  while  female  had  a
rate of  0%  (0  in 19  female  patients).  Our  findings  are  similar
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to  Kim  et  al.  study,  who  also  realized  that  KRAS  mutations
are significantly  related  with  smoking  habits  (p  =  0.014)  in a
total rate  of  30.8%  in smokers  while  in non-smokers  it was
only 5.7%.30,42
KRAS  mutations  have been  associated  with mucinous
differentiation, goblet  cell,  poor  differentiation  adenocar-
cinomas and  with  solid  patterns.48--52 However  in our  cases
we did  find  this mutation  in acinar  and  lepidic  patterns  and
in only  one  case  with  solid  pattern.  The lower  number  of
poorly differentiated  adenocarcinomas,  mucinous  and  solid
patterns could  in  part  explain  the  lower KRAS  mutation  rate.
EGFR  mutations  and  KRAS  mutations  have been  described
as mutually  exclusive  but  we found  1  case  of  KRAS  mutation
simultaneously with  EGFR  mutation.  So we  conclude  that
although EGFR  and  KRAS  mutations  are generally  mutually
exclusive, in  some  cases  they  can  coexist;  this  has  also  been
described by  other  authors.11,46,53--57 The  clinical,  therapeu-
tic and  prognostic  issues  concerning  this coexistence  need
to be  understood.
Although many  studies  demonstrated  that  EGFR  muta-
tions are  usually  related  with  an  amplification  in EGFR
locus, the  relationship  between  EGFR  mutations,  gene  copy
number, and  IHC expression  is still  unclear  and  without
relationship in our  study.40,42--44,58 We  have  demonstrated
correlation  between  mutational  EGFR  status  and  FISH  high
copy number.  We  did not  find any  correlation  with  IHC,
maybe because  gene  amplification  was  not  the  prevalent
event but  gene  polysomy  reflecting  aneuploidy,  a  frequent
genetic alteration  identified  in lung  carcinomas.
Increased  copy  number  of  EGFR  was present  in 40%
of our  cases  which  is comparable  to  the 36%  already
demonstrated.  In  our  study,  EGFR  mutations  had  7  times
more risk  (Odds  Ratio  = 7.016)  of having  EGFR  FISH  positive
(p =  0.001)  than  EGFR  wt.  We  conclude  that EGFR  muta-
tions are  concordant  with  an  increased  gene  copy  number
by FISH  (k  =  0.4595)  with  a  significant  correlation  coefficient
(r =  0.5303;  p =  0.0026).  This  is relevant  because,  knowing
that some  patients  having  high  EGFR  gene  copy  number  can
benefit from  TKI,  we might  consider,  specially  in  cases  where
mutational studies  are  inconclusive,  using  this information
in therapeutic  decisions.43,44 Concordance  of  the  EGFR  gene
copy number  by  FISH  and  protein  expression  by  IHC  was  seen
in 7  of  12  IHC-positive  cases.44
Lepidic/BA  non-mucinous  pattern  has  been  described  as
having mutations  of  EGFR  more  frequently.  Comparing  our
five different  patterns  (lepidic/BA,  acinar,  papillary,  solid
and micropapillary),  despite  not  having  statistical  signifi-
cance, EGFR  and  KRAS  mutations  were  higher  for the acinar
pattern with  a  rate  of  42.9%  and  17.9%  respectively  with
no statistical  significance  between  them,  followed  by  the
lepidic/BA pattern.  If  we aggregate  lepidic/BA  and  acinar
patterns, EGFR  mutations  are  more  frequent  in these  two
patterns when  compared  to  the other  patterns  all  together
(p =  0.008).  Recently  other  authors  showed  that EGFR  and
KRAS mutations  are  more  frequent  in  lung  carcinoma  with
adenocarcinoma differentiation  based  on  p63  and  TTF1
expression, p63  expression  being  the  most  useful  immuno-
histochemical marker since  they did  not  find  any mutation
in tumours  considered  p63  positive.51 In our  work  we  went
further correlating  the  mutational  status  also  with  the his-
tological patterns  present.  Generally,  when a mutation  is
present it  is  present  in all  the  histological  patterns  of  the
same  adenocarcinoma  (Tables  2--4).  Biopsies,  representing
only a  small  portion  of  a  tumour,  can  be used  to  determine
EGFR and  KRAS  mutational  status.
The  conclusions  referred  to  above  are  predictive  and
again raise  the controversies  explored  in  the  proposed  lung
adenocarcinomas classification:  a  small  biopsy  with  a  carci-
noma CK7  positive  and TTF1  positive  is  an  adenocarcinoma
(CK 5,6,18  negative)  and  has  to  be submitted  to KRAS  muta-
tion search  in  a  male  patient,  when  acinar,  solid  pattern  and
lepidic/BA (non-mucinous  type)  pattern  are present  and  also
to  EGFR  mutational  search  for  TKIs prescription  decision.
Also  to  summarize,  some  adenocarcinomas  show CK20
positivity in  mucinous  patterns/subtypes  and solid  patterns
show lower  expression  of nuclear  TTF1  and  higher  expression
of Ki67,  reflecting  probably  a  particular  cell origin  and  more
aggressive biological  behaviour  and  have  to  be reported  as
lung adenocarcinomas,  avoiding  poorly  differentiated  carci-
noma designation.
After this study, it  seems  that EGFR  and  KRAS  mutational
status can  be determined  in biopsies  representing  bronchial
pulmonary carcinomas  because  when a  mutation  is  present  it
is generally  present  in all  the histological  patterns,  needing
further equivalent  studies  supported  by  a practical  immuno-
histochemical panel.
Conclusions
The  differences  identified  between  the  adenocarcinoma
patterns reinforce  the  necessity  to  carefully  identify
the patterns  present  with  implications  for diagnosis
and pathogenic  understanding.  Correlation  was found  in
between EGFR  FISH results  and  mutational  status.  There
are adenocarcinomas  harbouring  different  EGFR  mutations
in different  patterns.  In general,  EGFR  mutation  is  present  in
all the patterns  of the  same  adenocarcinoma  reinforcing  the
possibility of  mutational  status  determination  in biopsies.
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Lung cancer is one of the most common causes of cancer deaths. The development of 
EGFR targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors 
have generated an interest in the molecular characterization of these tumors. KRAS 
mutations are associated with resistance to EGFR TKIs. EGFR and KRAS mutations have 
been considered as mutually exclusive. 
This paper presents three bronchial-pulmonary carcinomas, two adenocarcinomas and 
one pleomorphic sarcomatoid carcinoma, harboring EGFR and KRAS mutations. 
Case 1 corresponded to an adenocarcinoma with EGFR exon 21 mutation (L858R) and 
KRAS codon 12 point mutation (G12V); case 2, a  mucinous adenocarcinoma expressed 
coexistence of EGFR exon 21 mutation (L858R) and KRAS codon 12 point mutation 
(G12V); and case 3 a sarcomatoid carcinoma with EGFR exon 19 deletion – del 9bp and 
KRAS codon 12 point mutation (G12C - cysteine). 
Based on our experience and on the literature, we conclude that EGFR and KRAS 
mutations can indeed coexist in the same bronchial-pulmonary carcinoma, either in the 
same histological type or in different patterns. The biological implications of this 
coexistence are still poorly understood mainly because these cases are not frequent or 
currently searched. It is therefore necessary to study larger series of cases with the two 
mutations to better understand the biological, clinical and therapeutic implications. 
 CHAPTER 7 – MANUSCRIPT V 
96 
 
  Vitor Sousa et. al. diagnostic pathology 2015, 1:13
  ISSN 2364-4893 
 DOI: http://dx.doi.org/10.17629/www.diagnosticpathology.eu-2015-1:13 
 2 
Keywords: KRAS; EGFR; lung cancer; adenocarcinoma 
Virtual Slides: http://www.diagnosticpathology.eu/vs/2015_1_13/ 
 
 
Introduction 
Lung cancer is one of the most common causes of cancer deaths [1,2]. Despite 
improvements in diagnostic and surgical techniques and chemotherapy protocols, 
overall survival is still low [3,4]. The NSCLC designation includes different carcinoma 
types such as squamous cell carcinoma, adenocarcinoma, large cell carcinoma and 
pleomorphic carcinoma [5,6]. Lung adenocarcinomas account for about 28% and 42% of 
the bronchial-pulmonary carcinomas diagnosed in women and men respectively [6]. The 
newly proposed lung adenocarcinoma classification recognizes a lepidic pattern instead 
of bronchiole-alveolar pattern, acinar, solid, papillary, micropapillary patterns as well as 
mucinous adenocarcinomas. This classification reinforces the importance of pattern 
recognition in lung adenocarcinoma diagnosis [6]. 
The development of EGFR-targeted therapies, including monoclonal antibodies and 
tyrosine kinase inhibitors, has generated interest in the molecular characterization of 
these tumors. Patients with lung cancer who benefit from EGFR tyrosine kynase 
inhibitors (EGRF TKI) may show dramatic responses with gefitinib or erlotinib therapy 
[7-11].  
Activating EGFR mutations have been identified to predict EGRF TKI response [12-16].  
KRAS mutations have been associated with EGFR TKIs resistance [17,18].  
EGFR and KRAS mutations have been considered as mutually exclusive, as the KRAS-
MAPKinase signaling pathway is also one of the signaling pathways for EGFR [18-20].   
The objectives of this paper are to present three cases of bronchial-pulmonary 
carcinoma with coexisting EGFR and KRAS mutations and to discuss the clinical-
pathological and therapeutic implications. 
 
Material and Methods: 
Material 
This paper presents two adenocarcinomas and one pleomorphic carcinoma, harboring 
EGFR and KRAS mutations. Adenocarcinoma patterns present were registered. 
The tissue for the analysis was obtained from 4% formalin-fixed paraffin embedded 
sections of lung surgical specimens and transthoracic biopsy (third case). All patterns 
present were manually dissected for selection after identification on hematoxylin – 
eosin stained slides. 
Methods 
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EGFR exons 19 and 21 and KRAS codon 12 and 13 mutations were evaluated after DNA 
extraction and polymerase chain reaction (PCR) amplification; EGFR exon 19 was studied 
by fragment analysis and EGFR exon 21 and KRAS codons 12 and 13 were studied by 
Sanger direct sequencing. Tissue representative of the adenocarcinoma patterns was 
selected after identification on HE stained slides and manual dissection of the tissue. 
The percentage of neoplastic cells was registered (in the three cases it was over 50%). 
Genomic DNA was extracted from 5 μm section of paraffin-embedded tissue. For that, 
the QIAmp DNA Mini Kit (Qiagen, IZAZA, Germany) was used. One hundred nanograms 
(ng) of DNA was amplified in a 50 μl reaction solution containing 5 μl of 10x buffer 
(Roche, Germany), 2.5 mM MgCl2, 0.2 μM of each complementary primer, 200 μM 
deoxynucleoside triphosphate and one unit of DNA polymerase (Roche, Germany). A 5-
minute initial denaturation at 95ºC was used to perform the amplifications; this was 
followed by 40 cycles of 30 seconds at 95ºC, 1 minute at 60ºC (for exon 19) or 57ºC (for 
exon 21), 1 minute at 72ºC and 10 minutes of final extension at 72ºC. The EGFR gene 
mutations located at exons 19 and 21 were determined using the intron-based primers 
according to the published method [21]. EGFR mutations were analyzed / detected 
according to the published method [22]. Exon 19 deletion was determined by common 
fragment analysis using PCR with an FAM-labeled primer set, and the products were 
submitted to electrophoresis on ABI PRISM 3100 (Applied Biosystems®). All 
electropherograms were reanalyzed by visual inspection in order to check for mutations. 
To evaluate the L858R mutation, MyCcycler (Bio-Rad) was also used, and its products 
were then studied by direct sequencing. The same procedure was applied to KRAS 
except for amplification which was performed using  5-minute initial denaturation at 
95ºC; followed by 40 cycles of 30 seconds at 95ºC, 1 minute at 53ºC, 1 minute at 72ºC 
and  a 10 minutes of final extension at 72ºC. 
The same DNA samples were used for EGFR and KRAS mutational testing. The results 
were confirmed by double checking after another PCR reaction. Rules to avoid 
contamination were applied. Positive and negative (WT) controls were used in every 
test. Before sequencing an electrophoresis in agarose gel was performed to check the 
blank. Since 2012 our laboratory has participated in the European Society of Pathology 
(ESP) Lung External Quality Assessment Scheme (EQA) to ensure optimal accuracy and 
proficiency in lung cancer biomarker testing. Our score has been consistently ≥90%, 
considered as a successful participation. 
 
 
 
Results  
Case 1 
A 77-year-old man had a 3 cm central tumor in the left lower lobe, corresponding to an 
adenocarcinoma with acinar, lepidic, solid and mucinous patterns, pT1bN0. 
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EGFR exon 21 mutation (L858R) was present in the acinar and lepidic patterns (Figure 
1). 
 
Figure 1. Exon 21 (L858R) EGFR mutation. 
 
EGFR exon 19 was Wild Type (WT) in all patterns. 
KRAS codon 12 point mutation (G12V) was also present in the acinar and lepidic patterns 
(Figure 2) (Table 1). 
 
 
Figure 2.  Codon 12 KRAS (G12V) mutation.  
 
Case 2 
A 77-year-old woman had a 6cm right upper lobe mucinous adenocarcinoma (with 
mucinous lepidic and mucinous acinar patterns), pT2b N0. 
EGFR exon 21 mutation (L858R) was present in both patterns, while EGFR exon 19 was 
WT. 
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KRAS codon 12 point mutation (G12V) was also concomitant (Table 1). 
 
Case 3 
A 76-year-old man had an 8 cm nodule in the right lower lobe with nodular pleural 
invasion as well as malignant pleural effusion, staged as pT3N0M1a. A transthoracic 
biopsy revealed a pleomorphic carcinoma, with acinar and giant/large cells. 
EGFR exon 21 was WT and exon 19 deletion – del 9bp was present in both patterns 
(Figure 3) (Table 1). 
  
Figure 3. Exon  19 (Del 9bp ) EGFR mutation.  
KRAS codon 12 point mutation (G12C - cysteine) was also present in both patterns 
(Figure 4) (Table 1). 
  
Figure 4. Codon 12 KRAS (G12C - cysteine) mutation. 
Table 1: EGFR and KRAS mutations identified according to histologic patterns. WT – wild 
type; L858R - exon 21 EGFR point mutation; G12V – codon 12 KRAS mutation G12V; 
G12C – Codon 12 KRAS mutation G12C. 
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Case 
1 
Mutations 
/patterns 
Acinar Lepidic 
mucinous 
Solid Mucinous 
Exon 21 EGFR L858R L858R WT WT 
Exon 19 EGFR WT WT WT WT 
KRAS G12V G12V WT WT 
Case 
2 
Mutations 
/patterns 
Acinar mucinous Lepidic 
mucinous 
  
Exon 21 EGFR L858R L858R   
Exon 19 EGFR WT WT   
KRAS G12V G12V   
Case 
3 
Mutations 
/patterns 
Acinar Giant cells   
Exon 21 EGFR WT WT   
Exon 19 EGFR del 9bp Del 9bp   
KRAS G12C G12C   
 
Discussion 
EGFR and KRAS mutations are considered as driver mutations because they are 
responsible for the initiation, progression and maintenance of lung cancers. Since 2004 
the scientific community has known that pulmonary carcinomas harboring EGFR 
mutations are highly sensitive to EGFR TKIs [15].  
Several studies have shown that the classical brochioloalveolar carcinomas and mixed-
type adenocarcinomas have more frequently EGFR activating mutations [23-25]. Other 
studies have demonstrated that papillary, micropapillary and hobnail patterns are 
correlated with EGFR mutations [26, 27]. 
Dacic et al. demonstrated that EGFR mutated mixed-type adenocarcinomas showed the 
following predominance of primary histological patterns: acinar (20%), BA/lepidic 
(12.5%), mucinous (9%), papillary (3%), micropapillary (3%) and solid (0%); and KRAS 
mutated mixed-type adenocarcinomas showed acinar (32%), solid (18%), BA/lepidic 
(16%), mucinosous (16%), papillary (10%) and micropapillary (4%) [28]. Dacic et al. also 
demonstrated that tumors with a lymphocytic prominent response are less prone to 
have EGFR mutations and more likely to harbor KRAS mutations [28]. 
Intra - tumors heterogeneity for EGFR mutations has also been demonstrated [29,30]. 
KRAS mutations have been more frequently associated with mucinous differentiation, 
including mucinous BA/lepidic, acinar patterns, goblet cell morphology and poorly 
differentiated adenocarcinomas, especially in adenocarcinomas with solid patterns 
[28,31-37]. KRAS mutations are rare in squamous cell carcinoma and significantly more 
frequent in proximal lung adenocarcinomas (the bronchial type TTF1 negative) than 
EGFR mutations [38,39]. 
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Our two adenocarcinoma cases showed one lepidic pattern (second case) and the other 
(first case) mixed patterns where EGFR mutations are supposed to be more frequent. 
However the lepidic case had mucinous differentiation. KRAS mutation was present in 
the same area/patterns of the mixed adenocarcinoma (first case), namely in the acinar 
and lepidic patterns but not in the solid or mucinous patterns. In the second case it was 
present in the mucinous lepidic pattern, in accordance with the most frequent patterns 
harboring KRAS mutations in the literature. 
In our laboratory, taking these three cases into account, we have a rate of 2.1% EGFR 
and KRAS coexistence. In our laboratory, the overall mutation rate for EGFR is 20% and 
for KRAS is 11%. 
 None of our patients underwent EGFR TKI therapy, so we cannot discuss the therapeutic 
consequences of EGFR and KRAS mutation coexistence in our cases.  
EGFR mutations define a group of lung cancer which are dependent on EGFR signaling 
pathways and are more responsive to EGFR TKIs. EGFR mutations may also be a positive 
prognostic factor for advanced tumors treated with erlotinib [40].  
Recent works have also demonstrated that EGFR mutational status is associated with 
sensitivity to first-line EGFR TKI in patients with advanced staged tumors [41].  
Iressa Pan-Asia Study provided evidence that EGFR mutations are predictive of longer 
progression-free survival when treated with gefitinib compared with conventional 
chemotherapy protocols [42, 43]. 
The major signaling pathways for EGFR are RAS/MAPK and PI3K/AKT, with implications 
for cell proliferation, differentiation and survival [44].  Mutations on the downstream 
effectors of those pathways could be responsible to EGFR TKIs resistance [45,46]. KRAS 
is an important downstream effector in the MAPK pathway. Concomitancy of KRAS and 
EGFR mutations could seem redundant in their functional results. Mutant EGFR 
selectively activates AKT and STAT signaling pathways, which promotes cell survival [8]. 
KRAS mutations are associated with an unfavorable response to EGFR TKIs and 
resistance to conventional adjuvant chemotherapy with cisplatin/vinorelbine [18,47-
50]. The TRIBUTE study also demonstrated that patients with KRAS mutation treated 
with erlotinib failed to benefit from erlotinib plus chemotherapy [40]. 
Evidence suggests that a tumor can harbor EGFR and KRAS mutations, which means that 
upstream inhibition of EGFR will have no therapeutic effect in these cases [51]. 
Recently Jackman et al. found no impact of KRAS mutations on the overall survival in 
patients without EGFR mutations treated with EGFR TKIs [41]. The role of KRAS mutation 
as a negative predictor of response of lung cancer treated with cetuximab is not clear 
either [52, 53]. Because EGFR mutation is a predictor of EGFR TKIs response and EGFR 
and KRAS mutations are generally mutually exclusive, it is not clear whether the 
response to TKIs differs between tumors with KRAS mutations and those without KRAS 
and EGFR mutations [54]. 
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There is a report of two cases of patients with colonic adenocarcinoma metastatic to 
lung EGFR WT and with KRAS mutation with durable responses to erlotinib [30]. There 
are other rare cases of TKI minor or transient response in patients with KRAS mutation 
[41,55].  Choughule et al described in their series three patients with KRAS and EGFR 
mutations with partial response to EGFR TKI [56]. Benesova et al also found response to 
gefitinib in three of five patients with this coexistence [57].  These facts raise the idea 
that KRAS mutation is not always associated with a lack of efficacy of EGFR TKI. The 
authors hypothesize that EGFR activation is not only mediated through KRAS signaling 
but also involves other pathways like PI3K/AKT/mTOR, phospholipase C or STAT. 
Negative feedback loops could also down regulate RAS signaling pathways [30]. Another 
possible explanation includes eventual concomitant molecular abnormalities that could 
activate EGFR [30]. Epigenetic variations, alternative splicing or posttranslational 
modifications could explain non active KRAS isoforms [30]. These authors therefore 
conclude that a small portion of patients with KRAS mutations might paradoxically 
benefit from EGFR TKIs. 
One patient with KRAS mutations in the Southwest Oncology Group S0126 trial study 
responded to gefitinib, but none of four patients with both EGFR and KRAS mutations 
responded [58]. 
Zhu et al. also demonstrated that one patient with KRAS mutation responded to EGFR 
TKI [55]. The tumor had EGFR amplification but not mutation. It is argued that tumors 
with KRAS mutation are unlikely to respond to EGFR TKIs unless they have EGFR 
amplification [55]. 
Not all lung cancers with KRAS mutations are addicted to KRAS, demonstrated by in vitro 
studies [59]. Dependency was correlated with KRAS overexpression while the well-
differentiated epithelial phenotype is correlated with RAS dependency [59].  
Pao et al. first suggested that EGFR and KRAS mutations are mutually exclusive [18]. 
Other studies have also shown mutual exclusivity. Nevertheless combined EGFR and 
KRAS mutations do exist, though they are rare [40, 55, 56, 60, 61].  Li et al showed that 
when there was EGFR and KRAS mutation coexistence, EGFR mutations were more 
frequently identified in exon19 [61]. 
In our study, the EGFR and KRAS mutations present were always activating mutations, 
two identified in exon 21 and one in exon 19. These cases demonstrate that EGFR and 
KRAS mutations can coexist even in the same patterns of adenocarcinoma, although 
they have been discerned as mutually exclusive. 
Lung adenocarcinoma comprises a group of tumors that are heterogeneous as regard 
histopathology typing, patterns and genetic alterations; hence, it is important to review 
a large number of histological sections to characterize the patterns present and even 
the whole tumor. In future, a more accurate molecular profile needs to be defined to 
overtake tumor morphological and genetic heterogeneity in order to explain the 
coexistence of KRAS and EGFR mutations.  
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In the second case reported here, the EGFR mutation occurred in the lepidic pattern, 
although with mucinous differentiation. Nevertheless, there are EGFR mutations 
described in mucinous patterns. KRAS mutation is described as frequent in this pattern. 
In the first case, the mutations were present in acinar and lepidic patterns and not in 
solid and mucinous patterns. Thus, tumor heterogeneity does not explain all the cases 
of EGFR and KRAS mutation coexistence. In these cases, genetic instability could explain 
the simultaneous or possibly sequential occurrence of the two mutations. Different 
clones of cells present in the same patterns could also explain the coexistence. Nor 
should we exclude the possibility of coexistence in the same cells that could overcome 
the downstream KRAS mutations by alternative signaling pathways or other regulatory 
mechanisms. 
In the third case, EGFR and KRAS mutations were present in a pleomorphic sarcomatoid 
carcinoma. We know that KRAS mutations are more frequent in less differentiated lung 
cancers. These tumors are biologically aggressive and more prone to accumulate genetic 
instability and alterations.  
Pleomorphic and sarcomatoid carcinomas are rare. One study revealed no EGFR 
mutations and a frequency of 38% KRAS mutations in primary sarcomatoid lung 
carcinomas. However, high EGFR polysomy (23%) and EGFR protein overexpression 
were identified in all the cases. These authors hypothesized that EGFR overexpression 
and KRAS mutation could explain aggressive biological behavior and worse prognosis of 
these subset of NSCLC [62]. 
 
Conclusions 
Our findings strongly support the idea that EGFR and KRAS mutations can coexist in the 
same lung cancer, even in the same cell type of an adenocarcinoma. The biological 
implications of this coexistence are still poorly understood, mainly because these cases 
are not frequent, and bronchial-pulmonary carcinomas are not routinely studied in this 
extensive manner. In the future, studies of larger case series are required to better 
understand the biological, clinical and therapeutic implications of the discussed 
molecular alterations, based on uniformly designed studies. 
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INTRODUCTION  
 
Although bronchial-pulmonary carcinomas are still the most important cause of cancer-related 
death, personalized therapy and accurate diagnosis is believed to raise survival, after the 
recent advances in molecular targeted therapies [1-5].  
Targetable and predictive oncogenic mutations have been mainly identified in lung 
adenocarcinomas (ADC) and in never smokers’ tumours. Recently, several genomic and 
molecular alterations have been demonstrated in squamous cell/epidermoid carcinoma (SQC), 
such as fibroblast growth factor receptor 1 (FGFR1), PTEN and PIK3CA/AKT1 alterations [6].  
FGFRs belong to the family of receptor tyrosine kinases (including FGFR1, FGFR2, FGFR3 and 
FGFR4), encoded by 4 genes, FGFR1 located on chromosome 8p11.23-p11.22; FGFR2 on 
10q26; FGFR3 on 4p16.3; and FGFR4 on 5q35.2. They are responsible for the control of several 
physiological processes, whose deregulation may lead to cancer development [7-9].  
FGFR1, as a transmembrane tyrosine kynase receptor, promotes cell growth, differentiation, 
and survival by downstream signalling of PI3K-AKT, RAS-MEK-MAPK, STAT, SRC and PLC genetic 
cascades [7,10].  
FGFR1 promotes epithelial-mesenchymal transition (EMT) by activating the same pathways 
and favouring tissue remodelling, while upregulation leads to cell transformation and 
carcinogenesis [11-15].  
To the growing number of targeted therapies routinely applied for adenocarcinomas therapy, 
it may be added recent comprehensive molecular/genomic characterization of squamous cell 
lung carcinomas for new potential targetable mutations [16].  
FGFR1 is considered as a new potential target for specific tyrosin kinase inhibitors. Our study 
aimed to evaluate FGFR1 expression and gene copy number in adenocarcinomas, squamous 
cell lung carcinomas, pleomorphic carcinomas and adenosquamous carcinomas. EMT pathway 
was also explored in more complex lung carcinomas such as adenosquamous and pleomorphic 
carcinomas as well as adenocarcinomas, according to Vimentin and TTF1 expression, and in 
squamous cell carcinoma, joining CK7 expression. The purpose was to identify differences 
and/or similarities in between these groups of lung tumours in order to characterize the 
histological types for targeted therapy.  
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MATERIAL AND METHODS  
 
Material  
 
Tumour samples were selected from 76 bronchial pulmonary carcinomas submitted for 
surgical resection (34 adenocarcinomas, 24 squamous cell lung carcinomas, 10 pleomorphic 
carcinomas and 8 adenosquamous carcinomas).  
Clinical and pathological features are summarized in Table 1. The median age at diagnosis was 
65 years (range 40-87 years). 56 patients were male and 20 were female. 23 were non-
smokers, 29 ex-smokers and 24 current smokers. Male gender and smokers were more 
prevalent in squamous cell lung cancer. Adenocarcinomas also demonstrated male 
predominance, but in this case were more non-smokers and ex-smokers. A predominance of 
males and smokers was registered for pleomorphic and adenosquamous carcinomas. Stages I 
and II were more prevalent. Metastases were more frequently diagnosed in lymph nodes.  
Adenocarcinomas were classified in accordance to 2015 WHO criteria (concerning the main 
patterns and all represented patterns in decreasing percentage) and the following 
immunohistochemical combinations were considered as study sub-groups with positivity (pos) 
taken as over 75% tumoural cells: 1 – CK7 pos / TTF1 pos / Vimentine (Vim) pos: 14; 2 – CK7 
pos / TTF1 pos / Vim negative (neg): 9; 3 – CK7 pos / TTF1 neg / Vim neg: 6; 4 – CK7 pos / 
TTF1neg / Vim pos: 5. The squamous cell carcinomas were separated into two groups 
according to CK7 expression: 1 – CK7 neg: 17; 2 – CK7 pos: 7, with CK5.6 expression in all cases. 
Pleomorphic carcinomas and adenosquamous carcinomas were diagnosed according to the 
2015 WHO criteria [17].  
 
Methods  
 
At least two sections of each tumour were evaluated and the results were validated by two 
pathologists. Differentiation markers, such as CK7, TTF1, CK5.6 and Vim, were applied 
according to defined protocols (see Table 2).  
FGFR1 protein expression was evaluated by immunohistochemistry applying the FGFR1 
antibody. Endogenous peroxidase activity was quenched using 15 minutes of incubation in 3% 
diluted hydrogen peroxide (H2O2). For blocking nonspecific binding with primary antibodies, 
we used Ultra V Block (Ultra Vision Kit; TP-125-UB; Lab Vision Corporation; Fremont CA; USA). 
Primary antibodies against FGFR1 (Polyclonal; Thermo Scientific) at a dilution of 1/75 for 30 
minutes, were applied to the cells and incubated at room temperature. They were washed 
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with phosphate-buffered saline (PBS) (Ultra Vision; TP-125-PB; Lab Vision Corporation; 
Fremont CA; USA) ; and after this, for 15 minutes, the slides were incubated with the biotin-
labelled secondary antibody (Ultra Vision Kit; TP-125-BN; Lab Vision Corporation; Fremont CA; 
USA). Primary antibody binding was localized in tissues using peroxidase-conjugated 
streptavidin (Ultra Vision Kit; TP-125-HR; Lab Vision Corporation; Fremont CA; USA), and 3,3-
diaminobenzidine tetrahydrochloride (DAB) (RE7190-K; Novocastra Laboratories Ltd, 
Newcastle, United Kingdom) was used as chromogen, according to the manufacturer’s 
instructions. Haematoxylin was used to counterstain the slides which were then dehydrated 
and mounted. In parallel, known positive (squamous cell carcinoma with keratin pearls) and 
negative controls were used.  
The immunohistochemistry evaluation was undertaken by two experienced thoracic 
pathologists. The intensity of expression was registered in four grades: 0; 1+; 2+; and 3+. The 
percentage of positive cells was also registered, allowing a global score to be obtained by 
multiplying the intensity by the percentage of positivity. The results were then stratified into 4 
categories: 0-10% - negative/without expression; 11-100% - low expression; 101-200% 
moderate expression; 201-300% - high expression.  
FISH was carried out in FFPE using FGFR1 (8p11) / SE 8 (D8Z1) (Kreatech, Leica Biosystems). 
Sections were deparaffinized in xylene 15 min and dehydrated in ethanol (2 x for 5 min). 
Sections were pre-treated using a Citrate buffer in a pressure cooker for 4 min, followed by 5 
min in 2 X sodium citrate (SSC), 10 min in proteinase K solution at 37°C, washing in 2 X SSC for 
5 min and dehydrating for 2 min in increasing concentrations of alcohol (70, 90 and 100%) 
after which they were air dried. Ten microliters were applied to the slides, overlaid with a 
coverslip, which was sealed with rubber cement. Slides were denatured for 8 min at 78°C and 
hybridized for at least 16 h at 37°C in a humidity chamber. They were then washed post – 
hybridization in 50% formamide and in PBS buffer at 46°C for 4 min and 2XSSC for 2 min and 
air-dried, and the counterstain DAPI 4',6-diamidino-2-phenylindole was applied.  
The samples were analyzed using x100 oil immersion objective using a Nikon 80i fluorescence 
microscope with the appropriate filters. One hundred tumour cells were evaluated. A 
specimen was considered FGFR1 positive (‘amplified’) if: (1) the FGFR1/CEN8 ratio was ≥2.0; 
(2) the average number of FGFR1 signals per tumour cell nucleus was ≥6; (3) the percentage 
(%) of tumour cells with ≥15 FGFR1 signals or large clusters was ≥10%; (4) the % of tumour 
cells with ≥5 FGFR1 signals was ≥50%, with classifications 1 to 3 considered as a high-level 
amplification and classification 4 as a low-level amplification [18]. Two independent 
technicians and a pathologist applied the score. 
 
  CHAPTER 8 – MANUSCRIPT VI 
117 
RESULTS  
 
In non-tumour tissue, FGFR1 expression was seen in respiratory epithelium; pneumocytes and 
stromal cells showed no or rare expression (figure 1).  
We found significantly higher FGFR1 protein expression in all groups of tumours compared to 
non-tumour tissue (Table 3). Significantly higher expression was seen in ADC compared to SQC 
(p=0.0232). Significantly higher expression was also observed in pleomorphic carcinomas 
compared to SQC (p=0.0265). No significant differences in expression were found between 
adenocarcinomas and adenosquamous carcinomas (p= 0.158) and pleomorphic carcinomas 
(p=0.3190), between squamous cell carcinoma and adenosquamous carcinoma (p=0.9651), or 
between adenosquamous and pleomorphic carcinomas (p=0.1189) (Table 3).  
When comparing FGFR1 expression according to squamous cell carcinomas with or without 
CK7 expression, we found no significant differences (p=0.2502). There were also no significant 
differences between adenocarcinomas with or without TTF1 expression (p=0.123) or according 
to Vimentin expression (p=0.301) (Table 3)  
When immunohistochemical results were stratified according to two expression categories: 1+ 
and 2+ / 3+ cases, reflecting the intensity of expression, we found a tendency to higher 
expression in adenocarcinomas compared to squamous cell carcinomas (p=0.061), and 
significantly higher expression in pleomorphic carcinomas compared to adenocarcinomas 
(p=0.0212), squamous cell carcinomas (p=0.0004) and adenosquamous carcinomas (p=0.0015). 
No differences were observed between adenosquamous and adenocarcinomas (p=0.1122) and 
squamous cell carcinomas (p=1). No differences were also observed in squamous cell 
carcinomas according to CK7 expression (p=0.167), and in adenocarcinomas according to TTF1 
(p=0.4653) and Vimentin (p=1) expressions (Table 4). 
FGFR1 gene copy number, evaluated by FISH, identified 15 (19.7%) FISH-positive cases: 5 
(14.7%) adenocarcinomas; 5 (20.8%) squamous cell carcinomas; 3 (30%) pleomorphic 
carcinomas; and 2 (25%) adenosquamous carcinomas (Table 5).  
FGFR1 FISH-positive cases (amplification) were more frequent in squamous cell carcinoma 
compared to adenocarcinomas, but without significant differences. FGFR1 FISH-positive cases 
were also identified in adenosquamous carcinomas (2/8 - 25%) and pleomorphic carcinomas 
(3/10 - 30%). Although amplification was more frequent in squamous cell carcinoma than in 
adenocarcinoma, no significant differences were identified according to histology (Table 6). 
There were no significant differences in FGFR1 FISH results according to gender or smoking 
status, either for adenocarcinoma and squamous cell carcinoma (Table 7), though there was a 
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tendency for a higher frequency of FGFR1 amplification in the adenocarcinomas of smoking 
patients.  
No correlations were found between FGFR1 immunohistochemical expression and FISH results 
(Spearman Rank Correlation p=0.3323 and Linear Correlation p=0.681). 
 
DISCUSSION  
 
Cancer is driven by different types of genetic mutations, which need to be identified in order 
to understand tumour growth (oncogenic drivers), so that they can be targeted, bringing 
improvements in the survival rate [3-5]. Genetic driver events are infrequent and limited 
mostly to ADC and never smokers [3-5]. Squamous cell lung carcinoma, primarily a smoker’s 
disease, still lacks genetic targets and more effective targeted therapies [6,19]. FGFR1 and FGF 
have recently emerged as driving oncogenes, sufficient to drive tumour growth [20]. 
Alterations of the FGFR gene have been recognized in many epithelial malignancies (10%): oral 
squamous cell carcinoma, breast, gastric, bladder and ovarian carcinomas and in squamous cell 
carcinoma of the lung [6,21,22].  
Several reports have shown high levels of FGFR1 protein expression in lung carcinomas [23,24], 
co-expression of FGF and FGFR1 [25-28], and FGFR1 was found to be amplified in lung 
carcinomas [29]; FGFR1 amplification and overexpression are a frequent event in lung 
squamous cell carcinoma [6]. It is described by some authors as an early event, even identified 
in squamous metaplasia and dysplasia [19,27]. However, there are conflicting results as some 
authors did not identify FGFR1 amplification in T1 NSCLC [30]. While FGFR1 is frequently 
amplified in NSCLC, mutations are absent or extremely rare in NSCLC (both SQC and ADC) 
[6,19]. So, the copy number increase appears to be responsible for the activations of the 
FGFR1 pathway [6,19]. We consider that the use of NSCLC terminology should be avoided 
because it is not the most appropriate way of classifying lung carcinomas in order to apply 
targeted therapies.  
FGFR1 amplification is associated with a response to FGFR inhibitors [6,31]. Amplified cells 
showed robust phosphorylation of FGFR1 and their effectors molecules [6,31], where 
treatment with inhibitors resulted in less phosphorylation, less growth and apoptosis [6,31,32]. 
Inhibition of FGFR signalling pathway can be achieved by: dominant negative FGFR1; anti-FGF2 
Antibodies; FGFR TKIs; and antisense DNA [23,24,33]. There are several phase I and II clinical 
trials evaluating FGFR1 inhibitors, such as BIBF 1120 (Boehringer-Ingelheim), TKI 258 (Novartis 
- Ponatinib), AZD 4547 (AstraZeneca) and BGJ 398 (Novartis). One of the inclusion criteria for 
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most of these trials was FGFR1 amplification [31,34-36]. Therefore, evaluation of the FGFR1 
gene will gain a growing importance especially in squamous cell lung carcinoma patients.  
MYC expression has been described as a predictive biomarker for FGFR1 TKIs in squamous cell 
lung carcinomas probably due to pro-apoptotic functions of MYC that facilitate FGFR-inhibitor-
mediated cell death [37]. Tumour cells co-expressing MYC and FGFR1 amplification were more 
sensitive to FGFR inhibition, suggesting that patients with both FGFR1 and MYC alterations 
may benefit from FGFR inhibitor therapy [38].  
We know that about 80% of patients harbouring EGFR mutations initially shows response to 
EGFR TKIs, and they will eventually relapse [39-41]. Acquired resistance is associated with 
mortality and morbidity [39-41]. The FGF-FGFR pathway is one of the important mechanisms 
of “intrinsic” EGFR-TKI resistance [33]. This could be explained by activation of PI3K –AKT and 
MEK-ERK pathways [42]. Some authors have investigated the presence of FGFR1 amplification 
and EGFR mutations, which were considered as mutually exclusive [43].  
In our study, higher FGFR1 protein expression was seen in tumours compared to non-tumour 
adjacent parenchyma / bronchial epithelium, demonstrating that, even in the absence of 
FGFR1 gene copy number increase, the FGFR1 pathway could be implicated in lung 
carcinogenesis and tumour growth. Other authors have also found higher protein expression in 
lung carcinomas compared to non-tumour tissue [27]. Our results suggest that protein 
overexpression is frequent in lung carcinomas, with higher expression observed in 
adenocarcinomas and pleomorphic carcinomas compared to squamous cell lung carcinomas. 
No differences were found between adenocarcinomas, pleomorphic and adenosquamous 
carcinomas. Hence, in our results, squamous carcinomas showed lower immunohistochemical 
protein expression. However, Behrens et al did not find differences of FGFR1 protein 
expression between the carcinomas studied. Higher immunohistochemical expression in 
pleomorphic carcinomas compared to squamous cell carcinomas suggests that overexpression 
is important in this group of tumours, probably reflecting activation of the EMT pathway. As 
some authors have identified FGFR1 therapy efficacy in 3+ cases, we have also stratified our 
results according to this end-point [44]. Intense (3+) immunohistochemical expression was 
observed more frequently in adenocarcinomas compared to squamous carcinomas and in 
pleomorphic carcinomas compared to all the other types of carcinomas. These last results 
could reinforce the importance of FGFR1 in the activation of the EMT pathway. No differences 
were found between adenocarcinomas and adenosquamous carcinomas, reflecting the 
compound morphology of the latter and the carcinogenesis of both. Some squamous 
carcinomas also expressed CK7, reflecting a group of less differentiated tumours with some 
features overlapping with adenocarcinomas, without significant differences of FGFR1 
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expression and gene copy number, compared to the other squamous cell carcinomas studied. 
Between adenocarcinomas, no significant differences were found, with regard to the 
expression of TTT1 (TTF1 positive/TTF1 negative cases). Thus, our results suggest that TTF1 
expression, reflecting cell origin, has probably no implications on FGFR1 pathway activation. 
Also, adenocarcinomas expressing Vimentin, associated with EMT phenotype in carcinomas 
where biological behaviour is not yet clarified, had no significant differences of either FGFR1 
expression or gene copy number compared to Vimentin negative cases, suggesting that in 
adenocarcinomas FGFR1 pathway activation precedes or is independent of EMT activation.  
In the future, it will be necessary to clearly define the predictive biomarkers for anti-FGFR1 
treatment, as some authors have identified a response in tumours with FGFR1 amplification 
and EGFR 3+ [44]. It is important to understand the predictive value of protein expression to 
be used as a biomarker, after clear cut-offs, in order to select the patients will benefit more.  
We found FGFR1 amplification in 19.7% (15) of the studied cases: 5 adenocarcinomas (14.7%), 
5 squamous cell carcinomas (20.8%), 3 pleomorphic carcinomas (30%) and 2 adenosquamous 
carcinomas (25%). FISH positive cases were more frequent in squamous cell carcinomas, 
though without significant differences to adenocarcinomas. An Wa Seo et al have reported a 
lower rate in NSCLC (8.7%) and a higher rate in squamous cell carcinoma (18%) than in 
adenocarcinomas (3%) [45]. Sasaki et al showed that the FGFR1 gene copy number was 
increased in 32 (32%) lung bronchial-pulmonary carcinoma patients, representing higher 
frequencies than in our results. There were also higher in squamous cell carcinomas (41.3%) 
than in the other histological types (14.3%) [43]. Cihoric et al have reported a global rate of 
12.5%, significantly higher in squamous cell carcinomas (20.7%) compared to adenocarcinomas 
(2.2%) and large cell carcinomas (13%) [30]. Tran et al demonstrated squamous cell carcinomas 
as having an higher frequency of FGFR1 amplification and large cell carcinomas and 
adenocarcinomas with lower rates [46]. Other authors have shown FGFR1 amplification in 
squamous carcinomas varying according to the respective series: 10.5% (Kohler et al); 16% 
(Goke et al); 20% (Shildhaus et al); and 22% (Weiss et al) [6,18,47,48]. For adenocarcinomas, 
FGFR1 amplification rates also varied according to the series: 4.7% (Kohler et al); 0 % 
(Shildhaus et al); rare cases (Weiss et al) [6,18,47]. In a review of 6 papers, FGFR1 amplification 
ranged from 9 to 16% in squamous carcinoma and was found in a maximum of 32% for NSCLC 
[49].  
As FGFR1 amplification was also identified in adenosquamous and pleomorphic carcinomas, 
with no differences compared to the other histological sub-types, it seems that the FGFR 
pathway is also important in these tumours; hence, FGFR1 amplification and protein 
expression should be performed in these tumours in order to select patients for targeted 
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therapy. Cihoric et al also have found FGFR1 amplification in 16% of large cell carcinomas [30], 
as did Tran et al at lower rate [46]. In our work, we also found amplification in adenosquamous 
and pleomorphic carcinomas. Adenosquamous carcinomas showed pathological characteristics 
common to adenocarcinomas and squamous carcinomas [50,51]. Pleomorphic carcinomas 
were characterized when the squamous pattern, adenocarcinoma or large cell carcinoma also 
exhibited a spindle and/or giant cells in at least 10% of the tumour area [50]. These tumours 
share some characteristics of the EMT pathway. Behrens et al identified protein 
overexpression in bronchial-pulmonary carcinomas, without significant differences between 
histological subtypes [27]. In our results, we observed a tendency to higher expression in 
pleomorphic carcinomas in adenocarcinomas, when comparing to squamous cell carcinomas. 
Schultheis et al have also identified FGFR1 amplification in 5.6% of small cell lung cancers 
small, without age, gender, staging, tobacco or overall survival associations [52]. According to 
these authors, FGFR1 amplification testing should be considered in patients diagnosed with 
small-cell carcinomas [52].  
We did not find any associations between FGFR1 expression / gene copy number and clinical 
parameters, such as gender and smoking habits. Like us, Tran et al, and Kohler et al found no 
correlations with clinical parameters [46,47]. Zhang et al found associations of FGFR1 
amplification with male gender and smoker status [44], while Cihoric et al reported a higher 
FGFR1 amplification frequency in males (14.8%) and on smokers or ex-smokers [30]. Sasaki et 
al have demonstrated increased FGFR1 copy number correlations with gender (higher 
frequency in males) and smoking status (higher frequency in smokers), in lung bronchial 
pulmonary carcinomas [43]. However, no correlations (with smoking status, gender, or tumour 
stage) were identified when considering only squamous cell carcinomas [43]. An Na Seo et al 
have identified FGFR1 amplification significantly higher in male smokers [45]. We have, 
however, found a tendency to higher frequencies of FGFR1 amplification in adenocarcinomas 
of smoking patients.  
No correlations between FISH results (FGFR1 amplification) and FGFR1 protein expression 
were found in our series. Similarly, An Na Seo et al found no correlation between FGFR1 gene 
copy number and FGFR1 protein expression [45].  
A meta-analysis (6 studies) revealed no association of FGFR1 amplification with poorer survival 
[49]. Further studies will be needed to evaluate survival implications, as there are some 
conflicting studies: Volm et al demonstrated that high FGFR1 expression is associated with 
worse prognosis; Cihoric et al identified lower overall survival associated with FGFR1 
amplification in NSCLC; Tran et al demonstrated, on the other hand, a tendency for longer 
survival while Seo et al showed that FGFR1 amplification was associated with lower overall 
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survival and disease-free survival in patients diagnosed with squamous cell carcinoma, though 
not significant in multivariate analysis [28,30,45,46,49].  
As already mentioned, FGFR1 amplification is an inclusion criteria for phase I and II clinical 
trials. However, according to our data and those of other series, amplification may not reflect 
overexpression. Thus, it seems reasonable that Clinical Trials should also evaluate the 
predictive value of both FGFR1 gene copy number and protein expression, in order to 
definitively clarify which is the best predictive testing, knowing that some authors identified a 
response in tumours with FGFR1 amplification and EGFR 3+ [44].  
Some authors have also investigated EGFR mutations in their series, and EGFR mutations and 
FGFR1 increased copy number appeared to be as mutually exclusive [43]. 
 
CONCLUSIONS  
 
FGFR1 protein expression is present in the majority of the bronchial-pulmonary carcinomas, 
and is higher in ADC and Pleomorphic carcinomas. Higher expression in pleomorphic 
carcinomas may reflect the importance of FGFR1 controlling EMT pathways, as Vimentin 
expression is found in an indeterminate percentage of all histological types of lung carcinomas.  
FGFR1 amplification is identified in ADC (14.7%), SQC (20.8%), adenosquamous carcinoma 
(25%) and pleomorphic carcinomas (30%), without significant differences.  
Although FGFR1 amplification has been observed more frequently in squamous cell 
carcinomas, these results and literature suggest that the other histological types harbouring 
FGFR1 amplification, such as adenosquamous, pleomorphic carcinomas, adenocarcinomas and 
even small cell lung carcinoma, may benefit from targeted therapy. 
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Table 1: Clinicopathologic characteristics distribution according to lung carcinomas histological 
subtype – WHO 2015. 
CLINICOPATHOLOGIC CHARATERISTICS  
CHARACTHERISTIC ALL PATIENTS No./ % SQUAMOUS CARC. ADENOCARCINOMA ADENOSQUAMOUS  PLEOMORPHIC 
NUMBER PATIENTS 76 24 (31.6%) 34 (44.7%) 8 (10.6%) 10 (13.1%) 
AGE (YEARS) 
 
     
MEDIAN 65 64 63 67 72 
RANGE 40-87 40-87 47-82 53-81 56-82 
SEX 
 
     
MALE 56 (73.7%) 22 (91.7%) 22 (64.7%) 5 (62.5%) 7 (70%) 
FEMALE 20 (26.3%) 2 (8.3%) 12 (35.3%) 3 (37.5%) 3 (30%) 
SMOKING HISTORY 
 
     
NON-SMOKER 23 (30.3%) 3 (12.5%) 14 (41.2%) 2 (25%) 4 (40%) 
EX-SMOKER 29 (38.1%) 8 (33.4%) 11 (32.3%) 6 (75%) 4 (40%) 
SMOKER 24 (31.6%) 13 (54.1%) 9 (26.5%) 0 (0%) 2 (20%) 
pT STAGE 
 
 
 
     
T1 22 (28.9%) 8 (33.3%) 9 (26.5%) 4 (50%) 1 (10%) 
T2 43 (56.6%) 12 (50%) 20 (58.8%) 4 (50%) 7 (70%) 
T3 6 (7.9%) 3 (12.5%) 1 (2.9%) 0 (0%) 2 (20%) 
T4 1 (1.3%) 1 (4.1%) 0 (0%) 0(0%) 0 (0%) 
pTNM STAGE      
IA 20 (26.3%) 7 (29.2%) 8 (23.5%) 4 (50%) 1 (10%) 
IB 18 (23.7%) 4 (16.7%) 8 (23.5%) 2 (25%) 4 (40%) 
IIA 13 (17.1%) 7 (29.2%) 3 (8.8%) 1 (12.5%) 2 (20%) 
IIB 5 (6.6%) 1 (4.1%) 3 (8.8%) 0 (0%) 1 (10%) 
IIIA 11 (14.5%) 2 (8.3%) 7 (20.6%) 0 (0%) 2 (20%) 
IV 1 (1.3%) 0 (0%) 0 (0%) 1 (12.5%) 0 (0%) 
METASTASIS 
 
     
LYMPH NODE 27 (35.5%) 11 (45.8%) 13 (38.2%) 0 (0%) 3 (30%) 
DISTANT 3 (3.9%) 0 (0%) 1 (2.9%) 1 (12.5%) 1 (10%) 
  
Table 2: Immunohistochemistry method and antibodies applied. 
Primary 
antibody 
Manufacture Clone Method Positive control Antigen 
retrieval 
Dilution 
and 
incubation 
time 
Staining 
Pattern 
CK7 DAKO OV-
TL12/30 
LSAB Lung Pronase 
E 
(10’, RT) 
1:50, 30’ Cytoplasmic 
TTF1 DAKO 8G7G3/1 LSAB Small cell 
carcinoma 
EDTA  
(Mw,40’) 
1:100, 60’ Nuclear 
CK 
(5/6/18) 
Novocastra LP34 LSAB Skin Pronase 
E 
(10’, RT) 
1:100, 60’ Cytoplasmic 
Vimentin DAKO Vim3B4 LSAB Colon Citrato 
(Mw,20’) 
1:200, 30’ Cytoplasmatic 
LSAB - Labeled Streptavidin Biotin Method; Mw – microwave. 
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Table 3: Comparisions of FGFR1 protein expression between bronchial-pulmonary carcinomas 
and non-tumoural tissue. ANOVA results. ADC – Adenocarcinoma: SQC – Squamous cell 
carcinoma; ADSQC – Adenosquamous cell carcinoma; PLEOMC – Pleomorphic carcinoma 
STATISTICS / Differences p VALUE RESULTS  
ADC / Non tumour tissue p<0.0001 Higher expression in ADC 
SQC / Non tumour tissue p<0.0001 Higher expression in SQC 
ADSQC / Non tumour tissue p=0.0078 Higher expression in ADSQC 
PLEOMC / Non tumour tissue p=0.002 Higher expression in PLEOMC 
ADC / SQC p=0.0232 Higher in ADC 
ADC / ADSQC p= 0.158 Not significant 
ADC / PLEOMC p=0.3190 Not significant 
SQC / ADSQC p=0.9651 Not significant 
SQC / PLEOMC p=0.0265 Higher in PLEOMC 
ADSQC/ PLEOMC p=0.1189 Not significant 
ADC TTF1+ / ADC TTF1- p=0.123 Not significant 
ADC VIM+ / ADC VIM- p=0.301 Not significant 
SQC CK7-/SQC CK7+ p=0.2502 Not significant 
ANOVA results. ADC – Adenocarcinoma: SQC – Squamous cell carcinoma; ADSQC – 
Adenosquamous cell carcinoma; PLEOMC – Pleomorphic carcinoma. 
 
 
 
Table 4: Differences of FGFR1 protein expression between bronchial-pulmonary carcinomas, 
according to intensity of expression (1+ and 2+ / 3+ cases).  
STATISTICS / Differences VALUE p RESULTS 
ADC / SQC p=0.061 Not quite significant  
ADC / ADSQC p=0.1122 Not significant 
ADC / PLEOMC p=0.0212 Significant higher in PLEOMC* 
SQC / ADSQC p=1 Not significant 
SQC / PLEOMC p=0.0004 Significant higher in PLEOMC* 
ADSQC/ PLEOMC p=0.0015 Significant higher in PLEOMC* 
ADC TTF1+ / TTF1- p=0.4653 Not significant 
ADC VIM- / VIM+ p=1 Not significant 
SQC CK7- / CK7+ p=0.167 Not significant 
ADC – Adenocarcinoma: SQC – Squamous cell carcinoma; ADSQC – Adenosquamous cell 
carcinoma; PLEOMC – Pleomorphic carcinoma. 
 
 
 
Table 5: FISH FGFR1 results.  
FISH  FGFR1 RESULTS   
CHARACTHERISTIC All  patients No. (%) SQC. ADC ADSQC  PLEOMC 
NUMBER OF CASES 76 (100%) 24 (31.6%) 34 (44.7%) 8 (10.6%) 10 (13.1%) 
FISH RESULTS  
         NEGATIVE 61 (80.3%) 19 (79.2%) 29 (85.3%) 6 (75%) 7 (70%) 
         POSITIVE 15 (19.7%) 5 (20.8%) 5 (14.7%) 2 (25%) 3 (30%) 
ADC – Adenocarcinoma: SQC – Squamous cell carcinoma; ADSQC – Adenosquamous cell 
carcinoma; PLEOMC – Pleomorphic carcinoma. 
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Table 6: FISH FGFR1 results according to histology.  
FGFR1 FISH RESULTS  
STATISTICS / Differences VALUE p RESULTS 
ADC / SQC  p=0.227 Not significant 
ADC / ADSQC p=0.289 Not significant 
ADC / PLEOMC p=0.188 Not significant 
SQC / ADSQC p=0.6464 Not significant 
SQC / PLEOMC p=0.281 Not significant 
ADSQC/ PLEOMC p=0.392 Not significant 
Fischer exact test. ADC – Adenocarcinoma: SQC – Squamous cell carcinoma; ADSQC – 
Adenosquamous cell carcinoma; PLEOMC – Pleomorphic carcinoma. 
 
 
Table 7: FISH FGFR1 results according to gender and smoking status.  
 FISH Negative FISH Positive Statistics 
SQC 
Male 17 (70.8%) 5 (8.3%) p=0.620 
 Female 2 (20.8%) 0 (0%) 
ADC 
Male 17 (50%) 5 (14.7%)       p=0.137 
 Female 12 (35.3%) 0 (0%) 
SQC 
  Smoker (1) 10(41.7%) 3(12.5%) 1/2 - p= 1 
1/3 - p= 1 Ex-smoker (2) 6(25%) 2(8.3%) 
Non-smoker (3) 3(12.5%) 0(0%) 
ADC 
  Smoker (1) 6(17.6%) 3(8.8%) 1/2 - p=0.074 
1/3 - p=0.343 Ex-smoker (2) 11 (32.3%) 0 (0%) 
Non-smoker (3) 12(35.3%) 2(5.9%) 
Fischer exact test. ADC – Adenocarcinoma: SQC – Squamous cell carcinoma. 
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Figure 1: a - Adenocarcinoma (ADC) Vim positive (+) TTF1 negative (-), acinar pattern,  HE, 
200x; b - ADC Vim- TTF1-, papillary and micropapillary patterns, HE, 200x; c - ADC Vim+ TTF1+, 
micropapillary pattern, HE, 400x; d - ADC Vim- TTF1+, solid pattern, HE, 100x; e - ADC Vim- 
TTF1+ , cribriform pattern, HE, 100x; f - ADC Vim- TTF1-, solid  with clear cells, HE, 200x; g - 
ADC Vim- TTF1-, mucinous pattern, HE, 100x; h – squamous cell carcinoma (SQC), CK7 +, HE, 
100x; i – SQC, CK7-, HE, 200x; j – adenosquamous carcinoma,  HE, 100x; l – pleomorphic 
carcinoma (PLEOMC) with giant cells,  HE, 200x; m –PLEOMC with fusiform cells, HE, 200x.  
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Figure 2: a – normal respiratory epithelium, FGFR1, 100x; b – adenocarcinoma (ADC) Vim-
(negative) TTF1+ (positive), FGFR1 1+, 200x; c - ADC Vim+ TTF1-, FGFR1 2+, 200x; d - ADC  
TTF1+ Vim+, FGFR1 3+,  200x; e – squamous cell carcinoma (SQC) CK7 -, FGFR1 1+, 400x; f - 
SQC CK7 -, FGFR1 2+, 400x; g - SQC CK7 -, FGFR1 3+, 200x; h - SQC CK7 +, FGFR1 3+, 400x; i – 
pleomorphic carcinoma (PLEOMC), FGFR1 3+, 400x; j - PLEOMC, FGFR1 3+, 200x; l – 
adenosquamous carcinoma (ADSQC), FGFR1 -, 200x; m - ADSQC, FGFR1 3+, 200x. 
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Figure 3: a - FGFR1 amplification, FGFR1 (red) / CEP 8 (green), adenocarcinoma, 1000x; b - 
FGFR1 amplification, FGFR1 (red) / CEP 8 (green), squamous cell carcinoma, 1000x. 
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Abstract I (2010):  
The 16th International Charles Heidelberger Symposium on Cancer Research, Coimbra, 
Portugal, September 26-28, 2010. 
EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 AND P53 EXPRESSION IN PRENEOPLASTIC LESIONS 
OF BRONCHIAL EPITHELIUM 
Lina Carvalho,1-4* Joana E. Santo,1 Ana Alarcão,1-2 Patricia Couceiro, 1-2 Maria R. Silva, 1-3 Ana 
Gomes,2,4 Maria J. d’Aguiar,1 Lia. Teixeira,1 Vitor Sousa1-4 
1 Instituto de Anatomia Patológica – Faculdade de Medicina da Universidade de Coimbra, 
Coimbra, Portugal 
 2 Centro de Investigação em Meio Ambiente, Genética e Oncobiologia, Coimbra, Portugal 
3 Centro de Pneumologia – Faculdade de Medicina da Universidade de Coimbra, Coimbra, 
Portugal 
 4 Serviço de Anatomia Patológica dos Hospitais da Universidade de Coimbra, Coimbra, 
Portugal. 
* Presenting author.  
 
ABSTRACT 
A prognostic interpretation of preneoplastic lesions would have impact in bronchial carcinoma 
early diagnosis and through the study of Erb-B family receptors as they have an important role 
in lung carcinogenesis. The existence of drugs as tirosine kinase inhibitors (TKis) stressed the 
importance of studying gene alterations for selected chemoprevention schemes and 
characterization of carcinogenesis.  
Bronchial preneoplastic lesions were characterized by immunohistochemistry using the 
antibodies LP34 (high weigh molecular cytokeratin), CK7, Chromogranin A, Ki67, p53, C-erbB-2 
and EGFR. HER2 and EGFR gene copy number was also evaluated by fluorescent in situ 
hybridization (FISH) in those lesions.  
The expected results defined the origin cell for basal cell hyperplasia and squamous metaplasia 
as adaptative lesions and dysplasia. By known experiences and published data, beyond the 
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stem cell, the spectral evolution of bronchial preneoplastic lesions was demonstrated by 
characterizing basal cells (LP34) and their neoplastic potentiality.  
Dysplasias showed a higher expression of EGFR, Ki67 and p53 with a stepwise increase with the 
gravity of the respective grading. C-erbB-2 immunohistochemical overexpression was a rare 
event in preneoplastic lesions. Polysomy was the main mechanism for EGFR and HER2/neu 
higher gene copy number and together with increased proliferation index (Ki67) will account 
to preview bronchial carcinogenesis. 
BMC Proceedings 2010, 4(Suppl 2):P64 
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Figure 1: Poster I: EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 AND P53 EXPRESSION IN 
PRENEOPLASTIC LESIONS OF BRONCHIAL EPITHELIUM. 
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Abstract II  (2010):  
The 16th International Charles Heidelberger Symposium on Cancer Research, Coimbra, 
Portugal, September 26-28, 2010. 
 
EGFR UNUSUAL MUTATION STATUS IN LUNG ADENOCARCINOMAS 
 
Ana Alarcão,1-2* Vitor Sousa,1-4 Patrícia Couceiro, 1-2 Maria Silva, 1-3 Maria J. d’Aguiar,1 Lia 
Teixeira,1 Lina Carvalho1-4  
1 Instituto de Anatomia Patológica – Faculdade de Medicina da Universidade de Coimbra, 
Coimbra, Portugal 
 2 Centro de Investigação em Meio Ambiente, Genética e Oncobiologia, Coimbra, Portugal 
3 Centro de Pneumologia – Faculdade de Medicina da Universidade de Coimbra, Coimbra, 
Portugal 
 4 Serviço de Anatomia Patológica dos Hospitais da Universidade de Coimbra, Coimbra, 
Portugal. 
* Presenting author.  
ABSTRACT 
Lung cancer is the most common cause of cancer deaths in both men and women. 
Adenocarcinoma represents about 28% of the NSCLC cases in men and 42% in women. EGFR is 
a member of the ERBB family of tyrosine kinases (TK). EGFR mutations are more frequently 
observed in female, non-smokers, East-Asian and in patients with adenocarcinomas, and 
predict response to TK Inhibitors (TKIs). 
Sections of adenocarcinomas of the lung, formalin-fixed paraffin-embedded tissues (FFPE), 
were selected to analyze mutations in EGFR exons 19 and 21 by DNA extraction for polymerase 
chain reaction (PCR). Exon 19 was studied by fragment analysis and exon 21 was studied by 
direct sequencing. The analysis of FISH results was done by Cappuzzo’s score to EGFR gene. 
Determination of EGFR protein expression was done by immunohistochemistry (IHC) (Zymed, 
Laboratories) 
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The author’s present two cases of lung adenocarcinoma that harbours coexisting EGFR exon 19 
and 21 mutations and one case of EGFR multiple in frame-deletions. The patients were female 
(n=3), with mixed type adenocarcinoma overexpressing EGFR by IHC.   
Most reports demonstrate one EGFR mutation per adenocarcinoma. We demonstrated that a 
single adenocarcinoma can harbour more than one EGFR activating mutations.  
BMC Proceedings 2010, 4(Suppl 2):P61 
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Figure 2: Poster II: EGFR UNUSUAL MUTATION STATUS IN LUNG ADENOCARCINOMAS. 
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Abstract III (2010):  
The 16th International Charles Heidelberger Symposium on Cancer Research, Coimbra, 
Portugal, September 26-28, 2010. 
KRAS AND EGFR MUTATIONS COEXISTING IN LUNG ADENOCARCINOMA 
Vitor Sousa,1-4* Ana Alarcão,1-2 Patricia Couceiro, 1-2 Maria R. Silva, 1-3 Maria J. d’Aguiar,1 Lia 
Teixeira,1 Lina Carvalho1-4  
1 Instituto de Anatomia Patológica – Faculdade de Medicina da Universidade de Coimbra, Coimbra, 
Portugal 
 2 Centro de Investigação em Meio Ambiente, Genética e Oncobiologia, Coimbra, Portugal 
3 Centro de Pneumologia – Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal 
 4 Serviço de Anatomia Patológica dos Hospitais da Universidade de Coimbra, Coimbra, Portugal. 
* Presenting author. 
 
ABSTRACT 
Lung adenocarcinoma represents about 42% and 28% of NSCLC in women and men. 
Adenocarcinomas incidence is still rising being the most frequent type of NSCLC diagnosed in 
USA. Both EGFR and KRAS gene mutations can contribute to the development of NSCLC, 
namely adenocarcinomas. EGFR and KRAS mutations are considered by some authors as 
mutually exclusive explained by the fact that KRAS-MAPK pathway is one of the downstream 
signalling pathways of EGFR. Lung cancers with KRAS mutations are resistant to EGFR tyrosine 
kinase inhibitors.  
Sections of the adenocarcinoma of the lung, formalin-fixed paraffin-embedded tissues (FFPE), 
were selected to analyze mutations in EGFR exons 19 and 21 and KRAS - codons 12 and 13 by 
DNA extraction for polymerase chain reaction (PCR). Exon 19 was studied by fragment analysis 
and exon 21, codons 12 and 13 were studied by direct sequencing. The analysis of FISH results 
was done by Cappuzzo’s score to EGFR gene. Determination of EGFR protein expression was 
done by immunohistochemistry (IHC) (Zymed, Laboratories) 
The authors present a rare case with synchronous EGFR and KRAS mutations. The patient is a 
77 years old, male with a central 3cm mixed adenocarcinoma. The tumour showed EGFR 
protein overexpression identified by IHC and chromosome 7 high polyssomy by FISH.The 
authors call attention to the fact that although EGFR and KRAS mutations are almost always 
mutually exclusive in some cases they may coexist in the same neoplasia.  
BMC Proceedings 2010, 4(Suppl 2):P57 
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Figure 3: Poster III: KRAS AND EGFR MUTATIONS COEXISTING IN LUNG ADENOCARCINOMA. 
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Abstract IV (2010): 
Intercongress Meeting of the European Society of Pathology, Krakow – Poland, 31st August - 
4th September,  2010. 
 
EGFR and KRAS mutations in mixed type of Pulmonary Adencocarcinoma 
 
Author’s: Ana Alarcão1;2, Patrícia Couceiro1;2, Maria Silva1;2, Maria João d’Aguiar1, Lia Teixeira1, 
Vitor Sousa1-3, Lina Carvalho1-3. 
 
Institution: 1 Instituto de Anatomia Patológica – Faculdade de Medicina da Universidade de 
Coimbra, Coimbra, Portugal; 2 Centro de Investigação em Meio Ambiente, Genética e 
Oncobiologia, Coimbra, Portugal; 3 Serviço de Anatomia Patológica dos Hospitais da 
Universidade de Coimbra, Coimbra, Portugal. 
 
 
Background:  
The EGFR and KRAS genes act sequentially in the MAPK signaling pathway. The KRAS gene is 
located downstream in the transduction of signals transmitted from the transmembrane 
receptor EGFR to the nucleus through a series of intermediate genes. Patients with non-small-
cell lung cancer (NSCLC) with EGFR mutations are more sensitive to treatment with tyrosine 
kinase inhibitors (TKIs) without KRAS mutations. The different patterns recognized in 
adenocarcinomas were microdissected to identify mutations in both EGFR and KRAS in order 
to clarify their significance when selecting patients either to TKIs.  
Methods:  
Material and methods: Histological sections of 31 adenocarcinomas of the lung, FFPE, were 
selected to analyze EGFR exons 19 and 21 mutations and KRAS - codons 12 and 13, DNA was 
extracted for polymerase chain reaction (PCR). Exon 19 was studied by fragment analysis, exon 
21 and codons 12 and 13 were studied by direct sequencing.  
Results:  
From the 31 samples studied, 10/31 showed in-frame deletions, 4/20 L858R substitution in the 
EGFR, and 5/31 point mutations in codon 12 of KRAS. In all cases mutations were exclusive for 
EGFR and KRAS in alternative. Only one mixed adenocarcinoma showed EGFR in-frame 
deletions in bronchiolo-alveolar pattern and Wt in acinar pattern (KRAS Wt). 
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Conclusion:  
In this set of mixed type adenocarcinomas, the different histological patterns revealed to be 
inconsequent for KRAS and EGFR determination of mutations, reinforcing the technical 
feasibility and reliability of small biopsies of lung cancer to determine personalized therapy.  
 
Virchows Arch (2010) 457: 91-281 
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 Figure 4: Poster IV: EGFR and KRAS mutations in mixed type of Pulmonary Adenocarcinoma. 
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Abstract V (2011):  
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
 
KRAS Mutations in Lung Adenocarcinomas may be Relevant in Histological Patterns, EGFR 
Mutational Status and Male Smokers 
Lina Carvalho (1) (2) (3) (4), Ana Alarcão (1) (2), Patrícia Couceiro (1) (2), Maria R. Silva (1) (2) 
(3), M João d’Aguiar (1), Lia Teixeira (1), Teresa Ferreira (1), Vitor Sousa (1) (2) (3) (4) 
(1) Instituto de Anatomia Patológica – Faculdade de Medicina da Universidade de Coimbra, Coimbra, 
Portugal 
 (2) Centro de Investigação em Meio Ambiente, Genética e Oncobiologia, Coimbra, Portugal 
(3) Centro de Pneumologia – Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal 
 (4) Serviço de Anatomia Patológica dos Hospitais da Universidade de Coimbra, Coimbra, Portugal. 
 
Lung adenocarcinomas may show different patterns/subtypes and as EGFR and KRAS 
mutations rationalize personalized therapy, mutations were searched in all different patterns: 
acinar, papillary, micropapillary, solid and mucin producing, after immunohistochemistry 
characterization. 
KRAS and EGFR mutations in 31 lung resected adenocarcinomas were studied by polymerase 
chain reaction (PCR), fragment analysis and direct sequencing. 
There were 5/31 cases with KRAS point mutations, 3 of them G12V and 2 of them G12C; 26 
cases were Wt. In KRAS mutated cases, 4 had no EGFR mutations and one case exhibited exon 
21 EGFR point mutation in two patterns (BAC and Acinar) of the same mixed type 
adenocarcinoma. 
No statistical relevance was found between exon 2 KRAS status and age (for WT and mutated) 
(p=0,401). KRAS mutation was more frequent in male (p=0,000) and in smokers (p=0.014).  
EGFR mutations and KRAS mutations have been described as mutually exclusive but in this 
small series one case had KRAS and EGFR mutations simultaneously.  Although EGFR and KRAS 
mutations are generally mutually exclusive, they can coexist and clinical, therapeutic and 
prognostic issues concerning male smoking patients become relevant as may direct 
personalized therapy. 
Virchows Archiv 2011; Supplement 459: SI – S320. IF: 2.491 
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Figure 5: Poster V: KRAS Mutations in Lung Adenocarcinomas may be Relevant in Histological 
Patterns, EGFR Mutational Status and Male Smokers. 
 CHAPTER 9 – ABSTRACTS PUBLICATIONS 
148 
Abstract VI (2011):   
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
 
TTF1 Negative Solid Pattern in Lung Adenocarcinomas May Reflect Morphogenesis  
Lina Carvalho (1) (2) (3) (4), Ana Alarcão (1) (2), Patrícia Couceiro (1) (2), Maria R. Silva (1) (2) 
(3), M João d’Aguiar (1), Lia Teixeira (1), Teresa Ferreira (1), Vitor Sousa (1) (2) (3) (4) 
 
 
(1) Instituto de Anatomia Patológica – Faculdade de Medicina da Universidade de Coimbra, Coimbra, 
Portugal 
 (2) Centro de Investigação em Meio Ambiente, Genética e Oncobiologia, Coimbra, Portugal 
(3) Centro de Pneumologia – Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal 
 (4) Serviço de Anatomia Patológica dos Hospitais da Universidade de Coimbra, Coimbra, Portugal. 
 
Lung adenocarcinomas are classified according with histological subtypes/patterns. Thyroid 
transcription factor-1 (TTF-1) is a tissue-specific transcriptional factor important in 
differentiation and morphogenesis of lung/thyroid/brain and was applied to classify pulmonary 
adenocarcinomas and also to evaluate its expression in the reported patterns. 
In a series of 44 lung adenocarcinoma there were: 41 acinar, 5 papillary, 13 micropapillary, 14 
solid, 25 bronchiolo-alveolar (BAC) and 3 mucinous patterns. Applyed immunohistochemistry 
panel was: TTF1, CK7 and Ki67. 
TTF1 expression was higher in adenocarcinomas / normal lung (p=0.0009). Expression was 
greater in acinar (p=0.0014), BAC (p<0.0001) and micropapillary patterns (p=0,0019) than in 
normal parenchime. Mucinous pattern had lower expression / normal lung (p=0.02). There 
were no differences between normal lung and papillary (p=0.5074) and solid patterns 
(p=0.5659); 6/14 cases of solid pattern were TTF1 negative and expressed CK7 while Ki67 
expression was higher in this TTF1 negative group when compared to the TTF1 positive 
(p=0.0015). 
Decreased expression of TTF1 in some patterns identifies a small number of cases developing 
from pure CK7 positive cells (bronchial?). Solid pattern show lower nuclear expression of TTF1 
and combined with higher expression of Ki67 in TTF1 negative cases may reflect different 
morphogenesis and more aggressive biological behaviour. 
Virchows Archiv 2011; Supplement 459: SI – S320. IF: 2.491 
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Figure 6: Poster VI: TTF1 Negative Solid Pattern in Lung Adenocarcinomas May Reflect 
Morphogenesis. 
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Abstract VII (2011): 
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
Lung Adenocarcinomas Subtyping is not Relevant for EGFR Mutations, Gene Copy Number 
and Protein Expression  
Lina Carvalho (1) (2) (3) (4), Ana Alarcão (1) (2), Patrícia Couceiro (1) (2), Maria R. Silva (1) (2) 
(3), M João d’Aguiar (1), Lia Teixeira (1), Teresa Ferreira (1), Vitor Sousa (1) (2) (3) (4) 
 
(1) Instituto de Anatomia Patológica – Faculdade de Medicina da Universidade de Coimbra, Coimbra, 
Portugal 
 (2) Centro de Investigação em Meio Ambiente, Genética e Oncobiologia, Coimbra, Portugal 
(3) Centro de Pneumologia – Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal 
 (4) Serviço de Anatomia Patológica dos Hospitais da Universidade de Coimbra, Coimbra, Portugal. 
 
Lung adenocarcinomas simple/mixed type show various (till six) patterns whose clinical 
relevance must be tested. A series of 44 resected adenocarcinomas were studied with c-erbB1 
(clone 31G7), EGFR gene copy number by FISH and EGFR exons 19 and 21 sequenced.   
Being mixed type Adenocarcinomas, the following patterns were characterized in at least two 
sections: 41 acinar, 5 papillary, 13 micropapillary, 14 solid, 25 with non-mucinous bronchiolo-
alveolar (BAC) and 3 mucinous. 
EGFR higher expression in solid pattern was relevant and lower in BAC pattern. EGFR 
mutational status was present in 8/31 cases with exon 21 point mutations and in 10/31 cases 
exon 19 deletions; 4 cases had coexisting exon 21 and exon 19 mutations. Concordance 
between FISH results ad each mutation type (exon 21 and 19) was considered fair (k=0.3702 
and k=0.3841). 
The concordance between mutations and immunohistochemistry expression and between 
FISH and IHC was not relevant (k=0.2556 and k=0.2635). 
EGFR mutations are frequent and reflect their importance in lung adenocarcinomas 
pathogenesis. There is rough concordance with high gene copy number and in less extent with 
protein expression. Mutations were generally present in all the patterns of the same 
adenocarcinoma meaning that biopsies are prone to evaluation of EGFR mutational status. 
Virchows Archiv 2011; Supplement 459: SI – S321. IF: 2.491 
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Figure 7: Poster VII: Lung Adenocarcinomas Subtyping is not Relevant for EGFR Mutations, 
Gene Copy Number and Protein Expression. 
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Abstract VIII (2011): 
23rd European Congress of Pathology, Helsinki August 27– September 01 – 2011. 
 
ALK Gene Rearrangment in EGFR and KRAS Positive Lung Adenocarcinomas 
Authors: Lina Carvalho, Maria Reis Silva, Ana Alarcão, Patrícia Couceiro, Domingos Oliveira, 
Vítor Sousa, Lia Teixeira, Maria João DÁguiar, José Mário Ruivo 
 
Lung cancer is still the leading cause-related of death worldwide and adenocarcinomas 
harbour genetic changes to be further classified into clinical relevant molecular subsets. 
Tumours sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors often 
contain somatic mutations in the tyrosine domain of EGFR. While other tumours exhibit 
somatic mutations in KRAS which display primary resistance to those drugs. Another mutation 
is anaplastic large cell kinase gene (ALK) that is rearranged in approximately 5% of lung 
adenocarcinomas, indicates ALK inhibitors to be prescribed when EGFR and KRAS are wildtype. 
We tested 19 lung adenocarcinomas for ALK rearrangments by fluorescent in-situ hybridization 
(FISH) and immunohistochemistry (IHC), 14 cases harboured EGFR mutations and 5 KRAS 
mutations.  
Both techniques independently identified negative cases 17/19 (89%), except for one positive 
FISH and IHC case 1/19 (5%), with ALK rearranged gene (50 year old women). One FISH case 
was inconclusive. 
Our findings in this subset population of EGFR and KRAS mutation positive adenocarcinomas of 
5% ALK rearrangement suggests that with the emergence of moleculary-targeted therapies, it 
is reasonable to assume that all adenocarcinomas should be screened for ALK rearrangments, 
by dual testing IHC and FISH, to ensure accurate diagnosis. 
 
Virchows Archiv 2011; Supplement 459: SI – S320. IF: 2.491 
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Figure 8: Poster VIII: ALK Gene Rearrangment in EGFR and KRAS Positive Lung 
Adenocarcinomas. 
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Abstract IX (2012): 
24thEuropean Congress of Pathology, Prague, September 8 – 12, 2012  
ALK EXPRESSION IN PULMONARY ADENOCARCINOMAS 
Lina Carvalho (1) (2) (3) (4), Ana Alarcão (1) (2) (3), Ana Filipa Ladeirinha (1), Maria Reis Silva (1) 
(2) (3), M João d’Aguiar (1), Teresa Ferreira (1), Vitor Sousa (1) (2) (3) (4) 
 
(1) Institute of Pathology, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal  
 (2) CIMAGO – Research Center for Environment, Genetics and Oncobiology, Faculty of Medicine, 
University of Coimbra, Coimbra, Portugal  
(3) Centre of Pulmonology, Faculty of Medicine of the University of Coimbra, Portugal  
 (4) Service of Pathology, University Hospital of Coimbra, Coimbra, Portugal  
 
 
EML4-ALK crizotinib therapy needs validation at lower cost and rapid answer in Pathology 
routine.  
 
Histological/WHO 2004 and CK7, TTF1, CK5.6, CD56/chromogranin and vimentin panel 
classifications with ALK (clone 5A4, Novocastra Laboratories Ltd, Newcastle, United Kingdom) 
were applied to paraffin sections of 35 bronchial-pulmonary carcinomas: 20 adenocarcinomas, 
6 epidermoid carcinomas, 4 pleomorphic carcinomas (mixed type adenocarcinomas with 
large/giant/fusiform cells), 4 neuroendocrine carcinomas (NEC) (1 combined large cell NEC 
with adenocarcinoma and 2 with epidermoid carcinomas; 1 SCLC chromogranin positive 
combined with adenocarcinoma) and 1 adenosquamous carcinoma.  
 
The applied antibodies specified bronchial pulmonary carcinomas subtypes clearly. In 3 over 60 
years old non-smoking females mixed type adenocarcinomas ALK expression was over 50%: 
acinar, solid, micropapillary and microacinar patterns; one glandular mucinous pattern 
(mucinous BA pattern) and one  BA pattern, all expressing TTF-1.  
 
In this study, 3/20 adenocarcinomas of older women had ALK protein expression, only one 
with a mucinous pattern. As protein positivity cases comprise a lower number, FISH described 
by S. Lantuejoul seems to be the most appropriate method. It is now necessary to decide 
whether KRAS and EGFR mutations have to be determined together and/or select TTF-1 
positive adenocarcinomas (from terminal respiratory unit) raised by this approach. 
Virchows Arch (2012) 461 : S1-S332. IF: 2.676 
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Figure 9:  Poster IX: ALK expression in Pulmonary Adenocarcinomas. 
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Abstract X (2013): 
 XXIX Congresso de Pneumologia, Albufeira-Portugal, October 25 – 27, 2013 
 
Bronchial-Pulmonary Carcinoma Cases with EGFR, ALK and MET Alterations 
 
V Sousa (1) (2) (3) (4), MR Silva (1) (2) (3), A Alarcão (1) (2) (3), AF Ladeirinha (1), MJ d’Aguiar (1), T Ferreira 
(1), L Carvalho (1) (2) (3) (4)  
 
(1) Institute of Pathology, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal  
(2) CIMAGO – Research Center for Environment, Genetics and Oncobiology, Faculty of Medicine, 
University of Coimbra, Coimbra, Portugal  
(3) Centre of Pulmonology, Faculty of Medicine of the University of Coimbra, Portugal  
(4) Service of Pathology, University Hospital of Coimbra, Coimbra, Portugal  
 
 
Introduction 
ALK (encodes a tyrosine kinase receptor) rearrangements are present in 2-7% of lung 
carcinomas and are responsible for a constitutively active  oncogenic protein reported as 
exclusive of EGFR mutations and associated with EGFR inhibitors resistance but  highly 
sensitive to treatment with ALK–inhibitor crizotinib. MET amplification is also associated with 
EGFR inhibitors resistance. 
  
Material and Methods 
ALK rearrangement was studied by FISH with break-apart dual color probe (Abbott) and 
immunohistochemistry (IHC) - monoclonal antibody clone 5A4 (Leica) was applied to sections 
of a bronchial-pulmonary carcinomas in surgical specimens of all histological types. 
Simultaneously EGFR mutations were determined by DNA direct sequencing and EGFR and 
MET genes amplification, by FISH (Abbott).  
 
Results 
The authors present two cases showing MET, ALK and EGFR molecular alterations. 
One case diagnosed as pleomorphic carcinoma with ALK translocation, MET amplification and 
EGFR amplification.  
Another case diagnosed as an solid and acinar lung adenocarcinoma showed MET 
amplification, ALK translocation and exon 21 EGFR mutation (L858R) 
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Conclusion 
Concomitant EGFR and MET alterations were observed with ALK rearrangement. This could be 
the reflex of the biological complexity of cancer cells and of the carcinoma. Although rare this 
events raises questions concerning the clinical and therapeutical relevance of them.  
ALK status must be tested in advanced bronchial-pulmonary adenocarcinoma, as it could be 
responsible for TKI-resistence of EGFR mutated tumours that benefit from ALK-targeted 
agents. 
 
Key-words: ALK rearrangement, EGFR, MET. 
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Figure 10: Poster X: Bronchial-Pulmonary Carcinoma Cases with EGFR, ALK and MET 
Alterations. 
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Abstract XI (2013): 
Biennial Pulmonary Pathology Society (PPS) Meeting, Grenoble, June 25-28, 2013  
EGFR Mutations, MET, EGFR Amplification and ALK Rearrangement Simultaneous in Five 
Bronchial-Pulmonary Adenocarcinomas  
Silva MR (1) (2) (3), Alarcão A (1) (2) (3), Ladeirinha AF (1), D’Aguiar MJ (1), Ferreira T (1), Sousa 
V(1) (2) (3) (4), Carvalho L (1) (2) (3) (4), 
(1) Institute of Pathology, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal  
 (2) CIMAGO – Research Center for Environment, Genetics and Oncobiology, Faculty of Medicine, 
University of Coimbra, Coimbra, Portugal  
(3) Centre of Pulmonology, Faculty of Medicine of the University of Coimbra, Portugal  
 (4) Service of Pathology, University Hospital of Coimbra, Coimbra, Portugal  
 
Context 
ALK rearrangement was found in 2-7% of lung carcinomas resulting a constitutively active and 
oncogenic protein reported as exclusive of EGFR and KRAS mutations and associated with 
resistance to EGFR inhibitors but with sensitivity crizotinib.  
Design 
Sections of 126 bronchial-pulmonary carcinomas of all histological types, obtained from 
surgical specimens were screened for ALK positivity by FISH with break-apart dual color probe 
(Abbott) and immunohistochemistry (IHC) - monoclonal antibody clone 5A4 (Leica); EGFR and 
KRAS mutations were determined by DNA direct sequencing and EGFR and MET genes 
amplification, were explored by FISH (Abbott).  
Results 
IHC was applied in FISH ALK+ cases and of the 126 screened tumours, 9 adenocarcinomas (7%) 
were FISH ALK +, 3+ or 2+ score in IHQ, corresponding to 42-79 aged patients. Among these 9 
FISH-ALK+ cases, 3 had EGFR mutations and 2 had both EGFR and MET gene amplifications in 
FISH; KRAS was wild type. IHQ correlates with FISH for ALK gene rearrangement. 
Conclusion 
EGFR and MET alterations concomitant with ALK rearrangement have to be tested in advanced 
bronchial-pulmonary adenocarcinoma, to validate TKI-resistance of EGFR mutated tumours 
that benefit from ALK-targeted agents. EGFR mutations search continue again to be necessary 
in this context of targeted therapy. 
(2014) Pulmonary Pathology Society Biennial Meeting Abstracts. Archives of Pathology & 
Laboratory Medicine: May 2014, Vol. 138, No. 5, pp. 700-709. 
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Figure 11: Poster XI: EGFR Mutations, MET, EGFR Amplification and ALK Rearrangement 
Simultaneous in Five Bronchial-Pulmonary Adenocarcinomas. 
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Abstract XII (2014): 
5º Congresso de Pneumologia do Centro, June 26-27, 2014 
Pulmonary Squamous Cell Carcinoma can harbor EGFR mutations 
 
L Carvalho 1-3, MR Silva 1-3, A Alarcão 1-3, T Ferreira 1,2, MJ d´Aguiar 1,2, V Sousa1-3 
 
1. Institute of Pathology, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal  
2. CIMAGO – Research Center for Environment, Genetics and Oncobiology, Faculty of Medicine, 
University of Coimbra, Coimbra, Portugal  
3. Centre of Pulmonology, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal 
 
Introduction 
Lung Squamous Cell Carcinomas (SQCC) are tumours that arise from bronchial epithelial cells 
through squamous metaplasia/dysplasia and are characterized by keratinization and/or 
intercellular bridges. The presence of at least 10% of the tumour bulk exhibiting these 
differentiation features is required for the diagnosis. EGFR mutations are more frequently 
described in lung adenocarcinomas. 
Objective 
Activating mutations in EGFR are typically not present in SQCC. We examined the diagnostic 
accuracy of SQCC to relate with EGFR mutations analysis, supported in a small 
immunohistochemistry panel. 
Materials and Methods 
Fourty-seven surgical specimens with SQCC were studied. Immunohistochemical markers 
(TTF1, P63 and CK5/6, CD56, VIM) were used to confirm the diagnosis, to evaluate proliferative 
index and EMT differentiation. EGFR was studied by IHC (protein expression), FISH (copy 
number) and direct sequencing (mutational analysis). 
Results 
EGFR mutation (in-frame deletion in exon 19) was present in three SQCC, one diagnosed as 
clear cell variant; all TTF1 negative and with high weight cytokeratin expression. Proliferative 
index varied between 10 and 50% in these cases. EGFR protein expression was present as well 
as EGFR high copy number, by amplification (1 case) or by high polysomy (2 cases). 
Conclusion 
Authors present three cases of Lung Squamous Cell Carcinoma in never-smokers. EGFR 
mutations occur rarely in SCC with reported frequency of less than 5%; thus routine molecular 
testing is not usually recommended for SCC histology. Little is known about SQC harboring 
EGFR mutations. Although EGFR-TKIs seem to be generally less effective in EGFR-mutated 
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SQCC than in EGFR-mutated ADC patients, some EGFR-mutated SQCC patients can obtain 
clinical benefit from EGFR-TKIs. To better identify these patients, pathological parameters 
should be taken into consideration: absence of cellular pearl /keratin formation and 
large/clear cells, where CK7 and Vim are relevant; p63 as a unique marker leads to 
myoepithelial carcinoma interpretation. 
 
Key words: Squamous Cell Carcinoma, EGFR 
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Figure 12: Poster XII: Pulmonary Squamous Cell Carcinoma can harbor EGFR mutations. 
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CHAPTER 10 – Discussion and Conclusions 
DISCUSSION 
This scientific content reflects the candidate’s research in the Institute of Anatomic and 
Molecular Pathology of the Faculty of Medicine, University of Coimbra, as well as the diagnosis 
work carried out at the Pathology Department of HUC-CHUC, where most of the cases were 
collected. 
The sequence is as follows: basal cell hyperplasia (BCH) – squamous cell metaplasia (SM) – 
squamous dysplasia (SD). Bronchial-pulmonary carcinomas are discussed with emphasis on 
epidermoid carcinomas, secondly on adenocarcinomas, followed by adenosquamous and 
pleomorphic carcinomas. 
 
Epidermoid carcinoma preneoplastic lesions  
Knowledge accumulation related to molecular events occurring in preneoplastic lesions may 
allow a better understanding of carcinogenesis and the molecular pathways implicated. It may 
also help to define lesions at risk of evolving into invasive carcinomas, and help in the selection 
of patients for future chemoprevention schemes, always based on the expression of molecular 
or genetic tumours biomarkers. 
Preneoplastic lesions studied in Manuscript I (“EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and 
p53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and 
genetic study”) included BCH, SM, and SD including carcinoma in situ (CIS); these lesions are 
considered as a model for epidermoid carcinoma carcinogenesis. One of the reasons for 
studying these lesions was the frequency of their diagnosis in biopsies and surgical specimens, 
and their frequent identification alongside invasive epidermoid carcinomas. On the other 
hand, other recognized preneoplastic lung lesions, such as diffuse idiopathic neuroendocrine 
cell hyperplasia (DIPNECH) and atypical adenomatous hyperplasia (AAH), are less frequently 
identified in routine practice. The BCH – SM – SD sequence was also well established, as 
molecular events reflect the different biological phases of evolution. This sequence therefore 
constitutes a good model for investigating new molecular markers or genes, such as EGFR and 
HER2. 
 
The study of preneoplastic lesions allows a better comprehension of carcinogenesis, including 
the molecular mechanisms involved. Early diagnosis is essential to reduce mortality rates. We 
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also have to consider the relevance of molecular biomarkers in the context of preneoplastic 
lesions, with predictive value for invasiveness or with potential relevance in the context of the 
development of chemoprevention schemes and actual treatment. Lung carcinogenesis is a 
complex multistep process that originates in “normal” epithelium and preneoplastic lesions; 
hence, more information is needed concerning this type of lesions. We also know that some 
proteins and genes may constitute good biomarkers of the biological risk of progressing to 
invasive lesions. For all these reasons it is very important to study preneoplastic lesions [179]. 
Based on a small IHC panel (CK7, CK5.6) our results suggest that preneoplastic lesions of 
epidermoid carcinoma originate in basal cells of the respiratory epithelium. All lesions tested 
positive for CK5.6 and negative for CK7, the same pattern observed in the respiratory 
epithelium basal cells. In this work, Ki67 and p53 also constitute potentially biologically 
aggressive biomarkers, as we observed an increasing expression along the spectrum of lesions 
from BCH to CIS. As stated before, lung carcinogenesis is a complex multistep process where, 
based on our results, Ki67 and p53 participate in proliferation with implications for cell cycle 
and apoptosis control. 
Given the current importance of targeted therapy depending on biomarker expression, where 
EGFR and the signal pathway determine personalised therapy, we studied EGFR expression in 
these preneoplastic lesions, demonstrating its increasing expression in lesions on this 
spectrum; therefore, EGFR and the respective pathways may play a role in early steps of 
epidermoid carcinoma development, reflecting the importance of EGFR signalling transduction 
pathways in preneoplastic lesions. Other studies also corroborate these results [136,180-186]. 
The increment in EGFR gene copy number (FISH positive cases) was mainly by polysomy than 
by amplification; so amplification is not the major mechanism related to protein 
overexpression. Polysomy is considered an early genetic event that could also be used to 
identify more biologically aggressive lesions [34,134,180,187-189]. On the other hand, it seems 
that HER2 might not be involved in the first steps of epidermoid cancer development; other 
studies have found identical results [185,189,190]. Piyathilake et al did not find any stepwise 
increment of C-erbB-2 along the preneoplastic lesions, suggesting its lack of importance in lung 
epidermoid carcinoma carcinogenesis [185]. Several other reports also suggest that HER2 has 
less importance than EGFR in epidermoid lung carcinoma carcinogenesis [135,189,191]. 
 
EGFR, Ki67 and p53 might play a role in the identification of epidermoid carcinoma 
preneoplastic lesions at higher risk of developing epidermoid carcinoma. An increasing 
expression of these markers was observed. The study reinforced the importance of Ki67 as a 
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biomarker for dysplasia, a group of preneoplastic lesions characterized by higher proliferative 
index, also identified by other authors [187,188,192-195]. The “guardian” of genome integrity, 
which also regulates cellular proliferation and apoptosis, had a higher expression along the 
preneoplastic lesion sequence indicating that TP53 mutation and p53 accumulation are early 
molecular events, a finding corroborated by other published studies [110,135,196,197]. 
 
Significant correlation was found between the intense expression of EGFR protein and EGFR 
gene copy number; in the preneoplastic lesions studied, EGFR protein expression reflected 
gene copy number. Hirsch et al also identified a correlation between EGFR protein and EGFR 
gene copy number [198]. Other mechanisms could explain protein overexpression without 
amplification, such as lower internalization and degradation of EGFR protein or alterations in 
molecular control mechanisms [199,200].  No correlation was found between EGFR and Ki67 
protein expression, although there was an increased expression of both molecules along the 
spectrum of the studied lesions. Meert el al also identified a higher expression of Ki67 and 
EGFR in high-grade lesions compared to low-grade lesions, associated with proliferation, as a 
marker of malignant transformation [184,185,194,201]. 
 
EGFR protein overexpression as well as high gene copy number in the studied lesions raises the 
hypothesis of chemoprevention, whose development depends partially on the recognition of 
the importance of these biomarkers in carcinogenesis, and their ability to select patients that 
could benefit from targeted therapies. Reliable biomarkers must be identified in the 
carcinogenesis process so that modulation of their expression correlates with the evolution of 
the disease and could be easily reproducible in routine practice. In this context, routine 
biomarkers could comprise histological alterations, molecular patterns and cytogenetic 
alterations, validated in larger series, to also enable the microenvironment and patients’ habits 
to be understood [202]. At present there are no chemoprevention schemes with 
demonstrated benefits [202-207]. However, given that preneoplastic lesions are frequently 
asymptomatic, and cancer is characterized by a great genetic complexity through multiple 
molecular pathways alterations, it seems that if an alteration in a single gene or a small group 
of genes is not identified as associated to epidermoid carcinoma carcinogenesis, a scheme of 
chemoprevention must be capable of targeting multiple pathways to block epidermoid lung 
carcinoma carcinogenesis [206-208]. 
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Epidermoid carcinoma 
The results of the epidermoid carcinoma study are presented in Manuscript II “Polysomy and 
amplification of chromosome 7 defined for EGFR gene in epidermoid carcinoma of the lung 
together with exons 19 and 21 wild type”. To clearly define epidermoid differentiation, an IHC 
panel (including CK7, CD56, Chromogranin A and CK5/6) was used, which allowed us to 
confirm epidermoid differentiation in all our selected cases. Taking account of the results 
concerning EGFR and HER2 expression in the preneoplastic lesions, we aimed to explore their 
expression in the invasive counterpart of this spectrum, although we now know that EGFR 
mutations are more frequent in adenocarcinomas [180,189,198,209-212]. 
EGFR-FISH positive cases, by high polysomy or amplification, were mostly diagnosed in cases 
with EGFR protein overexpression, with a tendency to significance.  EGFR protein expression in 
FISH-positive cases could be explained by other molecular mechanisms such as lower 
internalization and degradation. Until our study, most of the studies concerning EGFR (IHC, 
FISH or mutational) were done in Non-Small Cell Lung Cancer (NSCLC) without histological 
typing. Our work added value by selecting only epidermoid carcinomas, based on histological 
and IHC characteristics. Cases of EGFR mutations in epidermoid carcinomas should be 
cautiously interpreted [209,211-215]. In our selected surgical cases, we found 3 cases out of 48 
(6.25%) with EGFR mutation, namely 3 exon 19 deletion and no exon 21 point mutation.  
Epidermoid carcinomas with EGFR mutations could be explained by the biological / genetic 
complexity of lung cancer, including adenocarcinoma differentiation, lower differentiation, or 
cases with epidermoid and sarcomatoid differentiation (EMT - epithelial mesenchymal 
transition characteristics) [209,211-224]. 
Fang et al identified a lower EGFR mutation rate (2%) in epidermoid carcinoma compared to 
adenocarcinomas, and a lower TKIs response rate [225]. Fiala et al identified 7.2% rate of EGFR 
mutation in epidermoid carcinoma, without significant EGFR TKIs benefit [211]. Other studies 
demonstrated variable response rates to EGFR TKIs [212,215,221,226]. 
Recently, Recktman and Travis et al evaluated a group of 95 epidermoid carcinomas 
p63+/TTF1- all without EGFR or KRAS mutations [220]. They also revised a group of formerly 
diagnosed epidermoid carcinomas with EGFR mutations, and concluded that those cases 
corresponded to adenosquamous or poorly differentiated adenocarcinomas with a 
“squamous” morphology, after IHC [220]. Thus, these authors claim that there are no EGFR 
mutations in epidermoid carcinomas. 
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Several other reports indicate the presence of EGFR mutations in adenosquamous carcinomas 
and pleomorphic carcinomas [213,214,216-218,224]. 
Jia et al observed that adenosquamous carcinomas had an EGFR mutation rate of 38%, 
identifying 5 cases with more than one mutation type. The KRAS mutation rate was 3.6% [213]. 
Kang et al identified an EGFR mutational rate of 44% in adenosquamous carcinoma, present in 
both patterns (adeno and squamous), and more frequent in young women and never-smokers 
[214].They found no relations with the histological pattern of the adenocarcinoma counterpart 
[214]. 
Tochigi et al found an EGFR mutational rate of 13% in adenosquamous carcinoma, also present 
in both patterns [218]. They also found a 13% mutational rate for KRAS, in a western 
population [218]. EGFR mutational rates were similar to the mutational rates for 
adenocarcinomas and KRAS mutation rates were lower [218]. Exon 19 del was more frequent; 
hence, they argue that adenosquamous carcinoma has a worse prognosis, due probably to 
exon 19 del associated with the prognosis [218]. Those mutations were present in both 
components of the adenosquamous carcinomas, suggesting that these are not collision 
carcinomas based on monoclonal theory [218]. This hypothesis is also raised by Kang et al, 
supported by studies with identical results [214]. 
During tumour progression, the morphological transformation of a carcinoma from epithelial 
phenotype to mesenchymal phenotype has been associated with a more aggressive behaviour 
and metastasis. Yauch et al explored the EMT concept and identified the loss of E-cadherin and 
higher Vimentin expression associated with the EMT pathway in EGFR TKIs insensitive cellular 
lineages; on the other hand, E-cadherin was upregulated in sensitive cellular lineages [227]. 
Cross-talk between E-cadherin and EGFR was suggested [227]. 
Italiano et al identified no EGFR mutations in pleomorphic carcinomas, where the KRAS 
mutation rate was 38%, suggesting that sarcomatoid carcinomas do not benefit from EGFR 
TKIs [224]. Lee et al instead, identified mutational rates of 14.8% for EGFR and 9% for KRAS in 
pleomorphic carcinomas [216]. 
Epidermoid carcinomas have a basal cell origin, as already stated. We know that there are 
poorly differentiated epidermoid carcinomas, some with an EMT phenotype and others co 
expressing CK7. These cases represent more complex carcinomas, which present 
characteristics that possibly indicate different molecular/genetic events or hybrid 
characteristics, where EGFR mutations could be found. Tumours with poorly differentiated 
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epidermoid lung carcinoma, especially with CK7 and/or Vimentin expression, may be 
submitted to EGFR mutation testing. In our routine molecular pathology practice, we also 
identified pleomorphic carcinoma with coexistence of EGFR and KRAS mutations, again 
morphology reflecting genetic/molecular complexity and events accumulation. We have also 
recently (Abstract XII – “Pulmonary Squamous Cell Carcinoma can harbour EGFR mutations”) 
presented three “epidermoid” carcinomas with EGFR mutations (all exon 19 deletions), 
without TTF1 expression. One had a solid pattern and necrosis, with p63 expression and TTF1, 
CK7, CK5.6 and Vimentin negativity, a second case had large cell phenotype and CK5.6, CK7 
and Vimentin positivity, while the third (clear cell variant) showed CK7 and CK5.6 positivity. 
Amplification was present in the first case and high polysomy in the remaining two cases.  CK7 
was generally expressed in cylindrical epithelial bronchial cells and pneumocytes. Thus, these 
three cases expressed characteristics common to bronchial adenocarcinomas. Epidermoid 
carcinomas with vimentin expression are also more complex carcinomas where EMT pathways 
are important, which explains their lesser morphological differentiation together with 
fusocellular phenotype or irregular infiltrative borders with large isolated cells. Consequently, 
epidermoid carcinomas with these phenotypes should be reported to clinicians, who should be 
made aware that these patients may benefit from EGFR mutation testing. Hence, epidermoid 
carcinomas with solid, large cells or clear cell phenotype or with CK7 or even Vimentin 
expression (EMT phenotype) are submitted to EGFR mutational analysis in our Hospital. 
In small biopsies, solid pattern adenocarcinomas could be difficult to interpret, as we found in 
these cases lower TTF1 expression. Some could be interpreted as NSCLC, a designation we 
definitely avoid. These TTF1 negative solid pattern adenocarcinomas have higher Ki67 
expression, indicating a more biologically aggressive behaviour. 
When considering adenosquamous carcinoma, a pattern-based approach is important as we 
know that EGFR mutations are more frequent in lepidic non-mucinous and acinar patterns 
[228-230]. 
Hence, a comprehensive pathological diagnosis is essential, incorporating 
immunohistochemical markers, such as p63 or CK5/6, CK7 and TTF1, as well as mucine 
detection by histochemical techniques. This is especially necessary in small biopsies 
representing poorly differentiated carcinomas with some “squamous” features or solid 
patterns, where it could be difficult to differentiate between a poorly differentiated 
epidermoid carcinoma and a solid pattern adenocarcinoma. In these small biopsies we must 
also take account of incomplete sampling; thus, some cases diagnosed as epidermoid 
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carcinoma in biopsies may be diagnosed as adenosquamous carcinoma in surgical specimens, 
after extensive sampling. We could argue for the possibility of EGFR mutation testing in 
biopsies with poorly differentiated epidermoid carcinomas, especially in cases diagnosed in 
never-smokers or with CK7 / Vimentin expression / TTF1 negative. 
We must take in consideration that our cases presented in Manuscript II, “Polysomy and 
amplification of chromosome 7 defined for EGFR gene in squamous carcinoma of the lung 
together with exons 19 and 21 wild type”, were selected by two pathologists, making use of an 
IHC panel in order to exclude adenosquamous or large cell lung carcinoma cases. These cases 
were selected from the SAP – HUC/CHUC archive, where total inclusion of lung carcinomas is 
mandatory; this practice allows us to better classify lung cancers, namely by allowing the 
identification of glandular or sarcomatoid areas. 
Although EGFR mutations are infrequent, the high gene copy number is a frequent event in 
epidermoid carcinoma (with polysomy present in 46.3% and amplification in 12.9% of the 
cases). It seems that EGFR gene copy may play a role in epidermoid lung cancer carcinogenesis, 
with mutations being a rare event.  
Some authors identified a response to TKIs (tyrosine kinase inhibitors) in NSCLC FISH EGFR 
positive cases, especially with amplification and others with EGFR protein overexpression 
[198,231]. In our work, the percentage of FISH-positive cases was high (46.3% with high 
polysomy and 12.9% with amplification). 
We can infer that EGFR TKI therapy is less prone to be effective in these epidermoid 
carcinomas. However, tumours that have areas with other morphological or 
immunohistochemical differentiation may benefit from the mutational search 
[211,215,226,232]. 
 
Adenocarcinoma  
Bronchial-pulmonary adenocarcinomas were studied, also following the strategy of EGFR and 
HER2 analysis, adding a new degree of complexity, namely evaluating expression according to 
histological subtypes / patterns. Knowing that there are several patterns / histological 
subtypes recognized, we studied the adenocarcinomas using a pattern-based approach, aiming 
to identify differences concerning the expression of differentiation markers and several gene 
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products related with different molecular pathways, by IHC methods (methods that could 
easily be used in routine diagnosis).  
In a first study, several molecular markers were evaluated: CK7, TTF1, CK20, CK 5/6, 
chromogranin A, Ki67, p53, RB, BCL2, Cyclin D1, APC, ERCC1, LRP, MRP1, EGFR and HER2 in an 
attempt to differentiate / identify the molecular pathways involved in cancer development 
according to the present patterns, and to establish expression differences for molecular 
markers for targeted therapy. Comparisons were made with adjacent normal lung tissue 
(bronchial epithelium and the epithelium of the terminal respiratory unit (TRU)).  
In the manuscript “Bronchial-Pulmonary Adenocarcinoma Subtyping Relates with Different 
Molecular Pathways”, the importance of pattern identification and classification of lung 
adenocarcinomas was recognized and emphasized by the newly proposed classification of lung 
adenocarcinomas [233]. 
Differences between patterns should be taken to account to improve diagnosis and prognosis 
and enhance therapy selection strategies. We studied differences in the expression of 
differentiation and proliferation markers, gene products related to apoptosis like p53 and 
BCL2, products of oncogenes, proteins involved in cell cycle control such as molecules related 
to chemotherapy resistance, and growth factor receptors like EGFR and HER2. 
In this work, we clearly identified differences in expression between all patterns studied and 
normal tissue. Together with the differences observed between patterns, this suggested, 
based on a dendogram analysis, that adenocarcinomas are molecularly different from normal 
adjacent tissue, and that acinar and BA/lepidic patterns are the most alike and papillary the 
most different. Cluster analysis revealed three clusters: papillary; solid; and a group composed 
of acinar, BA/lepidic and micropapillary.  
There were also clear differences concerning gender (females were more frequently non-
smokers, tumours were in earlier stages and with higher ERCC1 expression, involved in DNA 
repair).  
Staging correlated with higher TTF1 expression in stage IA, higher Ki67 expression in IIIA, 
higher APC expression in IIA and IIIA, higher RB expression in IB compared to IA, higher p53 
expression in IB, IIA and IIIA compared to IA, higher ERCC1 expression in IIIA than IIA and lower 
EGFR expression in stage IB compared to stage IA). Ki67, APC, and ERCC1 had higher 
expression in the higher stages and TTF1 lower expression in the higher stages, reflecting more 
aggressive and proliferative adenocrcinomas with less differentiation or even a non-TRU 
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bronchial adenocarcinoma. Higher ERCC1 expression is also associated with platin 
chemoresistance. Higher-stage adenocarcinomas are more prone to chemoresistance. 
There were two specific gene expression differences concerning patterns and HER2 and TTF1 
alterations. Papillary and solid patterns revealed lower TTF1 expression (identical to normal 
tissue), exhibiting a non-TRU/bronchial phenotype. Acinar, BA/lepidic and micropapillary 
patterns showed higher TTF1 expression corresponding to TRU origin. These patterns, 
especially lepidic and acinar, TTF1 positive, are those where EGFR mutations are said to be 
more frequent. TTF1 expression, identifying possible TRU origin, defines a subgroup of 
adenocarcinomas with molecular and biological particularities.   
The solid pattern also revealed lower HER2 and higher EGFR and ERCC1 expression (compared 
to papillary). In solid patterns, EGFR pathway activation was related with EGFR overexpression. 
There are some reports indicating that EGFR overexpression is related with poor prognosis or 
survival [224,234-238]. Based on these facts, we stated that solid pattern adenocarcinomas 
were less differentiated adenocarcinomas, with a worse prognosis. Papillary patterns showed 
higher HER2 and lower ERCC1 expressions.  
It seems that impaired DNA repair mechanisms are implicated in carcinogenesis when the 
papillary pattern is dominant. Adenocarcinomas showed higher TTF1 expression in acinar, 
BA/lepidic and micropapillary patterns corresponding to TRU adenocarcinomas that express 
TTF1 [239]; probably related with better prognosis when compared to non-TRU type 
adenocarcinomas [240].  This is also highlighted by some authors that identified an inverse 
correlation between TTF1 and Ki67, a marker of proliferation and biological aggressiveness 
[241]. Hence, TRU-type adenocarcinomas represent a biologically less aggressive group, based 
on TTF1 higher expression and in the absence of higher EGFR expression compared to normal 
tissue.  
In our results, there was no difference in Ki67 expression between patterns. We identified 
higher TTF1 expression in acinar and lepidic patterns, in TRU- type adenocarcinomas, 
corroborating the published results. TTF1, expressed in TRU type adenocarcinomas, has been 
associated with a good prognosis [241-246]. However Pelosi et al did not find a correlation 
between TTF1 expression and prognosis [247]. Several studies identified a correlation between 
TTF1 expression, like TRU type adenocarcinomas, and EGFR mutations [248,249]. TRU-type 
adenocarcinomas have also been associated with EGFR mutations [248-252]. It is also known 
that EGFR mutations are more frequent in lepidic and acinar patterns. EGFR protein expression 
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has been described as more frequent in TRU-type adenocarcinomas and also in epidermoid 
lung carcinomas [253].  
TTF1 has importance defining adenocarcinomas differentiation as well as providing crucial 
information for therapy planning in patients diagnosed with advanced lung adenocarcinoma, 
taking into consideration that EGFR mutations are more frequent in TTF1 positive TRU-type 
adenocarcinomas. On the other hand TTF1 negative adenocarcinomas, some representing 
non-TRU adenocarcinomas, are less prone to harbour EGFR mutations. 
The micropapillary pattern had higher RB expression, and the acinar pattern lower ERCC1 and 
higher EGFR expression when compared with normal tissue. Cyclin D1 seemed to be relevant 
in acinar and BA/lepidic patterns and not related with micropapillary pattern.  
Increased Cyclin D1 expression is associated  with G1 to S phase progression, inducing cellular 
proliferation [254]. The G1-S transition mediated by Cyclin D and CDK4 complexes occurs 
through retinoblastoma inactivation. Some reports have corroborated the bad prognosis of 
Cyclin D1 overexpression and pRb inactivation, and the importance of G1/S transition in lung 
cancer [255]. Thus, the cell cycle progression in acinar and lepidic patterns may be related to 
higher Cyclin D1 expression together with pRb inactivation. The loss of the RB gene is 
associated with cell proliferation and apoptosis [138]. In lung cancer, the frequency of the 
inactivation of the RB pathway is so high that it is considered a requirement for carcinogenesis 
[256]. 
 
ERCC1 protein expression in micropapillary, solid and BA/lepidic patterns indicated DNA repair 
preservation, while in acinar and papillary patterns, there was lower expression. Lung cancer 
with higher ERCC1 expression was associated with Cisplatin-based chemotherapy resistance as 
ERCC1 acts by removing DNA adducts, which relates to poor prognosis [257-262]. In our cases, 
micropapilary, solid and also lepidic patterns had ERCC1 expression, indicating their ability to 
remove Cisplatin adducts.  
BCL2 was overexpressed in all patterns, suggesting that there was inhibition of apoptosis. 
Higher BCL2 indicates that prevention of apoptosis is a ubiquitous phenomenon transversal to 
all the patterns of the adenocarcinomas [263]. 
MRP1 and LRP were overexpressed in all patterns and need further analysis to better 
understand the role of those proteins in the response to therapy.  
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MRP1 is a transporter of the cytokine cysteinyl leukotriene C4, releasing it in response to 
inflammatory stimulus, in order to confer cellular protection against toxic agents [264]. MRP 
molecules are associated with resistance to cytotoxic agents / therapies [265]. Functional 
active MRP1 expressed bronchial-pulmonary carcinoma cells correlate inversely with 
chemosensitivity [266]. In some studies, researchers showed that there were frequently high 
levels of MRP1 in NSCLC specimens; however, there is no consensus about the prognostic 
value of NSCLC with MRP1 expression [267]. Lung resistance-related protein forms part of the 
phenotype MRD (multidrug resistance), expressed in bronchial-pulmonary cell lines and 
correlated with cisplatin resistance [268]. In lung tissue, some researchers demonstrated that 
LRP is similarly expressed in normal bronchial cells and in NSCLC cells. The respiratory 
epithelial cells have detoxification mechanisms, and the LRP can deregulate this mechanism 
and confer resistance to chemotherapy [266,269-271]. In our selected cases there was higher 
MRP1 and LRP expression in adenocarcinoma patterns compared to normal tissue, indicating 
that during carcinogenesis there is an acquisition of drug resistance mechanisms, without 
correlation with any specific pattern. 
Adenocarcinoma subtyping / pattern recognition was considered to have great importance, 
and one of the most original aspects of our work is to compare the results obtained according 
to adenocarcinoma patterns. Pattern recognition/classification has important clinical and 
therapeutic implications as it has been demonstrated to have biological significance. 
Knowledge of molecular target expression according to the pattern is of great clinical utility 
and enables us to better recognize the probability of an adenocarcinoma harbouring a specific 
molecular target for personalized therapy, according to the patterns present in the diagnosed 
adenocarcinoma, where molecular alterations start to be clearly known. 
Molecular characterization of lung adenocarcinomas supports targeted therapies, especially 
for EGFR. Knowing the importance of targeted therapies and pattern recognition, we 
evaluated EGFR, HER2 expression, gene copy number and mutational status as KRAS 
mutational status, while also trying to correlate it with adenocarcinoma sub-typing, to better 
understand the value of pattern sub-typing in lung adenocarcinoma and anticipate molecular 
alterations.  
There are numerous references in the IHC and genetic studies literature to lung 
adenocarcinoma or NSCLC (under the old nomenclature). One important objective of this work 
was to look for EGFR and KRAS mutations together with FISH and IHC assays, always according 
to adenocarcinoma patterns. 
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We found a higher EGFR mutational rate (46%) than advocated in the literature, especially in 
western countries [45,172,173,180,198,219,272-278]. This could be explained by the selection 
of surgical stage adenocarcinomas, not including biopsy cases, the extensive selection of 
different areas of the same tumour for the assays, and the high number of female patients, 
where the risk for EGFR mutations is higher. Quality control is also a standard in the 
laboratory, according to the EQA program for testing biomarker mutations in non-small cell 
lung carcinoma, promoted by the European Society of Pathology. The laboratory has 
participated with a score of ≥ 90%, considered as a successful participation. It must be 
emphasized that other studies have shown EGFR mutational rates of 49% in females and 19% 
in males [277]. This may also reflect population features. Advanced stage tumours could 
explain genetic events accumulation, tumour heterogeneity and genetic instability. Tumour 
heterogeneity and genetic instability could also explain cases identified with more than one 
EGFR mutation type.  
 
Although EGFR mutations were more frequent in women, there were clear significant 
differences concerning exon 19 mutations but not exon 21 mutations. Like other publications, 
EGFR mutations were associated with female never-smokers [45,277,279]. Smoking cannot 
prevent EGFR mutations as there have been cases diagnosed in smokers, as also stated by 
other authors [279]. EGFR mutations were more frequent in acinar and lepidic patterns 
compared to the other patterns [228-231]. EGFR activating mutations have been described as 
more frequent in the classical bronchiole-alveolar pattern and in mixed-type adenocarcinomas 
[228-230]. Others have demonstrated that papillary, micropapillary and hobnail patterns were 
correlated with EGFR mutations [280,281]. Dacic et al demonstrated different EGFR mutation 
rate according to primary histological patterns: acinar (20%), BA/lepidic (12.5%), mucinous 
(9%), papillary (3%), micropapillary (3%) and solid (0%) [273]. 
KRAS mutations were more frequent in male adenocarcinoma cases and in smokers. These 
results were corroborated by other studies [173,223,273,279,282,283]. KRAS mutations were 
identified in acinar, lepidic and solid patterns. In the literature, KRAS mutations are associated 
with mucinous differentiation, goblet cells, and solid patterns and in non-TRU 
adenocarcinomas [8,273,284-290]. Dacic et al demonstrated different KRAS mutation rates in 
mixed-type adenocarcinomas that showed acinar (32%), solid (18%), BA/lepidic (16%), 
mucinous (16%), papillary (10%) and micropapillary (4%) patterns [273]. These differences 
could be explained by the lower number of mucinous and solid patterns in the studied sample 
and also by the absence of poorly differentiated adenocarcinoma cases. As in the literature a 
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correlation was found between EGFR gene copy number and mutational status. Amann et al, 
Hirsch et al and Takano et al also found correlations and some sensitivity for EGFR 
TKIs[198,291,292]. Although some studies demonstrated that EGFR mutations are usually 
related with amplification in EGFR locus, the relationship between EGFR mutations, gene copy 
number, and IHC expression is still unclear [213,215-217,231]. We found no correlation with 
EGFR expression, perhaps because gene amplification was not the prevalent event but gene 
polysomy, reflecting aneuploidy. 
One important aspect identified in this study was the fact that when a mutation was present, it 
was generally present in all the patterns of the same adenocarcinoma. These results support a 
monoclonal origin for the different patterns. Other molecular mechanisms must be implicated 
in different morphological differentiation, some already explored. This has important clinical 
and diagnostic implications; biopsies of an adenocarcinoma are reliable to determine EGFR and 
KRAS mutational status.  
KRAS and EGFR mutations coexistence was identified: there was one adenocarcinoma with 
KRAS and EGFR mutation coexistence (EGFR exon 21 L858R mutation in acinar and lepidic 
patterns and KRAS codon 12 point mutation G12V in acinar and lepidic patterns). In our daily 
diagnostic routine, we identified two more cases of bronchial-pulmonary carcinoma with this 
mutational coexistence status: one mucinous lung adenocarcinoma (EGFR exon 21 point 
mutation L858R and KRAS codon 12 point mutation G12V in acinar and lepidic mucinous 
patterns), and one pleomorphic giant-cell carcinoma (EGFR exon 19 deletion – 19 bp and KRAS 
codon 12 point mutation G12C). KRAS and EGFR mutations have generally been considered as 
mutually exclusive [274,275,277,279,283,293]. However, there are reports indicating their 
coexistence [173,274,294].   
A literature review was conducted into the predictive value of KRAS mutations and KRAS and 
EGFR mutation coexistence concerning EGFR TKIs. KRAS mutations are associated with EGFR 
TKIs resistance [274,283,295-298]. EGFR and KRAS mutation coexistence means that upstream 
inhibition of EGFR will have no therapeutic blockage [299]. Jackman et al found no survival 
impact of KRAS mutations in patients without EGFR mutations treated with EGFR TKIs [300]. 
Rare cases of TKI minor or transient response in patients with KRAS mutation are described 
[173,300]. Because EGFR mutation is considered a good predictor of EGFR TKIs response and 
EGFR and KRAS mutations are generally mutually exclusive, it is not clear whether the 
response to TKIs differs between tumours with KRAS mutations and those without KRAS and 
EGFR mutations [301]. This fact raises the idea that KRAS mutation is not always associated 
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with EGFR TKI resistance as EGFR activation was not only mediated through KRAS signalling, 
and negative feedback loops could downregulate RAS signalling [302]. Non-active KRAS 
isoforms could also be explained by epigenetic changes, alternative splicing or 
posttranslational modifications [302]. 
 
In our study, the EGFR and KRAS mutations present were always activating mutations. Other 
studies have identified rare NSCLC cases with EGFR and KRAS mutations [173,274,294].   
To better understand the biological and therapeutic implications, it is necessary to evaluate a 
larger number of cases of lung carcinomas harbouring both mutations, knowing that most 
published articles make reference to sporadic rare case reports. Coexistence of KRAS and EGFR 
mutations in the same tumour raises again the question of tumour heterogeneity.  
Although when an EGFR mutation is identified, it was generally present in all patterns of the 
same adenocarcinoma, there are cases where it was possible to find more than one type of 
EGFR mutation. One case of lung adenocarcinoma was reported with exon 19 EGFR del 9bp 
and 18bp present in acinar pattern and del 15bp in solid and micropapillary patterns. Two 
cases showed coexistence of exon 21 EGFR point mutation (L858R) and exon 19 EGFR del (of 
19, 18 1nd 9bp) present in different patterns of the same adenocarcinoma. Complex EGFR 
mutations patterns, like the presence of more than one mutation type, have been being 
described; for instance Huang et al identified 7 cases with two EGFR mutations out of a total of 
39 mutated cases [303]. 
These are rare cases that clearly demonstrate tumour heterogeneity in lung adenocarcinomas, 
reflecting some pattern heterogeneity; they may be the result of different neoplastic cell 
clones or more probably genomic instability and mutational acquisition in the later phases of 
carcinogenesis. Neoplastic cells might accumulate multiple molecular events in the EGFR gene 
in these adenocarcinoma cases. In our study, all EGFR mutations were activating mutations, so 
it could be argued that these adenocarcinoma patients would still benefit from EGFR TKIs. 
Several poster presentations with abstract published in different medical journals completed 
the investigation that sustains the actual discussion. 
In “TTF1 Negative Solid Pattern in Lung Adenocarcinomas May Reflect Morphogenesis”, some 
of the results presented in Manuscript IV – “Lung adenocarcinoma: sustained subtyping with 
immunohistochemistry and EGFR, HER2 and KRAS mutational status” – were illustrated, with 
incidences in accordance with mutational status and FISH EGFR results, a pattern-based 
approach that show that biopsies are prone to be used in the evaluation of EGFR mutational 
status. Till now the results and discussion have been centred particularly on EGFR and KRAS 
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mutational status using an adenocarcinoma pattern-based approach. Work carried out in the 
laboratory was also essential to improve technical and diagnostic skills that enabled the 
development of molecular diagnosis for clinical purposes at the Institute of Pathology. The 
knowledge acquired made it possible to advance to the diagnosis/evaluation of other genes, 
such as ALK and MET, all with therapeutic implications. In the last group of abstracts (VIII, IX, X 
and XI and XII), we searched for the results of the evaluation of these genes in lung bronchial 
carcinomas, especially adenocarcinomas. Abstract VIII – “ALK Gene Rearrangment in EGFR and 
KRAS Positive Lung Adenocarcinomas” reported one case with ALK rearrangement out of a  
total of 19 carcinomas, with either EGFR (14) or KRAS (5) mutations. Different EML4 exons can 
be fused with the ALK gene, and more than nine variants have been identified [304,305]. FISH 
is the actual method of choice for ALK rearrangement detection, although Reverse 
Trancription PCR (RT-PCR), immunohistochemistry and chromogenic in situ hybridization have 
been also proposed by different authors [305-307]. Results demonstrated that EGFR mutation 
and ALK rearrangement coexistence, although rare, can be diagnosed. Patients with both 
genetic alterations may show different sensitivities to targeted EGFR inhibition [308-311]. ALK 
and EGFR signalling are closely related, and the differential sensitivity in these cases may 
indicate that tumours were dependent on different oncogenes or that they had a dominant 
driver mutation [312,313]. Further studies, inolving more cases are necessary to clarify the 
interaction between EGFR and ALK signalling and the biological and clinical implications of 
EGFR and ALK genetic alteration coexistence. 
 
Abstract X – “Bronchial-Pulmonary Carcinoma Cases with EGFR, ALK and MET Alterations” 
presents a pleomorphic carcinoma with ALK translocation, MET amplification and EGFR 
amplification and an adenocarcinoma with ALK translocation, MET amplification and exon 21 
EGFR point mutation (L858R). Abstract XI – “EGFR Mutations, MET, EGFR Amplification and ALK 
Rearrangement Simultaneous in Five Bronchial-Pulmonary Adenocarcinomas” concerns a 
series of 126 cases of bronchial-pulmonary carcinomas including 9 FISH ALK positive cases with 
EGFR mutations and MET amplification. A correlation was found between ALK IHC and FISH 
results. These cases may reflect tumour heterogeneity and molecular complexity. MET 
amplification, like ALK translocation is responsible for EGFR TKI resistance, associated with 
poor prognosis [314-316]. There are trials ongoing with anti-MET antibodies (MetMAb) [147]. 
MET amplification may be detected by FISH or RT-PCR [143,145,317]. MET amplification is 
supposed to be unusual in untreated bronchial-pulmonary lung carcinomas, and the incidence 
varies between 2 to 4% [143,146,175,317,318]. MET amplification plays a role in acquired 
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resistance to EGFR inhibitors in patients with EGFR mutated tumours, and is identified in 5% to 
20% of these cases [144,175,314,319,320]. 
 
Bronchial-pulmonary carcinomas and FGFR1 
 
As oncogenic driver mutations have been mainly described for adenocarcinomas we 
considered to explore new molecular targets, especially for squamous cell lung carcinomas and 
other lung cancers, such as adenosquamous and pleomorphic lung carcinomas. FGFR1 was 
considered as a good candidate because amplification was recently described in lung 
carcinomas, more frequently in squamous cell carcinoma, with the recent development of 
molecular targeted therapies. So it was intended to evaluate FGFR1 protein expression and 
FGFR1 copy number in lung bronchial-pulmonary carcinomas, comparing the results between 
the histological types. Also, EMT pathway was explored in more complex lung carcinomas, 
such as adenosquamous and pleomorphic carcinomas as well as in adenocarcinomas, 
according to Vimentin and TTF1 expression. For squamous cell carcinoma, FGFR1 alterations 
were also explored according to CK7 expression. The purpose was to identify differences 
and/or similarities in between these groups of lung tumours in order to characterize the 
histological types for targeted therapy. 
 
Potential targetable molecular events are more frequently diagnosed in lung 
adenocarcinomas, especially of non smoker’s patients [321-323]. In squamous cell carcinoma, 
more prevalent in smokers, these molecular events / genetic driver mutations are less 
frequently identified [2,165]. For this reason, targeted therapies are not a reality in a daily 
routine for squamous cell lung cancer treatment [2,165]. So, new research in this field is crucial 
for the growing knowledge and to the development of new therapies strategies, we hope with 
increment in life expectancy and quality. In this context, FGFR1 and FGF emerged recently as a 
driver potentially targetable oncogenes [324]. There are several ongoing clinical trials with 
FGFR inhibitors, and in most of these clinical trials one of the inclusion criteria is FGFR1 
amplification [168-171]. Therefore, the assessment of FGFR1 gene status might become 
increasingly important in the future, especially for patients with squamous cell lung 
carcinomas. It is also important to clearly define the criteria to select patients for targeted 
therapies. Protein overexpression, gene copy number increases (by amplification) and 
mutations have been described in lung bronchial-pulmonary carcinomas [158-163,165]. 
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Amplification of the FGFR1 gene is actually considered the best criteria for patient’s selection 
for targeted therapy, as FGFR1 mutations are rare [2,165]. Therefore, FGFR1 amplification 
seems to be the most frequent responsible for the activation of FGFR1 pathways [2,165]. Also, 
it has been demonstrated response to FGFR inhibitors, in those patients with FGFR1 
amplification [165,168]. 
 
FGFR1 amplification as well as FGFR1 overexpression are frequently identified, mainly in 
squamous cell lung carcinomas [165]. These alterations have been considered as an early 
event, as they could be identified in squamous metaplasia and dysplasia, with some conflicting 
results [2,162,325]. 
 
Another important aspect to take in account is that patients with FGFR1 amplification may 
develop EGFR-TKI resistance [326], being the FGFR pathway a mechanism of “intrinsic” 
resistance. So it is important to identify genetic FGFR alterations in order to better understand 
therapy responses, and explain resistant cases. EGFR mutations and FGFR1 increased copy 
number have been considered as mutually exclusive [327]. However, there are cases reported 
of patients with FGFR1 amplification and high EGFR protein expression (overexpression) [328].  
 
We have demonstrated higher FGFR1 protein expression in tumours compared to non-tumour 
adjacent parenchyma / bronchial epithelium. This aspect may reinforce the importance of the 
FGFR1 pathway in lung carcinogenesis, even in the absence of FGFR1 gene copy number 
increase. Higher expression was seen in adenocarcinomas and pleomorphic carcinomas 
compared to squamous cell carcinomas. No differences were found between 
adenocarcinomas, pleomorphic and adenosquamous carcinomas.  
Higher expression in pleomorphic carcinomas suggests that overexpression may also be 
implicated in the activation of the EMT pathway. Overexpression could also be responsible for 
tumour growth and proliferation and invasiveness, related with a more aggressive behaviour. 
Protein FGFR1 expression showed no differences between adenocarcinomas and 
adenosquamous carcinomas, may be reflecting the compound morphology of the latter and 
the carcinogenesis of both.  
 
No differences of FGFR1 protein expression and gene copy number were found in the group of 
squamous cell carcinomas, according to CK7 expression (CK7 expression reflecting a group of 
less differentiated tumours with some features overlapping with adenocarcinomas). 
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Therefore, it seems that the grade of differentiation in squamous cell lung carcinoma has no 
relevance considering FGFR1 protein expression. 
For adenocarcinomas, our results suggest that TTF1 expression, reflecting cell origin, has 
probably no implications on FGFR1 pathway activation, as no significant differences were 
found related to the expression of TTT1.  
 
In contrast to the results obtained in the group of pleomorphic carcinomas, adenocarcinomas 
expressing Vimentin, associated with EMT phenotype in carcinomas, had no significant 
differences of either FGFR1 expression or gene copy number compared to Vimentin negative 
cases. This may indicate that in adenocarcinomas FGFR1 pathway activation precedes or is 
independent of EMT activation or even that activation of EMT pathways occur later than the 
activation of pathways related to tumour growth. Also, other pathways than FGFR1 activated, 
might be related with EMT phenotype in lung adenocarcinomas expressing Vimentin. 
 
FGFR1 amplification was identified in 19.7% (15) of the studied cases: 5 adenocarcinomas 
(14.7%), 5 squamous cell carcinomas (20.8%), 3 pleomorphic carcinomas (30%) and 2 
adenosquamous carcinomas (25%). Although FISH positive cases were more frequent in 
squamous cell carcinomas, no significant differences to adenocarcinomas were registered. 
FGFR1 amplification rates vary according to the different series published, ranging from 0% to 
4.7% for adenocarcinomas, from 9% to 41.3% for squamous cell lung carcinomas 
[165,325,327,329-334]. 
 
As FGFR1 amplification was identified in adenosquamous and pleomorphic carcinomas, it 
seems that the FGFR pathway is also important in these tumours. FGFR1 molecular profile was 
studied in a subset of 10 pleomorphic carcinomas. No differences of FGFR1 protein expression 
were identified according to the presence of a component of squamous cell carcinoma or 
adenocarcinoma, as all showed intense expression. However, FGFR1 amplification was 
identified in 2/2 (100%) of the pleomorphic carcinomas with a squamous cell carcinoma 
component and in 1/8 (12.5%) of the pleomorphic carcinomas with a component of 
adenocarcinoma.  
 
FGFR1 protein expression is higher and frequent in pleomorphic carcinomas compared to 
adenocarcinomas and squamous cell carcinomas. Higher FGFR1 expression may reflect a more 
aggressive behaviour, related with the activation of pathways related to tumour growth and 
also reflect the importance of FGFR1 in the EMT pathway in this subtype of lung carcinomas. 
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As these molecular events are frequent in pleomorphic carcinomas, it seems prudent to 
evaluate FGFR1 protein expression and gene copy number in this subtype of lung carcinomas.  
FGFR1 molecular testing should also be done in adenosquamous carcinomas, hence FGFR1 
protein expression and gene amplification was also identified in adenosquamous lung 
carcinomas.  
 
We did not found any associations between FGFR1 expression / gene copy number and clinical 
parameters, such as gender and smoking habits. Therefore, according to our results, it seems 
that clinical parameters should not be used to select patients for targeted therapy. Other 
investigators also found no correlation with clinical parameters [330,333]. We have, however, 
found a tendency to higher frequencies of FGFR1 amplification in adenocarcinomas of smoking 
patients and other authors identified correlations with male gender and smoking habits, 
raising the question of the importance of clinical parameters in the patient selection 
[325,327,328,332].  Therefore, in the future, more and larger studies must be done to address 
this question. 
 
As already mentioned, FGFR1 amplification is an inclusion criteria for clinical trials. However, 
according to our data and those of other series, amplification may not reflect overexpression. 
Therefore, in the future, Clinical Trials should also determine the predictive value of both 
FGFR1 gene copy number and protein expression, in order to definitively clarify which is the 
best predictive testing. 
 
Some take home messages related to FGFR1 molecular testing in lung bronchial-pulmonary 
carcinomas emerge from our study and the literature review. FGFR1 protein expression was 
identified in all subtypes of lung bronchial-pulmonary carcinomas, especially in pleomorphic 
carcinomas. FGFR1 amplification, although more frequent in squamous cell carcinoma, was 
also identified in adenocarcinomas, adenosquamous and pleomorphic carcinomas. Therefore, 
it is important to do not exclude from molecular testing patients with lung bronchial-
pulmonary carcinomas, other than squamous cell carcinomas. It is also important to clear 
define, in future studies, the predictive value of both FGFR1 amplification and FGFR1 protein 
expression by evaluating these parameters in clinical trials.  
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Conclusions 
 
Epidermoid carcinomas and adenocarcinomas are distinct entities with different pathological, 
biological and molecular characteristics. 
 
Epidermoid carcinoma: 
Epidermoid carcinoma preneoplastic lesions have a basal cell origin. 
Stepwise higher Ki67, p53 and EGFR expression from basal cell hyperplasia to squamous 
dysplasia reinforce their importance as potentially significant gravity biomarkers for 
preneoplastic lesions. 
EGFR and HER2 high gene copy number was mainly due to high polysomy, rather than to 
amplification; amplification is not the main mechanism for protein overexpression in 
epidermoid carcinoma preneoplastic lesions. 
Recognition of preneoplastic lesion biomarkers may allow targeted screening and follow-up, 
especially if chemoprevention schemes are available. 
Epidermoid carcinomas had EGFR protein overexpression, together with high gene copy 
number (by high polysomy and amplification). EGFR mutations were infrequent. 
High gene copy number is a frequent event in lung epidermoid carcinoma, suggesting that 
EGFR gene copy may play a role in epidermoid lung cancer carcinogenesis.  
In small biopsies, we must also take account of incomplete sampling, and some cases 
diagnosed as epidermoid carcinoma could be diagnosed as adenosquamous carcinoma in 
surgical specimens with extensive sampling. 
Epidermoid carcinomas with solid, large cells or clear cell phenotype or with CK7 or even 
Vimentin (EMT phenotype) expression should be submitted to EGFR mutational analysis. 
 
Epidermoid carcinomas with vimentin expression are more complex carcinomas where EMT 
pathways are important, which explain why they are less morphologically differentiated and 
have fusocelular phenotype or irregular infiltrative borders with large isolated cells. Thus, 
epidermoid carcinomas with these phenotypes should be reported to clinicians in order to 
make them aware that these patients may benefit from EGFR mutation testing. In fact, 
epidermoid carcinomas with solid, large cells or clear cell phenotype or with CK7 or even 
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Vimentin expression (EMT phenotype) are routinely submitted to EGFR mutational analysis in 
our hospital. 
We could argue that EGFR mutational testing should also be used in biopsies with poorly 
differentiated epidermoid carcinomas, especially in cases diagnosed in never-smokers or with 
CK7/Vimentin expression. 
 
Bronchial-pulmonary adenocarcinoma: 
A comprehensive pathological diagnosis incorporating immunohistochemical markers such as 
p63 or CK5/6, CK7 and TTF1, as well as mucine detection by histochemical techniques, is 
essential, especially in small biopsies representing poorly differentiated carcinomas or those 
with some “squamous” features or solid patterns, in which it is difficult to differentiate 
between a poorly differentiated epidermoid carcinoma and a solid pattern adenocarcinoma. 
 
Adenocarcinomas are molecularly different from normal adjacent lung tissue. 
 
There was generally higher expression of the products of genes studied in the 
adenocarcinomas compared to normal adjacent cells reinforcing their importance in lung 
adenocarcinoma carcinogenesis.  
 
Adenocarcinomas in non-smoking females were diagnosed in earlier stages and had higher 
ERCC1 expression. 
Advanced-stages (IIA and IIIA) adenocarcinomas had higher Ki67, APC, ERCC1 expressions and 
lower TTF1 expression reflecting more mitotically aggressive adenocarcinomas and a possible 
non-TRU origin. 
 
Differences of expression were identified between adenocarcinoma patterns. Papillary and 
solid patterns revealed less TTF1 expression, identical to normal tissue exhibiting a non-
TRU/bronchial phenotype. Acinar, BA/lepidic and micropapillary patterns showed higher TTF1 
expression (TRU type). 
 
Solid patterns showed lower expression of nuclear TTF1 and higher expression of Ki67, 
reflecting aggressive biological behaviour, to be reported to clinicians in order to avoid poorly 
differentiated carcinoma reports.  
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TTF1 provides significant guidance for therapy concerning advanced lung adenocarcinoma, as 
EGFR mutations are more frequent in TTF1 positive TRU-type adenocarcinomas. On the other 
hand, TTF1 negative adenocarcinomas, some representing non-TRU adenocarcinomas, are less 
prone to harbor EGFR mutations. 
The solid pattern revealed lower HER2 expression and higher EGFR and ERCC1 expression 
compared to the papillary pattern. The papillary pattern showed higher HER2 and lower ERCC1 
expressions. The micropapillary pattern showed higher RB expression. Acinar showed lower 
ERCC1 and higher EGFR expressions. Cyclin D1 seems to have more importance in the acinar 
and BA/lepidic patterns than in the micropapillary. ERCC1 protein expression in micropapillary, 
solid and BA/lepidic patterns indicate DNA repair and in acinar and papillary patterns there 
was lower expression. BCL2 was overexpressed in all patterns, suggesting that there is 
inhibition of apoptosis.  
 
Chemotherapy resistance might be explained in part by MRP1 and LRP overexpression in 
adenocarcinomas. Micropapillary, solid and lepidic patterns are also the patterns where ERCC1 
expression was relevant, indicating  an ability to remove Cisplatin adducts. 
 
Higher MRP1 and LRP expression in adenocarcinoma indicate acquisition of drug resistance 
mechanisms during carcinogenesis. 
The differences identified between the adenocarcinoma patterns reinforce the need to 
carefully specify the patterns due to their implications for diagnosis, pathogenic understanding 
and therapeutic outcome. 
 
Cluster analysis yielded three clusters: 1 – papillary; 2 – solid; and 3 – lepidic/BA, acinar and 
micropapillary. 
 
 In adenocarcinomas, a correlation was found between EGFR FISH results and mutational 
status.  
 
In general, EGFR mutations were present in all the patterns of the same adenocarcinoma, 
reinforcing the possibility of mutational status determination in biopsies.  
 
Although rare, EGFR and KRAS mutation can coexist.  The coexistence of KRAS and EGFR 
mutations in the same tumour again raises the question of tumour complexity. 
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Complex EGFR mutations (coexistence of more than one type) were detected in 
adenocarcinomas, clearly demonstrating a molecular complexity that might be related to 
different cell clones or genomic instability, responsible for the accumulation of multiple 
molecular events in the EGFR gene. 
 
Bronchial-pulmonary carcinomas and FGFR1 
FGFR1 protein expression was identified in all subtypes of lung bronchial-pulmonary 
carcinomas, especially in pleomorphic carcinomas. FGFR1 amplification, although more 
frequent in squamous cell carcinoma, was also identified in adenocarcinomas, adenosquamous 
and pleomorphic carcinomas. Therefore it is important to do not exclude from molecular 
testing patients with lung bronchial-pulmonary carcinomas, other than squamous cell 
carcinomas. 
 
Bronchial-pulmonary carcinomas have particular biological, clinical and therapeutic 
implications. The importance of precise pathological diagnosis, avoiding NSCLC terminology, 
and adenocarcinoma pattern recognition is highlighted, as bronchial-pulmonary carcinogenesis 
particularly related to biomarker predictive value for targeted therapy, concerning EGFR, KRAS, 
ALK and MET.  
 
Lung cancer is a complex biological and genetic entity that has proved challenging for research. 
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